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Parkinson's disease (PD) is the second most common neurodegenerative disorder, 
after Alzheimer's disease (AD), occurring at a rate of 0.1%-0.2% of the population. 
The incidence of PD increases with advancing age, affecting 1% of the population 
over the age of 65. Extensive loss of dopaminergic neurons and aggregation of the 
protein α-synuclein (α-syn) into ubiquitin-positive Lewy bodies (LBs) represents a 
major neuropathological hallmark of PD. The impact of LB pathology on the disease 
pathogenesis is still largely unknown, with evidence suggesting small soluble 
oligomeric assemblies that precede LB development are the causative agent in PD. 
At present, the generation of large nuclear-associated LBs from endogenous wild-
type α-syn, translationally regulated under its own promoter in human cell culture 
models, requires costly and time-consuming protocols.  
The primary objective of this thesis was to develop a more physiologically relevant 
cell culture model of PD that recapitulates the development of LB inclusions. Using a 
cell culture model of fully differentiated human SH-SY5Y neuroblastoma cells grown 
in three-dimensions (3D), cells were shown to develop LB-like pathology upon 
exposure to exogenous α-syn species. In contrast to most cell- and rodent based PD 
models, which exhibit multiple diffuse α-syn aggregates throughout the cytoplasm, a 
single large nuclear inclusion that is immunopositive for α-syn and ubiquitin is rapidly 
obtained in our model. However, phosphorylation of α-syn within these inclusions 
was not observed. This was achieved without the need for overexpression of α-syn 
or genetic modification of the cell line.  
 
To further explore the mechanism of LB formation the recently discovered 
programmed cell death pathway ferroptosis was investigated. Ferroptosis is an iron-
dependent cell death pathway that shares similar pathogenic features with PD 
including elevated iron concentration, GSH depletion, lipid peroxidation and 
increased ROS. However, there are currently no studies that have explored whether 




Viability assays within the 3D cell culture model following treatment with ferroptosis 
and apoptosis inducers and qPCR of ferroptotic targets demonstrated resistance to 
this mechanism of programmed cell death. Nevertheless, treatment with iron was 
associated with some features of ferroptosis including increased ROS, some lipid 
peroxidation and reduced levels of glutathione peroxidase 4 (GPX4). 
Phosphorylation of α-syn at serine 129 (S129) was increased upon iron treatment 
and reduced following treatment with a ferroptosis inhibitor, liproxstatin-1. These 
results demonstrate the potential implications of iron exposure, α-syn aggregation, 
and ferroptosis in the pathogenesis of PD. 
 
The system described in this thesis provides an ideal tool to screen compounds to 
intervene therapeutically in LB formation, and to investigate the mechanisms 
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Chapter 1 : General Introduction 
1.1 Protein aggregation in disease 
Protein aggregation and accumulation is associated with a wide range of disease 
states, termed amyloidoses. In these conditions, misfolded protein assembles into 
misfolded amyloid cross-β conformations that are deposited mainly in the 
extracellular space of tissues (Sipe et al., 2014). Non-pathogenic amyloid formations 
that have a normal, physiological role have been discovered in mammalian tissue as 
well as lower-order organisms, such as Escherichia coli (E. coli) (Fowler et al., 2006; 
Li et al., 2012; Biesecker et al., 2018). Amyloid formation has been implicated in over 
30 human diseases, with many proteins determined to be amyloidogenic at least in 
vitro (Sipe et al., 2014, 2016). Systemic amyloidoses in which amyloid fibrils are 
deposited throughout the body is related to proteins such as immunoglobulin light 
chain (AL), (Apo) serum amyloid A (AA) and transthyretin, among others 
(Wechalekar, Gillmore and Hawkins, 2016) (Table 1.1). Amyloidosis can also affect 
single organs and has been associated with type 2 diabetes in the case of 
accumulation of islet amyloid polypeptide (IAPP) in the Islets of Langerhans 
(Andisheh and Marie, 2013). An amyloid fibril protein is defined by the Nomenclature 
Committee of the International Society of Amyloidosis as: ‘a protein that occurs in 
body deposits and exhibits affinity for Congo red and green, yellow or orange 
birefringence when the Congo red-stained deposits are viewed with polarised light’ 
(Howie and Brewer, 2009; Sipe et al., 2014, 2016). The process of amyloidogenesis 
has also been linked to several neurodegenerative diseases including Alzheimer’s 
disease (AD; amyloid-β and tau in amyloid plaques and neurofibrillary tangles), 
Parkinson’s disease (PD; α-syn in LBs), prion diseases (amyloid plaques) and 
Huntington’s disease (PolyQ expanded huntingtin in inclusion bodies) (Klatzo, 
Gajusek and Zigas, 1959; Macdonald et al., 1993; Stelzmann, Schnitzlein and 







Fibril protein Associated disease Target organs 
Immunoglobulin light/heavy 
chain† 
Primary amyloidosis; associated with 
plasma cell dyscrasia and multiple 
myeloma 
All organs, except 
CNS 
Serum amyloid A† Secondary systematic amyloidosis; 
Associated with chronic infections 
and inflammatory diseases  
All organs except CNS 





Apolipoprotein A I, II, IV† Cardiovascular disease I: Heart, liver, kidney, 
testis, larynx, skin 
II: Kidney 
IV: Kidney medulla 
and systemic 
Apolipoprotein C II, III Cardiovascular disease II: Kidney 
III: Kidney 
Lysozyme Lysozyme systemic amyloidosis Kidney 
Aβ † and Tau* AD, inclusion body myositis, fronto-
temporal dementia, Pick’s disease, 
progressive supranuclear palsy  
Aβ and Tau: CNS 
α-syn* PD, multiple system atrophy (MSA), 
dementia with LBs (DLB), LB variant 
of AD 
CNS 
Prion protein† CJD, Kuru, Gerstmann-Straüssler-
Scheinker syndrome, fatal insomnia  
CNS 
Islet amyloid polypeptide† Type 2 diabetes Islets of Langerhans, 
insulinomas 
Table 1.1-1. Amyloid proteins and their associated diseases in humans. Table adapted from Sipe et al. 2016 and 
Uversky 2008. * Protein aggregates are found intracellularly as well as extracellularly. † Amyloid fibril proteins 
also found to cause disease in animals. Abbreviations: Aβ, amyloid-beta; α-syn, α-synuclein; CNS, central 
nervous system; DLB, dementia with Lewy bodies; LB, Lewy body; MSA, multiple system atrophy 
1.2 Parkinson's disease 
1.2.1 Pathophysiology of Parkinson's disease 
PD is the second most common neurodegenerative disorder after AD in the UK, 
affecting approximately 1% of the population over the age of 65 with increasing 
prevalence with advancing age (Bousset et al., 2013; Parkinson’s UK, 2018). First 
described nearly 200 years ago in ‘An Essay on the Shaking Palsy’ authored by 
James Parkinson, PD is a complex and currently incurable neurodegenerative 
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disease. Although clinically heterogeneous, PD is characterised by the cardinal 
motor symptoms of tremor at rest, bradykinesia, postural instability, and rigidity. In 
later stages of the disease, motor symptoms are accompanied by autonomic 
disturbances and, in up to 80% of patients, cognitive impairment (Chaudhuri and 
Schapira, 2009; Lees, Hardy and Revesz, 2009; Sveinbjornsdottir, 2016). The 
disease has distinct neuropathology, characterised by the progressive loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNPc) region of the 
midbrain and the presence of proteinaceous inclusions in neurons termed LBs and 
Lewy neurites (LNs) comprised mainly of an aggregated form of the protein α-syn 
(Fig. 1.1) (Spillantini et al., 1997; Takeda et al., 1998; Langston et al., 2015). 
LB pathology in surviving neurons is synonymous with the neuropathology of PD and 
other synucleinopathies including DLB and MSA. These proteinaceous inclusions 
are mainly comprised of an abnormal misfolded form of α-syn in association with 
other proteins such as ubiquitin, neurofilament protein, and heat shock proteins but 
may also contain the microtubule-associated tau protein and neurofibrillary tangles 
commonly associated with AD (Ueda et al., 1993a; Spillantini, Divane and Goedert, 
1995; Goedert et al., 2013). LBs are present as amorphous protein inclusions in the 
cell body of neurons in contrast to LNs which are spindle, thread-like aggregates 
typically present in neurites. Although the involvement of LBs in the development 
and progression of PD is still largely unknown, alongside details as to their formation, 
the immunoreactivity of α-syn in these inclusions has since garnered attention as the 
protein implicated in the pathogenesis of PD, DLB and MSA (Milber et al., 2012). 
Mutations in the SNCA gene that encodes α-syn, including genomic duplications, 
triplications, and point mutations, are typically associated with an early-onset and 
more aggressive form of PD, implicating α-syn in the development of the disease 
(Polymeropoulos et al., 1997; Spillantini et al., 1997). 
Catecholaminergic and serotoninergic neurons can also be affected as the disease 
progresses, disrupting connectivity in a large number of brain regions (Wirdefeldt et 
al., 2011; Berman et al., 2016). The Braak hypothesis identifies six neuropathological 
stages that consist of α-syn-containing inclusions confined to the medulla 
oblongata/pontine tegmentum and olfactory bulb/anterior olfactory nucleus (stage 1 
and 2) progressing to the SNPc and other nuclei of the midbrain and forebrain (stage 
3 and 4), culminating in the neocortex (stage 5 and 6) in which clinical symptoms 
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arise as the stages progress (Del Tredici et al., 2002; Wolters and Braak, 2006; Rey 
et al., 2013). Motor symptoms are not experienced in patients until approximately 50-
60% of the SNPc neurons are depleted, resulting in a dopamine deficit of 80-85% 
which is partially rescued by supplementation of the dopamine precursor, levodopa 
(L-DOPA) (Oertel and Schulz, 2016). In the development of this staging model, 
Braak and colleagues proposed the 'dual-hit' hypothesis (Hawkes and Braak, 2007) 
in which a pathological insult initiates the progression of PD subsequently spreading 
to vulnerable regions in a potential ‘prion-like’ spread.  
 
Figure 1.1. Pathology of Parkinson's disease. Horizontal midbrain sections from normal (left) and Parkinson's 
disease brains (middle) demonstrate the loss of pigmented neurons from the SNPc in disease. Classical 
Haematoxylin and Eosin (H&E) staining of LBs in neurons of the SNPc highlight the presence of spherical, 
intracytoplasmic inclusions measuring between 8 and 30 µm in diameter with an eosinophilic hyaline core and 
pale staining peripheral halo (right, arrow). Image adapted from Mackenzie, 2001.    
The significant loss of neuromelanin-pigmented neurons in the SNPc and the 
subsequent dopamine deficit of the nigrostriatal system represents the most 
important hallmark of PD. Braak and colleagues (2003) in the seminal, yet debated, 
study relating α-syn immunoreactivity of LBs and LNs in post-mortem brain samples 
of both clinically-diagnosed PD and incidental Lewy pathology highlighted a potential 
spread of pathology. In this study, the spread of pathology occurs in a predictable 
sequential pattern resulting in progression from either the brainstem or olfactory 
centres along vulnerable neuronal subsets, culminating in degeneration of neurons 
of the SNPc (Braak et al., 2003). Although the Braak staging scheme is largely 
accepted by scientists and clinicians, not all the observations made in patients with 
LB pathology are represented in this staging scheme (Burke, Dauer and Vonsattel, 
2008; Jellinger, 2019). For example, the Braak staging scheme suggests the spread 
of pathology and thus clinical symptoms of parkinsonism develop as the staging 
progresses from 1 through to 6 (McCann, Cartwright and Halliday, 2016). However, 
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patient symptoms do not necessarily represent the staging scheme, with only ~51% 
of patients conforming to Braak staging in some studies (Zaccai et al., 2008; Beach 
et al., 2009; Jellinger, 2009). There are reported individuals with a Braak staging of 
only 2 with clinical PD symptoms, in contrast to individuals with Braak staging of 6 
without observable symptoms (Ahlskog, 2007; Zaccai et al., 2008; Jellinger, 2019). 
Taken together, the Braak staging scheme may not be appropriate for all types of 
PD. In addition, patients presenting with DLB were omitted from the original Braak 
staging scheme (Burke, Dauer and Vonsattel, 2008). This is important as patients 
that present with an initial diagnosis of DLB may progress to develop a condition 
indistinguishable from PD (Lippa et al., 2007; Jellinger and Korczyn, 2018). 
1.2.2 Aetiology and pathogenesis of Parkinson's disease 
The aetiology of PD is complex and not completely understood, but is hypothesised 
to involve the interplay between genetic, environmental and lifestyle factors as well 
as the presence of pre-existing medical conditions and previous infections 
(McCulloch et al., 2008; Wirdefeldt et al., 2011). Mechanisms in which these factors 
contribute to the pathogenesis of idiopathic PD are likely linked, with multiple themes 
emerging including mitochondrial dysfunction, oxidative stress, inflammation, 
proteasomal and lysosomal impairment (Fig. 1.2) (Khan et al., 2019). 
Epidemiological studies have consistently associated environmental factors including 
exposure to pesticides such as rotenone and 1-methyl-4-phenyl-1, 2, 3, 6,-
tetrahydropyridine (MPTP) as risk factors in the development of the disease, linked 
to human exposure through contaminated food products, drinking water and 
occupational exposure related to agricultural working (Lai et al., 2002). Illicit drug use 
in the 1980s of 'synthetic heroin' containing MPTP was clinically linked to the 
development of L-DOPA-responsive acute parkinsonism and MPTP is commonly 
used to induce PD pathology in various animal models (Langston et al., 1983, 1984). 
Both MPTP and rotenone-based animal models have enabled researchers to 
delineate key aetiologic pathways associated with PD including impaired 
mitochondrial function and free radical generation, although this model does not fully 
recapitulate PD disease processes, due to the absence of LB formation (Przedborski 
and Jackson-Lewis, 1998; Shimoji et al., 2005; Perier and Vila, 2012). Rotenone has 
been demonstrated to down-regulate the protective chaperone protein HSC70 (70-
kDa heat shock cognate), involved in the catabolism of α-syn which effectively 
6 
 
fragments α-syn fibrils into non-toxic monomers, suggesting a critical role of this 
protein in preventing PD (Sala et al., 2016). Occupational exposure to manganese 
induced parkinsonian symptoms determined to be clinically distinct from PD. 
However, the presence of altered levels of transition metals in the SNPc of PD 
patients has indicated altered metal homeostasis in the development of the disease 
(Gorell et al., 1997; Jankovic, 2005; Lan et al., 2016). In contrast, and typically with a 
larger sample size than previous epidemiological studies regarding metal exposure 
in PD patients, van der Mark et al. (2015) didn't observe any statistically significant 
associations in the development of PD due to occupational exposure to metals or 
aromatic/chlorinated solvent exposure (van der Mark et al., 2015). One caveat of the 
study reveals that specific metals were not able to be analysed separately, therefore 
the effects of single metals may be masked in the results (van der Mark et al., 2015). 
PD has also been related to head trauma and exposure to previous infection, 
suggesting an inflammatory mechanism, substantiated by the presence of activated 
microglial cells and inflammatory cytokines of the SNPc in both post-mortem 
samples and models of PD (Lieberman, 1996; Gagne and Power, 2010; Panicker et 
al., 2015; Ransohoff, 2016). Ageing is the strongest risk factor, although there is a 
small percentage of patients with an early-onset form of the disease (Reeve, Simcox 
and Turnbull, 2014). This association is largely attributed to mitochondrial 
dysfunction and oxidative stress, key themes in ageing and specifically in relation to 
neurodegeneration (Federico et al., 2012). An increased incidence of PD in the male 
population is potentially explained by increased occupational exposure to toxins, the 
protective role of oestrogens and recessive susceptibility genes on the X 
chromosome (Inestrosa, Marzolo and Bonnefont, 1998; Baldereschi et al., 2000; 
Wooten et al., 2004; Moisan et al., 2016). Lifestyle factors such as smoking and 
caffeine consumption are inversely correlated with the risk of PD, suggesting these 
activities have a protective effect on PD risk, by delaying disease onset yet with no 
impact on disease progression (Ascherio et al., 2001; Kandinov, Giladi and Korczyn, 
2007, 2009; Moccia et al., 2016). In the case of smoking, cigarettes contain a 
multitude of compounds, such as nicotine and hydroquinone, which have been 
shown to inhibit the formation of α-syn fibrils potentially stabilising soluble oligomeric 
forms of α-syn and thus preventing the formation of a toxic species (Hong, Fink and 




Figure 1.2. Pathogenesis of PD. Some of the key features of PD pathogenesis (grey) include protein misfolding 
and aggregation, synaptic/ lysosomal/ ubiquitin-proteasomal/mitochondrial dysfunction and oxidative stress. 
Highlighted in blue are some of the contributors to disease pathogenesis, with many converging across the 
different molecular features of PD including aging and α-syn. 
The pathogenesis of PD involves a cascade of events leading to cellular death (Fig. 
1.2). Cell loss, although predominant in the SNPc, is not restricted to this region of 
the brain and instead includes many other non-dopaminergic regions of the brain 
including the noradrenergic locus coeruleus, the cholinergic nucleus basalis of 
Meynert, and the autonomic nervous system (Heiko Braak, Tredici, et al., 2003). The 
selective vulnerability of dopaminergic neurons, in particular, has been the subject of 
intense investigation given that as much as 70% of dopaminergic cell loss 
accompanies the diagnosis of PD (Giguère, Nanni and Trudeau, 2018). Intracellular 
aggregates of α-syn and the propagation of these aggregates are discussed further 
in Chapter 4.  
1.2.3 Genetics of Parkinson's disease 
PD is usually sporadic; however, familial forms of PD account for approximately 10% 
of all cases and have either autosomal dominant (AuD) or autosomal recessive 
(AuR) modes of inheritance (Table 1.2) (Pchelina, Emel’ianov and Usenko, 2014). 
AuD forms of PD are associated with a toxic gain-of-function phenotype attributed to 
mutations in the leucine-rich repeat kinase 2 (LRRK2) (PARK8), SNCA (PARK1), 
PARK3, omi/HtrA2 (PARK13) and ubiquitin-carboxy-terminal hydrolase L1 (UCH-L1) 
(PARK5) genes. AuR genes that cause a loss-of-function phenotype include parkin 
(PARK2), PINK1 (PARK6), DJ-1 (PARK7), ATP13A2 (PARK9), PLA2G6 (PARK14) 
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Gene Protein Mode of 
inheritance 
Function and possible role in PD 
SNCA 
(PARK1) 
α-syn AuD Function: Involved in dopamine metabolism, SNARE vesicle trafficking and as a cellular ferrireductase (Davies, Moualla and 
Brown, 2011; Huang et al., 2019). 
Role in PD: The major component in LBs, α-syn is thought to contribute to cellular toxicity and spread of disease (Spillantini, 
Divane and Goedert, 1995). Missense mutations (A53T, A30P, E56K, H50Q) associated with increased propensity to form toxic 
oligomeric species (Ostrerova-Golts et al., 2000; Greenbaum et al., 2005; Bharathi, Indi and Rao, 2007; Porcari et al., 2015). 
LRRK2 
(PARK8) 
LRRK2 AuD Function: LRRK2 phosphorylates a subgroup of RAB GTPases, regulating vesicular trafficking and immune responses, protecting 
against pathogenic infection (Alessi and Sammler, 2018). Mounting evidence suggests LRRK2 phosphorylates tau, important 
given the pathological accumulation of tau in PD patients and the accumulation of tau in LBs (Ishizawa et al., 2003; Bailey et al., 
2013). 
Role in PD: The most common mutation, G2019S, is associated with two to three-fold increase in LRRK2 kinase activity, 
potentially associated with defects in lysosomal function and enhancing neuronal transmission of tau (Phu et al., 2018). 
PARKIN 
(PARK2) 
Parkin AuR Function: Encodes the E3 ubiquitin ligase targeting several proteins for proteasomal degradation, including mitochondria  
(Arkinson and Walden, 2018). 
Role in PD: Dysfunction in mitochondrial clearance leading to the accumulation of damaged mitochondria (Arkinson and Walden, 
2018). Alteration in E3 ligase activity leads to the accumulation of Parkin substrates and subsequent impairment of autophagy-
lysosomal pathways (Wallings et al., 2019).  
DJ-1 
(PARK7) 
DJ-1 AuR Function: Several functions of including regulating mitochondrial integrity, ROS scavenging (e.g. deglycase function), metal ion 
binding, transcriptional regulation, chaperone-mediated autophagy regulator (Andres-mateos et al., 2007; Björkblom et al., 2013; 
Richarme et al., 2015; Xu et al., 2017; Andreeva et al., 2019) 
Role in PD: PD-related mutations result in the loss of structure of DJ-1, increased degradation and/or dimerisation (Malgieri and 
Eliezer, 2008). Oxidation of DJ-1 at Cys-106 functions as a ROS scavenger and the loss of this activity contributes to increased 
oxidative stress (Andres-mateos et al., 2007; Lev et al., 2013). DJ-1 deficiency is associated with reduced expression of 
LAMP2A, the receptor required for CMA-mediated α-syn degradation, therefore leading to the accumulation of α-syn (Xu et al., 
2017). In addition, DJ-1 acts as a binding partner for α-syn which can influence the aggregation process of pathological forms of 
α-syn. Taken together, DJ-1 function acts to reduce levels of α-syn to prevent the formation of toxic protein aggregates 
(Shendelman et al., 2004; Zondler et al., 2014).  
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GBA GCase AuR Function: Associated with the lysosomal storage disorder, Gaucher’s disease (Wong and Krainc, 2016). GCase is an 
intermediate enzyme in glycolipid metabolism which cleaves a glucose moiety from glucosylceramide (Hruska et al., 2008).  
Role in PD: Associated with GBA1 mutations, with an estimated 7-12% patient with PD carrying this mutation (Sidransky et al., 
2009; Do et al., 2019). Loss of GCase activity by various factors (loss of GCase function, increased storage of intermediates, 
decreased transport of GCase from the ER/CMA disruption) facilitates accumulation of α-syn (Mazzulli et al., 2011; Do et al., 
2019). GCase appears to be important in maintaining levels of monomeric levels of α-syn within the cell, therefore preventing the 
development of potentially toxic α-syn aggregates (Mazzulli et al., 2011; Gruschus, 2015). GBA1 mutations can alter the ratio of 




PINK1 AuR Function: PINK1 contains a mitochondrial targeting sequence, which facilitates recruitment of the protein to damaged and aged 
mitochondrial. Binding of PINK1 to mitochondria is associated with the recruitment of cytosolic Parkin, promoting the autophagic 
degradation of mitochondria via mitophagy (Valente et al., 2004; Narendra et al., 2008). 
Role in PD: Loss of function mutations in PINK1 (along with Parkin) are the most common causes of AuR early-onset PD 
(Valente et al., 2004). Loss of function of both PINK1 and Parkin alter several important mitochondrial processes including the 
maintenance of mitochondrial integrity, mitophagy, regulating fission/fusion dynamics, and regulating local translation of 
mitochondrial genes (Arkinson and Walden, 2018; Ge, Dawson and Dawson, 2020). In addition to mitochondrial dysfunction, loss 
of PINK1 may alter the immune response via alteration of glial activation, contributing to an overreactive immune response and 
subsequent cellular damage (Sun et al., 2018). 
Table 1-2 . Genetics of Parkinson’s disease. Abbreviations: α-syn, α-synuclein; AuD, autosomal dominant; AuR, autosomal recessive; CMA; chaperone-mediated autophagy; 
GBA, glucosylceramidase; GCase, glucocerebrosidase; GlcCer, glucosylceramide; GlcSph, glucosylsphingosine; LRRK2, leucine-rich repeat kinase 2; PINK1, PTEN induced 
putative kinase 1; SNARE, soluble NSF attachment protein receptor.
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and FBXO7 (PARK15) (Wirdefeldt et al., 2011; Cookson, 2012). A large-scale 
genome-wide meta-analysis identified 28 independent risk variants across 24 loci for 
PD (Nalls et al., 2015).  
The first mutation linked to PD was mapped to chromosome 4q21-q23 in the SNCA 
gene which encodes α-syn, the major protein component of LBs (Polymeropoulos et 
al., 1997; Spillantini et al., 1997). SNCA gene mutations include genomic 
duplications, triplications and point mutations and are typically associated with an 
early-onset of PD, implicating the role of α-syn in the development of PD (Singleton 
et al., 2003; Farrer et al., 2004; Kara et al., 2015; Konno et al., 2016). Duplications 
and triplications of the SNCA correlate with a toxic gain-of-function phenotype, 
suggesting that the overexpression of α-syn is toxic (Singleton et al., 2003; Chartier-
Harlin et al., 2004). Patients with triplications rather than duplications of SNCA 
typically present with a more severe form of the disease, both with earlier onset and 
faster disease progression (Lesage and Brice, 2009). Five rare missense (point) 
mutations, A53T (Polymeropoulos et al., 1997), A30P (Kruger et al., 1998), E46K 
(Zarranz et al., 2003), H50Q (Appel-Cresswell et al., 2013; Proukakis et al., 2013) 
and G51D (Lesage et al., 2013) have all been linked to early-onset. A53T, A30P, 
and E46K mutant proteins have a higher propensity to accelerate α-syn to form 
oligomers, in comparison to wild-type (WT) protein; with A53T and E46K enhancing 
fibrillisation in vitro and in vivo (Conway, Harper and Lansbury, 1998; O. M. A. El-
Agnaf et al., 1998; Kahle et al., 2000; Li, Uversky and Fink, 2001; Greenbaum et al., 
2005). The A53T mutation destabilises the α-helical domain of α-syn, thus facilitating 
the adoption of the β-sheet conformation (Biere et al., 2000) whereas the E46K 
mutation is thought to increase intermolecular interactions, accelerating dimerisation 
and generation of oligomers (Rospigliosi et al., 2009). It is interesting to note that 
A53T, A30P, and E46K mutants activate microglia more strongly than WT α-syn, 
suggesting a role of mutant protein in inducing a pro-inflammatory response, 
potentially exacerbating the disease process (Hoenen et al., 2016).  
Meta-analyses have identified genes that are associated with an increased 
susceptibility to develop PD. A genetic predisposition may, therefore, increase the 
likelihood of developing the disease. LRRK2 (PARK8) mutations account for 10% of 
AuD familial and 3.6% of sporadic PD, with over 40 different variants found, including 
the missense mutation Gly2019Serine (G2019S) (Berg et al., 2005; Lesage and 
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Brice, 2009). Mutations in LRRK2 (PARK8) are linked to mitochondrial impairment 
through compromised oxidative phosphorylation and mitochondrial dynamics leading 
to a loss of mitochondrial function in neuronal cells (Sanders et al., 2014). Recently, 
identification of an AuD disease-linked mutation in the TMEM230 gene which 
encodes a synaptic vesicle transmembrane protein has implicated impaired synaptic 
vesicle trafficking in the disease pathogenesis (Deng et al., 2016). Gaucher's 
disease, caused by mutations in the glucosylceramidase (GBA) gene, encoding a 
lysosomal membrane protein, also represents a higher genetic risk factor in the 
development of disorders of α-syn aggregation (Sardi, Cheng and Shihabuddin, 
2015). Patients with the GBA1 mutation associated with lysosomal trafficking defects 
and impaired calcium homeostasis are estimated to have an increased risk in the 
development of PD of up to 30% at 80 years of age, accounting for approximately 5-
10% of all PD patients (Schöndorf et al., 2014; Sardi, Cheng and Shihabuddin, 2015; 
Schapira, 2015; Wong and Krainc, 2016). 
1.2.4 The potential role of iron in Parkinson’s disease 
PD, AD, MSA, DLB, amyotrophic lateral sclerosis, Huntington's disease, PSP, and 
frontotemporal dementia are all neurodegenerative diseases where insoluble protein 
aggregates co-localise with iron (Arawaka et al., 1998; Dickson et al., 1999; Kwan et 
al., 2012; Chen et al., 2013; Jenkins et al., 2014; Lee et al., 2017; Sheelakumari et 
al., 2017). Iron accumulation has therefore been implicated as a common theme in 
neurodegeneration, given the pathologically distinct iron accumulation and clinically 
different disease presentation.   
The loss of pigmented neurons of the SNPc represents the major pathological 
feature of PD. In addition to dopaminergic cell loss from the SNPc, surviving neurons 
contain abnormally aggregated forms of α-syn and elevated iron concentrations 
(Dexter et al., 1987; Gorell et al., 1995). An additional risk factor for the development 
of PD is the association of aging and increased iron levels across brain regions 
(Zecca et al., 2001; Acosta-cabronero et al., 2016; Wang et al., 2016). Deposits of 
iron have been observed in animal models, post-mortem brains of patients and in 
vivo using iron-sensitive MRI imaging of PD patients (He et al., 1996; Luigi Zecca et 




Under normal physiological conditions, the redox recycling activity of iron between 
ferrous (Fe2+) and ferric (Fe3+) makes this metal important in many reactions within 
the brain. However, when intracellular iron levels are dysregulated, this can lead to 
oxidative stress. Iron is essential in the synthesis and metabolism of 
neurotransmitters, for generating ATP by electron transport in mitochondria and the 
synthesis of lipid components for myelination. Specifically for dopaminergic neurons, 
iron plays an important role as a co-factor for the enzyme tyrosine hydroxylase (TH) 
(Goodwill, Sabatier and Stevens, 1998; L. Zecca et al., 2004; Richardson et al., 
2010). TH catalyses the reaction of L-tyrosine to L-DOPA, a fundamental step in the 
production of dopamine (Molinoff and Axelrod, 1971). Dopamine is packaged in 
vesicles at acidic pH to prevent autoxidation into harmful reactive quinone species 
(dopamine-o-quinone), hydrogen peroxide and superoxide (Graham, 1978; Zucca et 
al., 2015; Umek et al., 2018). Within certain environments, including in the presence 
of divalent metals, dopamine can be enzymatically deaminated by monoamine 
oxidase (MAO) to create dihyroxyphenylacetic acid (DOPAC) and H2O2 along with 
hydroxyl radicals, contributing to an oxidative stress environment (Maker et al., 1981; 
Linert et al., 1996). Iron accumulation has been shown to be protective by 
detoxification of excess dopamine (o-quinones and aminochromes) into melanin that 
precedes neuromelanin biosynthesis (Izumi et al., 2005). 
The catecholaminergic neurons that comprise the SNPc have a pronounced 
blackened appearance due to the presence of neuromelanin, a cytoplasmic insoluble 
pigment comprised of dopamine, dopamine metabolites, proteins, lipids and metal 
ions (iron, copper, and zinc) (Wakamatsu et al., 2003; Izumi et al., 2005). Iron is the 
most abundant metal ion stored within the neuromelanin (at ~ 10 μg/mg of 
neuromelanin pigment) in dopamine neurons of the SNPc, the sequestration of iron, 
therefore, prevents Fenton’s reaction and the subsequent formation of ROS (Zecca 
et al., 2001; L. Zecca et al., 2004). Neuromelanin can bind iron with either high or 
low affinity (Bmax 3.27 and 16.62 nmol/mg melanin, respectively), and in cases of iron 
overload, high-affinity sites within neuromelanin become saturated (Double et al., 
2003). When saturated, iron binds to low-affinity sites leading to reactive/toxic forms 
becoming available. This process is known to occur in PD leading to oxidative stress 
within the neurons affected (Faucheux et al., 2003; Zecca, Casella, et al., 2008). 
Although neuromelanin is neuroprotective, the release of neuromelanin by dying 
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neurons induces neurodegeneration through activation of microglia in the CNS, as 
previously reported in PD patients. In addition, the MPTP-induced model of PD 
whereby extracellular melanin is situated close to activated microglia is associated 
with neurodegeneration (Langston et al., 1999; Zecca, Wilms, et al., 2008; Viceconte 
et al., 2015).  
The ROS environment of the SNPc due to high concentrations of iron and dopamine 
is therefore proposed as a crucial mediator in the pathogenesis of PD (Jenner et al., 
1992). Further to the increased levels of iron, decreased levels of GSH and lipid 
peroxidation have been demonstrated to affect the SNPc in patients (Dexter et al., 
1989; Sian et al., 1994; de Farias et al., 2016). A link between increased dietary 
(non-heme) iron has been shown to dramatically increase the risk of PD by ~30% 
(Logroscino et al., 2008). Mutations in genes relating to iron homeostasis and 
metabolism are also linked to PD, and other neurodegenerative disorders including  
AD (Rhodes and Ritz, 2013; Fan et al., 2018). For example, hereditary 
haematochromatosis, a genetic disorder defined by abnormal iron handling and 
excessive iron accumulation in systemic tissues has been linked to PD (Costello et 
al., 2004). Mutations in the PLA2G6 (PARK14) gene, which encodes a calcium-
dependent phospholipase A2, are associated with L-DOPA responsive 
dystonia/parkinsonism and also characterised by high levels of brain iron (Gregory et 
al., 2008; Ferese et al., 2018). Ferroptosis, an iron-dependent cell death pathway, 
has been linked to the mechanism of cell death in PD and is discussed further in 
Chapter 5 (Dixon et al., 2012; Do Van et al., 2016). 
1.3 α-Synuclein is associated with Parkinson's disease  
1.3.1 Structure and function of α-synuclein 
α-Syn is a 140-residue protein encoded by the SNCA (PARK1) gene located on 
chromosome 4 and has since garnered attention as the protein implicated in the 
pathogenesis of PD (Fig. 1.3) (Spillantini, Divane and Goedert, 1995). The NAC 
domain of α-syn was identified as a component of β-amyloid plaques in patients with 
AD and later as the major immunoreactive component in LBs and Lewy neurites 
(Ueda et al., 1993b; Spillantini et al., 1997; Takeda et al., 1998). Although there are 
several physiological roles designated to α-syn, the precise function of the protein 
remains poorly understood. A vast amount of experimental data, both from animal 
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and cell models, indicate α-syn has roles in several physiological processes 
including; regulation and trafficking of synaptic vesicles through lipid interactions 
(Cabin et al., 2002; Zaltieri et al., 2015); neuronal plasticity (Rasia et al., 2005; Liu et 
al., 2007; Burré et al., 2011; Cremades et al., 2012; Lashuel, Overk, Abid Oueslati, 
et al., 2013; Burré, Sharma and Südhof, 2014); neurotransmitter release (Burré et 
al., 2011); dopamine biosynthesis (Tavassoly et al., 2014); microtubule organisation 
(Cartelli et al., 2016); metal homeostasis (Tavassoly et al., 2014); mitochondrial 
function, and as a ferrireductase (Davies, Moualla and Brown, 2011).  
 
Figure 1.3. Structure of α-syn. α-syn is a 14kDa, 140-residue protein with three distinct regions; a highly 
conserved N-terminal, NAC region and an acidic C-terminal. The N-terminus has a series of imperfect KTKEGV 
repeat motifs involved in lipid binding and prone to forming amphipathic helixes (Davidson et al., 1998; Bussell 
and Eliezer, 2003). Missense mutations associated with familial PD are located in this region. The central (non-
amyloid-β component) NAC region confers β-sheet potential, and is prone to aggregation and misfolding 
(Giasson et al., 2001). The acidic C-terminal is largely unfolded and slightly negatively charged region that acts 
as both a chaperone for other proteins and inhibiting α-syn assembly by interfering with molecular interactions of 
the NAC region (Murray et al., 2003; Halliday and McCann, 2008).Phosphorylation of serine at position 129 is the 
most common posttranslational modification associated with α-syn, corresponding to approximately 90% of α-syn 
found in Lewy bodies (Walker et al., 2013).  Lipid-interactions of α-syn (bottom diagram, image credit: (Gallegos 
et al., 2015) recruits an α-helical conformation in the N-terminus in contrast to the unstructured nature of the C-
terminus (Ulmer and Bax, 2005; Plotegher et al., 2014). 
1.3.2 α-Syn as a functional tetramer 
There is controversy as to whether α-syn exists functionally as ‘natively unfolded’ 
monomer that acquires α-helical content following binding to lipid structures or 
whether the protein is present as a function tetramer in vivo (Davidson et al., 1998; 
Ulmer and Bax, 2005; Bartels, Choi and Selkoe, 2011). Principally, data from protein 
conformation studies uses the expression of high concentrations of protein either in 
vitro or in vivo and preparation via denaturing samples using heat and/or chemical 
denaturation, all which have been found to abolish potential tetrameric structure 
formation (Bartels, Choi and Selkoe, 2011; Pochapsky, 2015). The suggestion of a 
tetrameric structure of α-syn was initially suggested in a seminal study by Bartels 
and colleagues (Bartels, Choi and Selkoe, 2011). In vivo cross-linking experiments 
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revealed the presence of a tetrameric species of α-syn with a mass of ~55-60 kDa in 
erythrocytes, human cell lines (M17D, HeLa, HEK293, and COS-7), and mammalian 
brain tissue. Other investigations by two-dimensional gel analysis, scanning 
transmission electron microscopy (STEM) with particle analysis, and sedimentation 
equilibrium analytical ultracentrifugation (SE-AUC) also suggested a tetrameric 
conformation. The capture of α-syn images using STEM under non-denaturing 
conditions yielded a homogenous distribution of spherical particles measuring ~3.0-
3.5 nm in diameter, with a size distribution at ~55 kDa when analysed by unbiased 
automatic sampling. SE-AUC investigations, a technique used to establish the native 
state of proteins independent of their conformations, yielded an average molecular 
weight of 57.8 kDa. These investigations provide several independent lines of 
evidence to suggest the native structure of α-syn, at least in erythrocytes and the cell 
lines investigated, is a tetramer with a MW ~58 kDa (Bartels, Choi and Selkoe, 
2011). Interestingly, this tetramer formation resists aggregation into ThT-positive 
aggregates when compared to recombinant α-syn over a time course sufficient to 
induce fibril formation, suggesting therapeutic potential (Bartels, Choi and Selkoe, 
2011; Dettmer et al., 2015). A subsequent study characterised a soluble tetramer of 
α-syn recombinantly expressed in E.coli, with characteristics of WT α-syn derived 
from erythrocytes (Bartels, Choi and Selkoe, 2011; Wei Wang et al., 2011). In the 
latter study, tetrameric α-syn does not form pores in membranes, is not toxic when 
added to cells in culture, resists aggregation, increased cellular concentrations shift 
the cellular equilibrium towards monomer, and disease-associated mutants (A30P, 
A53T, and E46K) render the protein more disordered when compared to WT protein 
(W. Wang et al., 2011). The tetramer model for α-syn structure rationalises the 
localisation of mutations known to bring on early-onset PD, including A53T, A30P, 
and E46K mutations (Bartels, Choi and Selkoe, 2011; W. Wang et al., 2011; Dettmer 
et al., 2015). The location of the A53T, A30P, and E46K mutations in the N-terminal 
domain of α-syn result in the destabilisation of tetrameric structure resulting in a 
significantly decreased tetramer:monomer ratio in cells (between 10-40% depending 
on cell type). This finding strongly suggests destabilisation of a tetrameric structure 
facilitates subsequent pathological aggregation of monomer into disease-associated 
structures (Dettmer et al., 2015). 
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Follow-up studies disputing this finding, have again suggested the normal cellular 
structure of α-syn exists as an intrinsically disordered monomeric protein (Binolfi, 
Theillet and Selenko, 2012; Fauvet et al., 2012; Burré et al., 2013; Araki et al., 2016; 
Theillet et al., 2016). These studies provide several lines of evidence for the 
presence of a monomeric structure of α-syn in living cells and when purified under 
non-denaturing conditions, again in various cell and tissue types including 
erythrocytes, mammalian cells, and E. coli (Fauvet et al., 2012; Theillet et al., 2016). 
Using in-cell nuclear magnetic resonance (NMR) imaging, α-syn was shown to 
maintain a disordered conformation in the cell, which upon molecular crowding, 
became slightly more compact than in free solution (Theillet et al., 2016). The 
presence of a soluble tetramer in the study by Bartels et al. has since been 
suggested to be dependent on the oxidative environment of the erythrocyte in which 
much of the biochemical characterisation was undertaken (Killinger et al., 2019). α-
Syn is highly expressed in erythrocytes and haemoglobin in erythrocytes oxidatively 
catalyses the formation of intramolecular dityrosine bonds resulting in populations of 
dimers and tetramers of α-syn (Barbour et al., 2008; Elhadi et al., 2019). The latter of 
which is hypothesised to occur rapidly during purification of α-syn from erythrocytes 
(Killinger et al., 2019). In conjunction with the presence of α-syn bound to vesicles in 
erythrocytes, the purification of α-syn from erythrocytes may preferentially produce a 
tetrameric structure bound to vesicle membranes. Therefore, it is likely the 
aggregate-resistant tetramer described is stabilised via oxidative crosslinking due to 
the oxidative environment of erythrocytes (Killinger et al., 2019). This, however, does 
not suggest no tetrameric structure in vivo but instead that the assembly of a 
tetrameric structure is highly dependent on the cell type and biochemical factors 
during purification. For example, tetrameric populations are most prevalent have in 
human erythroid leukaemia cells and absent from gastrointestinal neuronal cells 
(Dettmer et al., 2013; Corbille, Neunlist and Derkinderen, 2016). 
1.3.3 The physiological role of α-syn 
α-, β-, and γ-synucleins are highly expressed throughout the brain, with the 
expression of α- and β-synuclein associated with the presynaptic terminal of neurons 
(Galvin et al., 2001). Neuronal expression of α-syn is heterogeneous throughout the 
CNS, with high expression of α-syn in the SNPc, caudate nucleus, putamen, and 
ventral pallidum nuclei (Galvin et al., 2001; Taguchi et al., 2016). These regions 
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closely follow vulnerable regions affected in PD (H. Braak et al., 2003; Hawkes and 
Braak, 2007). The location of α-syn within presynaptic terminals, its interaction with 
synaptic vesicles and vesicle-associated membrane protein 2 
(VAMP2/synaptobrevin-2), SNARE (soluble N-ethylmaleimide-sensitive-factor 
attachment protein receptor)-complex chaperoning activity, and high expression 
levels of the protein in areas requiring synaptic modifications (e.g. song-learning in 
the zebra finch) support a role for α-syn in neurotransmitter storage and release 
within the synapse (Clayton and George, 1999; Kahle et al., 2000; Murphy et al., 
2000; Burré et al., 2011). Mechanisms of dopamine compartmentalisation in the 
storage pool and readily releasable pool maintain an important role in 
neurotransmission. For exocytosis of synaptic vesicles, and release of dopamine to 
the synaptic cleft, SNARE proteins on the plasma membrane (syntaxin and 
synaptosome-associated protein 25) interact with SNARE proteins on synaptic 
vesicles (SVs; VAMP2) to allow fusion to the membrane following stimulation 
(Lautenschläger, Kaminski and Schierle, 2017). α-Syn can induce vesicle-vesicle 
interactions associated with SVs through its lipid-binding functionality and interaction 
with VAMP2. The amphipathic helix of monomeric α-syn acts as a curvature-sensing 
and stabilizing protein, able to insert into the lipid surface of membranes with 
negatively charged lipids, most notably of which is present in synaptic vesicles 
(Pranke et al., 2011; Westphal and Chandra, 2013). Cholesterol in the SV 
membrane promotes a double-anchor mechanism of SV clustering, wherein upon 
binding to cholesterol in SV membranes, α-syn undergoes a conformation change to 
expose the NAC region (Fig. 1.3) (Fusco et al., 2017a). This interaction promotes the 
clustering of SVs, through the interaction of bound α-syn and other SVs (Man et al., 
2020). The direct interaction of α-syn and VAMP2 on the surface of SVs, 
independent of the NAC region, maintains close contact of VAMP2 with t-SNAREs to 
promote SV clustering at the plasma membrane and neurotransmitter release 
(Haberman et al., 2012; Ninkina et al., 2012; Sun et al., 2019). There are several 
lines of evidence for a role of α-syn as a molecular chaperone in SNARE-complex 
activity. α-syn shares structural and functional homology with 14-3-3 and cysteine-
string protein α (CSPα) chaperone proteins (Ostrerova et al., 1999; Perez et al., 
2002; Bronk et al., 2012). Knockout of the cochaperone, CSPα, in a murine model 
results in lethal neurodegeneration, which is rescued upon expression of α-syn and 
associated with chaperoning assembly of SNARE-complexes (Burré et al., 2011; 
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Ninkina et al., 2012). Moreover, depletion of α-syn is associated with increased 14-3-
3 protein expression (Greten-Harrison et al., 2010).  
Synthesis of dopamine by the enzyme TH, the storage of dopamine in vesicles, and 
the subsequent release of dopamine as a neurotransmitter is critical to the function 
of dopaminergic neurons. α-syn can interact to modulate dopamine production 
through interaction with proteins involved in dopamine homeostasis. Firstly, α-syn 
can inhibit the production of dopamine through interaction with the enzyme TH 
(Perez et al., 2002). Under normal circumstances, 14-3-3 protein binds phospho-TH 
to enhance the activity of TH, thus promoting conversion of L-tyrosine to L-DOPA by 
TH. L-DOPA is subsequently converted to dopamine via aromatic L-amino acid 
decarboxylase. On the other hand, α-syn interacts with TH to inhibit its activity by 
reducing TH phosphorylation (Perez et al., 2002). In addition, as a protein involved in 
iron homeostasis, α-syn can regulate the availability of iron required for TH activity 
(Wu et al., 2011). Secondly, α-syn interacts with VMAT2 and DAT to modulate the 
storage and reuptake of DA following release to the synaptic cleft (Yavich, Tanila 
and Vepsa, 2004). Overexpression of α-syn disrupts storage of dopamine through 
the inhibition of VMAT2 activity, resulting in increased cytosolic dopamine levels and 
significantly enhanced presence of intracellular reactive oxygen species (Guo et al., 
2008).  
Interaction between α-syn and metals have been investigated extensively and have 
allowed us to elucidate a function for α-syn in the homeostasis of metals. As 
discussed in Section 1.2.4, dyshomeostasis of metals and toxic accumulation of 
metals, specifically iron, is associated with the pathogenesis of PD and other 
neurodegenerative disorders (Li et al., 2017). Iron regulation is tightly controlled by 
the binding of iron regulatory protein (IRP) to iron-responsive elements (IREs) in the 
mRNA of proteins responsible for iron import, export, and storage of iron (Fig.1.4) 
(Sipe, Lee and Beutler, 2002; Rouault, 2013). For example, in physiological 
conditions of low levels of cellular iron, binding of IRP to the IRE in 5’ untranslated 
region (UTR) of the mRNA of the iron storage protein ferritin, prevents translation of 
the protein. Reduced levels of ferritin subsequently increase the concentration of 
bioavailable Fe2+ in the LIP by preventing the storage of iron. In situations of 
abundant cellular iron, IRPs bind cellular iron preventing binding to the IRE in the 
mRNA of ferritin, resulting in the translation of ferritin. To store iron, ferritin oxidises 
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Fe2+ from the LIP to Fe3+ (Muhoberac and Vidal, 2019). With a predicted iron-
response-element (IRE) in a 46 nucleotide stretch within the 5’ UTR region of α-syn, 
similar to IREs of ferritin and other proteins in iron regulation, α-syn is hypothesised 
to function in the regulation of cellular iron (Friedlich, Tanzi and Rogers, 2007). The 
receptor-mediated uptake of TfR via clathrin-coated endocytosis is hypothesised to 
involve interaction between α-syn and dynamin, directly influencing Fe3+ import by 
the cell. In support of this, ablation of α-syn expression in a transgenic murine model 
alters the cellular iron levels by altering the expression of ferritin and transferrin (TfR) 
(Baksi, Tripathi and Singh, 2016). In dopaminergic neurons, regulation of cellular 
levels of Fe2+ and Fe3+ is important to reduce the formation of ROS via Fenton’s 
chemistry, whilst enabling utilisation of Fe2+ for dopamine biosynthesis (cofactor for 
TH) and other cellular processes. Indeed, ratios of Fe2+ and Fe3+ are altered in PD 
patient brains, highlighting the importance of iron regulation to the survival of 
dopaminergic neurons. α-syn, as a metal-binding protein, acts as a cellular 
ferrireductase to maintain levels of Fe2+ in cells in the presence of copper (II) ions 
(Davies, Moualla and Brown, 2011).  
 
Figure 1.4. Schematic of brain iron homeostasis. Binding of Fe3+-loaded transferrin (Tf) to transferrin 
receptor 1 (TfR1) results in the internalisation of this complex to the endosomal component whereby Fe3+ is 
reduced to Fe2+ by acidification to aid in release of Fe3+ from bound transferrin and the actions of the 
ferrireductase Steap3 (Ohgami et al., 2005). Fe2+ is transported out of the endosome to the cytosol via 
divalent metal transporter 1 (DMT1). Fe2+ is associated with a transitionary pool of chelatable of redox-
active iron known as the labile iron pool (LIP) (Kakhlon and Cabantchik, 2002). Iron in this pool is available 
for utilisation in various cellular processes, exported out of the cell by ferroportin (FpN), or stored in a 
complex with ferritin or neuromelanin (in SNPc neurons). Reprinted by permission from Elsevier: License 
Number 4816461364330. Elsevier, Free Radical Biology and Medicine, Targeting dysregulation of brain 
iron homeostasis in Parkinson's disease by iron chelators, Orly Weinreb,Silvia Mandel,Moussa B.H. 




The ferrireductase activity of α-syn was initially determined using recombinant 
human α-syn generated from E. coli with a Vmax of 2.72, 2.52, 2.37, and 2.62 
nmol/min/mg for wildtype, E46K, A30P, and A53T, respectively. Overexpression of 
α-syn in a human neural cell line resulted in both the increase in cellular Fe2+ and 
increased ferrireductase activity when compared to cell lines without this genetic 
modification (Davies, Moualla and Brown, 2011). More recently, in vivo 
ferrireductase activity of α-syn has been determined in an AAV6-α-syn-
overexpressing rat model and reduced levels of α-syn correlate with reduced 
ferrireductase activity in post-mortem PD striatum (McDowall et al., 2017). The data 
generated by McDowall et al. (2017) highlight the active form of α-syn with 
ferrireductase activity as a tetramer associated with membranes in SH-SY5Y cells 
overexpressing α-syn (Mcdowall et al., 2017). In disease, the loss of function of α-
syn as a ferrireductase may contribute to an accumulation of Fe2+ with pathological 
consequences associated with ROS due to Fenton chemistry and initiation of cell 
loss in relation to ferroptosis (Do Van et al., 2016).  
1.3.4 Post-translational modifications of α-synuclein 
α-Syn undergoes several post-translational modifications (PTMs) including 
acetylation, phosphorylation, oxidation, nitration, ubiquitination and truncation that 
modulates the structure and function of the protein (Fig. 1.4). In LBs, α-syn has been 
reported to contain the PTMs of phosphorylation (at S129; referred to as p-α-syn), 
ubiquitination (K12, 21 and 23), truncation (N115, D122, Y133 and D135) and 
ubiquitous N-terminal acetylation (Anderson et al., 2006). This pattern of 
phosphorylation, truncation, ubiquitination and acetylation is also observed in the 
detergent-insoluble fraction of patients with familial PD (A53T mutation) and MSA, 
suggesting a common pathogenic pathway in synucleinopathies (Anderson et al., 
2006). 
Several phosphorylation sites in α-syn are known and are located in the C-terminal 
domain on the amino acids tyrosine, threonine or serine (Y125, S129, Y133 and 
Y136) (Oueslati, Fournier and Lashuel, 2010). Ninety percent of α-syn within 
deposits is phosphorylated at S129 in PD patients compared to 4% in controls, 
suggesting accumulation of p-α-syn over a certain threshold leads to the formation of 




Figure 1.5. Major post-translational modifications on α-syn. Image adapted from (Zhang, Li and Li, 2019). 
al., 2007). Additionally, the presence of this PTM in the soluble fractions of normal 
and diseased brains highlights a role of α-syn S129 in normal cellular metabolism 
(Anderson et al., 2006; Muntané, Ferrer and Martinez-Vicente, 2012). 
Phosphorylation at S129 modulates the capacity of α-syn to bind biological 
membranes, culminating in an inhibitory effect, whereby a decrease in the affinity of 
α-syn with phospholipids is observed (Visanji et al., 2011; Nübling et al., 2014). 
Overexpression of the main kinase responsible for phosphorylation of α-syn (polo-
like kinase 2; PLK2) enhances the turnover of α-syn and the significantly shorter half-
life of p-α-syn (54.9 ± 6.4 min compared to >240 min in non-phosphorylated αsyn) 
demonstrates p-α-syn is selectively targeted for degradation by the ubiquitin-
proteasome and autophagy-lysosomal pathways (Chau et al., 2009; Machiya et al., 
2010; Oueslati et al., 2013). Although 90% of α-syn is phosphorylated at this position 
in LBs, phosphorylation at S129 is not required for the development of LB-like 
aggregates (Anderson et al., 2006; Luk et al., 2009; Arawaka et al., 2017). Using an 
S129 mutant, S129A, LB-like aggregates developed in the absence of 
phosphorylation, suggesting phosphorylation occurs after LB formation (Luk et al., 
2009; Volpicelli-Daley et al., 2011). In support of this, several phosphorylation 
kinases (CK2, GRK5 and LRRK2) located in association with α-syn in LBs are able 
to efficiently phosphorylate aggregated forms of α-syn (Arawaka, 2006; Ryu et al., 
2008; Qing et al., 2009; Waxman and Giasson, 2011). In patients with PD, 
accumulation of insoluble p-α-syn is thought to be a late-stage event disease due to 
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the positive correlation of p-α-syn and severity of disease (Beach et al., 2009; Walker 
et al., 2013).  
More than 90% of eukaryotic proteins are acetylated (Arnesen et al., 2009). 
Acetylation represents the major PTM of α-syn, with 15 putative acetylation sites 
located in the N-terminal region of the protein (Fig. 1.4) (Anderson et al., 2006; 
Fauvet et al., 2012; de Oliveira et al., 2017). α-Syn is constitutively N-terminally 
acetylated in its normal physiological state, specifically on lysine residues 6, 34, 45 
and 96 (Bartels et al., 2010). N-terminal acetylation of α-syn is important for the 
interaction of α-syn with lipids by increasing α-helical content and preventing the 
ability of the protein to aggregate by destabilising the oligomerisation state of α-syn, 
thus protecting against toxicity (Bartels et al., 2014; Bu et al., 2017).  
Ubiquitin, a 76-amino acid protein, is responsible for marking proteins for 
degradation and subsequent targeting of proteins to large protease complexes 
including the 26S proteasome (Swatek and Komander, 2016). Ubiquitin is 
conjugated to proteins through the action of three enzymes: ubiquitin-activating 
enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin-ligating enzyme (E3) 
(Schulman and Harper, 2009; Ye and Rape, 2009; Callis, 2014). In addition to a role 
in degradation of substrates, other regulatory functions of ubiquitin have been 
described including the regulation of protein activity and control of cellular 
localisation of proteins (Ronai, 2016). In the normal function of α-syn, it is postulated 
that ubiquitination controls vesicle fusion in presynaptic terminals (Goedert et al., 
2013). The association of PD-linked mutations to ubiquitin signalling (e.g. PARKIN, 
PINK1) and the presence of mono-, di- and tri-ubiquitinated α-syn in LBs suggest the 
involvement of α-syn ubiquitination in disease (Sampathu et al., 2003; Walden and 
Muqit, 2017). Ubiquitination of α-syn at K6, K12 and K21 moderately inhibit the 
formation of fibrils, whereas residues K32, K34 and K96 showed a strong inhibitory 
effect (Rott et al., 2008; Hejjaoui et al., 2011; Meier et al., 2012). In contrast, 
residues at K10 and K23 can readily form fibrils (Meier et al., 2012).   
14 
 
1.3.5 Normal degradation of α-synuclein 
 
Figure 1.6. Schematic representation of the ubiquitin-proteasome pathway. The ubiquitin-activating enzyme (E1) 
activates ubiquitin (Ub) prior to binding of Ub to E1. Ub is transferred from E1 to a ubiquitin-conjugating enzyme 
(E2). A ubiquitin ligase (E3) recruits Ub-E2 and transfers Ub to the substrate. Successive rounds of Ub 
conjugation results in the formation of lysine 48-linked polyubiquitin chains on substrates. Following substrate 
recognition by the 19S regulatory subunit of the 26S proteasome, deubiquitylating enzymes (DUBs) remove 
ubiquitin molecules from substrates before degradation (Clague, Coulson and Urbé, 2012). Targeted degradation 
by β1, β2, and β5 proteolytic subunits of the 20S core particle degrades the substrate into corresponding short 
peptide sequences. Peptides are further degraded by aminopeptidases (APPs) into amino acids (Rousseau and 
Bertolotti, 2018). Free Ub molecules generated by DUBs are recycled for further use in targeting substrates for 
degradation. Image adapted from (Eldridge and Brien, 2010). 
In the cell, two main systems are responsible for the degradation of intracellular 
proteins; the ubiquitin-proteasome system (UPS) and autophagy-lysosome system 
(ALS). The UPS targets the clearance of short-lived, damaged, and misfolded 
proteins in the cell via ubiquitylation and subsequent proteasomal degradation to 
ensure turnover of proteins to maintain amino acid homeostasis (Fig. 1.6) 
(Suraweera et al., 2012; Rousseau and Bertolotti, 2018). Proteins tagged with 
ubiquitin, usually as 48-linked polyubiquitin chains attached to lysine residues of 
proteins, and presence of an unstructured region in proteins serves as a signal for 
degradation (Prakash et al., 2004; Finley, 2012; Yu and Matouschek, 2017). 
Typically, longer proteins (>150 residues) require the addition of a polyubiquitin tag 
to promote efficient proteolysis by the proteasome whereas proteins with <150 
residues can be degraded following monoubiquitylation (Shabek et al., 2012). Once 
ubiquitylated, substrates are targeted to the proteasome (Ronai, 2016). The 26S 
proteasome is a multi-subunit enzyme consisting of both a regulatory (19S) and core 
(20S) unit (Yoshimura et al., 1993; Collins and Goldberg, 2017). The 19S subunit 
has crucial mechanisms to control function of the proteasome through substrate 
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recognition, deubiquitination of polyubiquitin chains, and unfolding of protein 
substrates before degradation of proteins in the narrow proteolytic chamber of the 
20S core unit (Smith et al., 2005; Lander et al., 2012). The 20S core unit comprises 
both α- and β-subunits, forming four stacked heteroheptameric rings (Unno et al., 
2002; Kunjappu, Hochstrasser and Wolf, 2014). α- Subunits function as a gate 
mechanism to prevent unwanted access to the proteolytic chamber (Latham, Sekhar 
and Kay, 2014). β-Subunits function as the catalytic mechanism for the degradation 
of substrates. Of the seven β-subunits, only the β1, β2, and β5 units have proteolytic 
activity, known as caspase-like, trypsin-like, and chymotrypsin-like activity, 
respectively (Groll et al., 1999; Kunjappu, Hochstrasser and Wolf, 2014). The 
resulting peptides leave the proteasome and are further broken down to their 
constituent amino acids by the action of aminopeptidases (Saric, Graef and 
Goldberg, 2004).     
Autophagy, meaning ‘self-eating’ in Greek, targets longer-lived macromolecules and 
dysfunctional organelles to the lysosome for clearance (Fig. 1.7) (Galluzzi et al., 
2018). The ALS serves two major functions with the cell: removal of deleterious 
intracellular components, and recycling of macromolecules to ensure proteome 
renewal (Lawrence and Zoncu, 2019). In normal cellular conditions, autophagy 
occurs at constitutively low levels but can be altered in conditions of cellular stress. 
Cellular stress, including presence of protein aggregates and cellular ROS, causes 
activation of autophagy processes (He et al., 2017). The ALS consists of three 
subtypes, differing on how targets are delivered to the lysosome; chaperone-
mediated autophagy (CMA), microautophagy, and macroautophagy (Kaushik and 
Cuervo, 2018). For CMA, proteins in the cytosol are targeted for degradation to the 
lysosome through the interactions of the chaperone protein HSC70, LAMP2A, and 
substrates targeted for degradation (Cuervo and Dice, 1996; Agarraberes and Dice, 
2001; Schneider, Suh and Cuervo, 2014). The chaperone protein HSC70 recognises 
a KFERQ motif on targeted substrates and delivers it to the lysosomal surface 
protein LAMP2A (Bandyopadhyay et al., 2008; Kirchner et al., 2019). Interaction of 
HSC70 and the substrate with the cytosolic region of LAMP2A results in the 
formation of a LAMP2A-transmembrane pore, allowing for the translocation of 
substrates to the lysosomal lumen (Cuervo and Dice, 1996; Rout et al., 2014). In 
microautophagy, lysosomes directly engulf cytosolic material through membrane 
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invagination to the lysosomal lumen (Sattler and Mayer, 2000). In a similar 
mechanism of substrate translocation in CMA, a KFERQ motif on a cytosolic protein 
substrate is recognised and delivered to the lysosome via interaction with HSC70 
(Tekirdag and Cuervo, 2018). In contrast to CMA, microautophagy does require 
interaction with LAMP2A on the lysosomal membrane to introduce the substrate to 
the lysosomal lumen but instead involves lysosomal membrane invagination 
(Kaushik and Cuervo, 2018). Macroautophagy requires the fusion of another 
organelle, the autophagosome, with the lysosome in order to degrade target 
substrates. Briefly, formation of a double-membraned organelle, the 
autophagosome, sequesters proteins for degradation before fusion with lysosomes 
(Nakamura and Yoshimori, 2017). For all types of autophagy, once in the lysosomal 
lumen, substrates are degraded by the actions of hydrolases capable of degrading 
proteins, DNA, RNA, polysaccharides, and lipids (Yim and Mizushima, 2020).  
 
Figure 1.7. Autophagic pathways. Three types of autophagy have been identified as microautophagy, 
chaperone-mediated autophagy (CMA) and macroautophagy (Li, Li and Boa, 2012; Cuervo and Wong, 2013; 
Feng et al., 2013). Autophagy operates under tight transcriptional and post-transcriptional regulation and typically 
mediates cryoprotective effects (Wani et al., 2015). Five key stages of macroautophagy are: (1) phagophore 
formation or nucleation; (2) Atg5-Atg12 conjugation and interaction with Atg16L and multimerisation at the 
phagophore; (3) LC3 processing and insertion into the extending phagophore membrane; (4) capture of random 
or selective targets for degradation; and (5) fusion of the autophagosome with the lysosome, resulting in 
proteolytic degradation by lysosomal proteases (Glick, Barth and Macleod, 2010; Gong et al., 2013). For 
microautophagy, substrates are targeted to the lysosome via KFERQ and HSC70. At the lysosome, invagination 
of the lysosomal membrane results in the delivery of substrates to the lysosomal lumen. In CMA, the KFERQ 
motif on targets for degradation are recognised by the chaperone protein HSC70 and delivered to the lysosomal 
membrane. At the lysosomal membrane, interaction of cytosolic substrates and HSC70 with the lysosomal 
surface protein LAMP2A results in the formation of a transmembrane pore in the lysosomal membrane, capable 
of translocating substrates to the lysosomal lumen. In the lumen, hydrolase enzymes degrade substrates (Yim 
and Mizushima, 2020). Reprinted by permission from Springer Nature: License Number 4658831389575, 
Springer Nature, Nature Reviews Molecular Cell Biology, The coming of age of chaperone-mediated autophagy, 
Susmita Kaushik et al. Apr 6, 2018 (Kaushik and Cuervo, 2018). 
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Both the ALS and the UPS are involved in the normal degradation and clearance of 
α-syn (Webb et al., 2003). Initial studies suggested that α-syn is principally degraded 
by the proteasome. In one of the first studies of proteasomal inhibition, using the 
chemicals n-acetyl-leu-leu-norleucinal, lactacystin, or MG132, the formation of α-syn-
positive inclusions were seen in cultured neurons suggesting degradation of the 
protein occurs via a proteasome-dependent mechanism (Bennett et al., 1999; 
Mclean, Kawamata and Hyman, 2001). Later studies also indicated a role for the 
proteasome in α-syn degradation, including in a murine model of PD where nigral 
proteasome inhibition led to increased levels of p-α-syn (at S129) and motor deficits 
(Webb et al., 2003; Emmanouilidou, Stefanis and Vekrellis, 2010; Ebrahimi-fakhari et 
al., 2011; Bentea et al., 2015). However, not all studies demonstrated a similar 
accumulation of α-syn following proteasomal inhibition (Martín-Clemente et al., 2004; 
Emmanouilidou, Stefanis and Vekrellis, 2010). Using both murine and cell models, 
Martίn-Clemente and colleagues (2004) suggest overexpression of α-syn was not 
associated with altered proteasome function. The differences in these studies have 
been suggested to involve experimental differences in the presence or absence of 
epitope tags, stable or transient expression of α-syn, and cell-specific effects 
(Emmanouilidou, Stefanis and Vekrellis, 2010; Stefanis et al., 2019). These studies 
did not characterise the species of α-syn degraded, however, it was determined an 
intermediate soluble oligomeric species to be selectively targeted to and degraded 
by the 26S proteasome (Emmanouilidou, Stefanis and Vekrellis, 2010). Instead, 
lysosomal inhibition led to the increase of all species of α-syn examined, suggesting 
a role for ALS in the normal degradation of α-syn species (Emmanouilidou, Stefanis 
and Vekrellis, 2010; Batelli et al., 2011).  
For ALS degradation of α-syn, CMA and macroautophagy have been suggested as 
the autophagic pathways responsible for degradation of α-syn (Paxinou et al., 2001a; 
Cuervo et al., 2004; Vogiatzi et al., 2008; Stefanis et al., 2019). α-Syn contains the 
KFERQ sequence required for CMA degradation systems and overexpression of WT 
α-syn in murine models results in the upregulation of both LAMP2A and HSC70 
critical to the function of the CMA pathway (Mak et al., 2010; Kirchner et al., 2019). A 
more complex picture of α-syn degradation pathways emerge given how upon 
inhibition of one proteolytic system, the other can be activated to promote 
degradation. For example, in PC12 cells overexpressing A53T mutant α-syn, the 
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addition of a proteasomal inhibitor MG132 is sufficient to induce increased numbers 
of autophagosomes associated with macroautophagy, highlighting the activation of 
ALP to promote clearance of α-syn (Lan et al., 2015).  
1.3.6 Aggregation of α-synuclein 
Monomeric α-syn exists as a natively unstructured protein at physiological pH due to 
its low intrinsic hydrophobicity and high net charge (Eliezer et al., 2001; Fauvet et al., 
2012; Theillet et al., 2016). α-Syn undergoes aggregation into cross-β-sheet rich 
amyloid fibrils akin to filaments found in LBs (Fig. 1.5) (Uversky et al., 2002; Fauvet 
et al., 2012). In vitro, α-syn aggregation follows a nucleation-dependent sigmoidal 
growth curve as measured by Thioflavin T (ThT) kinetic assays. Monitoring the 
aggregation kinetics by fluorescence demonstrates sigmoidal growth associated with 
three distinct phases: lag phase, the signal remains constant due to lack of fibrillar 
species and lack of nucleation centre for the development of fibrils; elongation 
phase, ThT fluorescence rapidly increases as monomers aggregate to form fibrillar 
species; stationary phase, ThT fluorescence reaches its maximum intensity as fibril 
structures formed remain in thermodynamic equilibrium with soluble proteins (Wood 
et al., 1999; Wördehoff and Hoyer, 2018). Various factors contribute to the increased 
propensity for α-syn aggregation including temperature, lowering pH, ligand binding, 
presence of familial α-syn mutations and metals such as iron and copper (Wood et 
al., 1999; Uversky, Li and Fink, 2001; Winner et al., 2011; Buell et al., 2014; Xiao et 
al., 2018). Oligomers populated during the lag phase of fibril formation are thought to 
be a key pathological species implicated in the toxicity in PD and other 
neurodegenerative diseases such as AD and may help explain the discrepancy with 




Figure 1.7. Aggregation kinetics of amyloid. (A) Simplified diagram highlighting primary nucleation events in α-
syn fibrillogenesis. Several species populate the pathway to fibril formation including dimers, soluble oligomers, 
β-sheet-rich intermediates, small fibrils in addition to monomer, oligomers and larger fibrils. (B) Representative 
ThT fluorescence aggregation kinetics of fibril formation over time and the species that occupy these regions. 
Monomeric α-syn populates the lag phase (nucleation phase) which is characterised by low ThT fluorescence. In 
the elongation phase (fibril growth phase), oligomers are formed and ThT fluorescence increases. ThT 
fluorescence intensity increases upon binding of ThT to fibrillar species formed in the stationary phase. Figure 
adapted from (Ghosh et al., 2017). 
In vitro, under physiological conditions, α-syn assembles into fibrillar structures akin 
to the insoluble, fibrillar structure found within LBs through a series of intermediate 
species, known as oligomers and protofibrils (Brown et al., 2018). The term 
'oligomer' does not correspond specifically to a particular multimeric species of α-syn 
but designates a multimer that has not acquired fibrillar structure (Danzer et al., 
2007). 'On-pathway' soluble oligomers precede the formation of insoluble fibrils 
through a series of oligomeric and protofibrillar structures (Brown et al., 2018). 'Off-
pathway' oligomers are multimeric α-syn species arrested in an oligomeric structure 
and do not form fibrils (Winner et al., 2011; Fagerqvist et al., 2013). Toxicity of α-syn 
has been designated to both 'on-pathway' and 'off-pathway' oligomers by various 
mechanisms of action. Despite strong evidence that α-syn oligomers are the toxic 
species associated with PD, the heterogeneity of oligomer preparations and the 
ability of fibrils and oligomer to aggregate/disaggregate prevents a definitive 
mechanism of toxicity in disease (Cremades et al., 2012). 
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Oligomers of α-syn can be produced through the interaction of various ligands 
present in neurons of the SNPc including dopamine, lipids, iron, copper and 
hydrogen peroxide (Ostrerova-Golts et al., 2000; Cappai et al., 2005; Smith et al., 
2008; Xu et al., 2015; Mason et al., 2016; Han, Choi and Kim, 2018). The interaction 
of α-syn with metal ions (e.g. iron) leads to a conformational change resulting in 
abnormal protein folding (Uversky, Li and Fink, 2001). Recombinant protein studies 
have identified specific metal-binding sites in the monomeric α-syn sequence that 
induce the formation of oligomers (PAIK et al., 1999; Binolfi et al., 2006a, 2012). Fe3+ 
has a higher affinity for α-syn binding at D121, N122 and E123 (1.2 × 1013 M−1) 
compared to Fe2+ (5.8 × 103 M−1) (Binolfi et al., 2006a). Phosphorylation at S129 or 
Y125 increases the binding affinity of α-syn for Fe2+ at residues 107-140 (Lu et al., 
2011). Binding of Fe3+ accelerates the aggregation of both WT and mutant and can 
lead to the formation of stable oligomers (in lipid membranes) (Bharathi, Indi and 
Rao, 2007; Schmidt et al., 2012).  
The exact nature of a pathological α-syn species capable of propagating throughout 
brain regions in vivo is unknown. Oligomers and fibrils can be produced in vitro 
through a variety of different methods and are likely to exert different biological 
functions. Oligomeric species can be produced by various protocols that differ in 
morphologies, including spherical, chain-like and annular oligomers. For example, 
incubation of monomeric protein for a shorter time period and lower temperature 
than fibrils followed by centrifugation has been shown to produce a species of 
annular oligomer capable of cell-to-cell transmission (Danzer et al., 2007; Illes-Toth 
et al., 2015). Importantly, not all oligomeric species are capable of seeding (Danzer 
et al., 2007; Fagerqvist et al., 2013). Danzer et al. (2007) initially described protocols 
that produce two distinct types of oligomers: a seeding type (Type B and Type C) 
and a pore-forming membrane capable of inducing neuronal cell death (Type A). 
Additionally, it is difficult to study the conformations of α-syn that relate to spreading 
of pathology due to the inability to experimentally reproduce protocols in which cells 
only form one type of oligomeric species, as highlighted by the identification of 
varying proportions of multimers in experimental models (Dettmer et al., 2013; 
Corbille, Neunlist and Derkinderen, 2016). This experimental caveat has prevented 
the identification of oligomeric conformations responsible for cell-to-cell transmission 
in a physiological conformation (Grozdanov and Danzer, 2018).  
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1.4 Cellular toxicity associated with α-synuclein 
Numerous studies have investigated the cellular toxicity associated with α-syn and 
have highlighted both gain-of-function and loss-of-function mechanisms in which α-
syn modulates toxicity (Fig. 1.8). If the normal conformation of α-syn exists as an 
aggregation-resistant tetramer, the loss of this structure would result in the loss of 
ferrireductase activity within the cell. The loss of ferrireductase activity in the cell 
would result in dyshomeostasis of iron (Fe3+/Fe2+) and accumulation of the ROS-
associated Fe2+. In this sense toxicity would be secondary to the loss of α-syn 
function, with ROS-modification of cellular components and subsequent initiation of 
cell death pathways attributed to excess Fe2+ (McDowall et al., 2017; Sian and Peter, 
2020). In a gain-of-function mechanism, α-syn can gain a toxic conformation capable 
of interacting with various cellular components resulting in cellular dysfunction (Sian 
and Peter, 2020). Several in vitro and in vivo studies have implicated α-syn 
aggregation, principally the generation of prefibrillar oligomeric species, as the toxic 
species responsible for neurodegeneration in PD (Kahle et al., 2000; Danzer et al., 
2007; Outeiro et al., 2008; Karpinar et al., 2009; Choi et al., 2013, 2015). The 
intracellular and extracellular neurotoxic effects of oligomers have been described as 
toxic consequences of the interaction between α-syn oligomers and cells both in vitro 
and in vivo. During the course of fibril formation, α-syn oligomers have been shown 
to have a high affinity for binding lipids (Smith et al., 2008). The highly lipophilic 
oligomers promote strong membrane interactions and are able to insert into the 
bilayer due to the presence of an oligomeric core rich in β-sheet structures (Fusco et 
al., 2017b). Binding of α-syn oligomers to cellular membranes has been shown to 
disrupt cellular membrane integrity resulting in calcium influx and subsequent cell 
death (Volles et al., 2001; Danzer et al., 2007; Tsigelny et al., 2012; Illes-Toth et al., 
2015). The interaction of α-syn oligomers with mitochondrial membranes leads to 
fragmentation of mitochondria and complex I impairments, leading to an 
accumulation of cellular ROS and mitochondrial l defects resulting in cell death 
(Ludtmann et al., 2018). Distinguishing the mechanism of α-syn toxicity is difficult, 
given the heterogeneity of α-syn aggregation products and the likely interaction of 
cellular pathways that mediate stress responses and subsequent cell death. Some of 
the mechanisms in which aggregated species of α-syn interacts with cellular 




Figure 1.8. Pathways implicated in α-syn-induced cellular toxicity. α-Syn interacts with various cellular pathways. 
In disease, α-syn interacts with these pathways to induce cellular dysfunction and cellular toxicity. These 
interactions result in organelle dysfunction (A), defects in inter-organelle contacts (B), and dysfunctional 
organelle dynamics (C) which contribute to cellular dysfunction and subsequent cell death. Reprinted by 
permission from Elsevier: License Number 4820860567834. Springer Nature, Nature Medicine, α-synuclein 
toxicity in neurodegeneration: mechanism and therapeutic strategies, Yvette C Wong et al. Feb. 7, 2017 (Wong 
and Krainc, 2017). 
1.4.1 Pore-forming and calcium influx 
One of the most studied cytotoxic effects of α-syn-mediated toxicity is the interaction 
of α-syn species with cellular membranes. Formation of pores in biological 
membranes, produced as a consequence of α-syn lipid interactions is consistent with 
the diameter of annular and tubular protofibrils (Lashuel et al., 2002), leading to 
membrane perturbation that results in calcium (Ca2+) influx and subsequent cell 
death (Furukawa et al., 2006; Danzer et al., 2007; Gallegos et al., 2015; Illes-Toth et 
al., 2015; Angelova et al., 2016). The N-terminal region of the protein is important for 
promoting strong membrane interactions and thus subsequent cellular toxicity 
(Bartels et al., 2010; Fusco et al., 2017a). Ellipsometry analysis of fragmented fibril 
structures on natively-derived SH-SY5Y cell membranes demonstrates increased 
membrane disruption, highlighting a toxic gain-of-function mechanism, in contrast to 
fibrillar structures found in amyloid plaques that exert minimal biological activity 
(Smith et al., 2015). Continuous Ca2+ influx in SNPc neurons is important to 
modulate the physiological release of dopamine, therefore the pace-making activity 
of SNPc neurons is finally modulated by Ca2+(Dryanovski et al., 2013). Alterations in 
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Ca+ signalling by α-syn by either interfering with Ca2+ channels and/or altering of 
Ca2+ influx/efflux generate metabolic stress and mitochondrial damage (Ronzitti et 
al., 2014; Guzman et al., 2018).  
1.4.2 Mitochondrial dysfunction 
Many genes associated with the onset of familial forms of PD converge on 
mitochondrial function (e.g. DJ-1, PINK1 etc.), thereby highlighting the crucial role of 
the organelle in the pathogenesis of PD (Cieri, Brini and Calì, 2017). The 
endogenous expression of α-syn has been reported to be required for the normal 
activity of mitochondria given the localisation of α-syn to mitochondria in various 
experimental models (Li et al., 2007; Nakamura et al., 2008; Di Maio et al., 2016; 
Devoto et al., 2017; Miraglia et al., 2018). Mitochondria in the SNPc of post-mortem 
PD patient samples reveal the accumulation of α-syn (X. Wang et al., 2019). The 
lipid-binding capabilities of α-syn, including the specific binding to the mitochondria-
specific phospholipid cardiolipin, associates the protein with mitochondrial 
membranes and mitochondria-associated membranes (MAMs) (Devi et al., 2008; 
Parihar et al., 2009; Martin et al., 2014; Dudek, 2017; Paillusson et al., 2017).  
α-Syn-induced toxicity of mitochondria has been associated with several processes 
including mitochondrial protein import (Devi et al., 2008; Di Maio et al., 2016), Ca2+ 
signalling in mitochondria (Oueslati, Fournier and Lashuel, 2010; Surmeier and 
Schumacker, 2013), mitochondrial fusion/fission (Nakamura et al., 2011; Xie and 
Chung, 2012), mitophagy (Lahiri and Klionsky, 2017), impairment of complex I and 
energy defects (Devi et al., 2008; Ludtmann et al., 2018; Martínez et al., 2018). The 
high energy demands of dopamine neurons of the SNPc require the continuous 
production of ATP from mitochondria (Bolam and Pissadaki, 2012; Surmeier, Obeso 
and Halliday, 2017). Impairment of complex I by α-syn can lead to energy deficits 
and the production of toxic cellular ROS (Reeve et al., 2015a). Recently, oligomeric 
α-syn was shown to impair complex I respiration through the selective oxidation of 
ATP synthase, leading to mitochondrial lipid peroxidation and cell death (Ludtmann 
et al., 2018). Using a SNCA triplication-bearing iPSC model, the aggregation of α-
syn from monomeric protein into oligomeric species was shown to associate with the 
mitochondrial membrane (Reeve et al., 2015b; Ludtmann et al., 2018). This 
interaction of soluble β-sheet-rich oligomers with the mitochondrial membrane 
directly induced the opening of the permeability transition pore (PTP) (Ludtmann et 
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al., 2018). β-sheet-rich structures of oligomers interact with inner mitochondrial 
membrane proteins (ATP synthase) and act to inhibit complex I, which in turn, 
generates ROS and produces bio-energetically compromised mitochondria 
(Ludtmann et al., 2018).   
1.4.3 Synaptic dysfunction 
Given the localisation of α-syn within synaptic vesicles and its suggested function as 
a chaperone protein in SNARE-vesicle trafficking and DAT modulation, α-syn is 
important for maintaining normal synaptic function (Iwai et al., 1995; Totterdell, 
Hanger and Meredith, 2004; Burré et al., 2011; Butler et al., 2015). In addition, α-syn 
interacts with other synaptic proteins, including synapsin III, to modulate synaptic 
function in dopaminergic neurons through the organisation of synaptic vesicles 
(Zaltieri et al., 2015; Atias et al., 2019). Supporting the function of α-syn in synaptic 
regulation, knockout mouse models of α/β-syn result in altered synaptic features 
including synaptic structure, synaptic plasticity, neurotransmitter release and 
decreased dopamine levels (Chandra et al., 2004; Greten-Harrison et al., 2010; 
Oaks et al., 2013). 
Synaptic dysfunction is thought to be one of the early changes in PD, before the loss 
of dopaminergic neurons (Chesselet and Richter, 2011; Kordower et al., 2013; 
O’Keeffe and Sullivan, 2018). Overexpression of α-syn in the rat midbrain reveals 
significant synaptic disruption in vivo as analysed by positron emission tomography 
(PET) radioligand to vesicular monoamine transporter-2 (VMAT2) and animals 
displaying progressive motor impairment (Kirik et al., 2002; Phan et al., 2017a). 
Importantly, elevated expression of α-syn induced synaptic dysfunction in the 
absence of neuronal loss, but with the accompanying pathological accumulation of 
insoluble p-α-syn (Phan et al., 2017b). Moderate overexpression of α-syn results in 
the aggregation of α-syn found selectively at presynaptic terminals in a mouse model 
of PD (Kramer and Schulz-Schaeffer, 2007; Spinelli et al., 2014). Under these 
conditions, aggregates are not observed in cell bodies and this is associated with a 
significant decrease in the presynaptic protein synapsin. Taken together, α-syn 
aggregation in presynaptic terminals is related to changes in synapse transmission 
(through reduction in synapsin protein), ultimately leading to a ‘dying back' of axonal 
processes (Yasuda et al., 2013; Spinelli et al., 2014). In cell culture models, 
abnormal accumulation of α-syn aggregates is linked to interfering of axonal 
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transport of synaptic proteins or inhibition of synaptic vesicle reclustering leading to 
reduced neurotransmitter release (Nemani et al., 2010; Scott et al., 2010).  
1.4.4 Autophagy-lysosomal/proteasomal impairment  
The ALP is critical to the normal degradation of monomeric, soluble oligomeric 
species, and aggregated forms of α-syn. Impairment of the ALP in pathological 
conditions is therefore associated with the accumulation of α-syn species, which can 
interact with essential cellular processes or be released to the extracellular 
environment. Although deficiency in ALP function will result in accumulation of α-syn, 
α-syn itself can have detrimental effects to the function of the ALP by a ‘dual loop’ 
effect (Arotcarena, Teil and Dehay, 2019). Overexpression of WT α-syn impairs 
lysosomal activity and autophagosome function (Winslow et al., 2010). Interestingly, 
dopamine-modified α-syn is associated with inhibitory effects on ALP function by 
several mechanisms (Martinez-vicente et al., 2008). These mechanisms include 
forming oligomeric species at the lysosomal membrane, binding to the LAMP-2A 
protein on the lysosomal membrane,  and preventing translocation of substrates to 
the lysosomal lumen, therefore blocking the degradation of CMA cellular substrates 
(Ho et al., 2020). In both idiopathic PD patients and an iPSC model expressing WT 
α-syn, α-syn is capable of altering the hydrolase activity of enzymes associated with 
the lysosomal lumen, including Cathepsin B, GCase, β-galactosidase, or β-
hexosamidase (Mazzulli et al., 2011, 2016). Rather than altering total levels of 
hydrolases, α-syn altered the location of Rab1, a key regulator of ER-Golgi 
trafficking, therefore preventing trafficking and subsequent maturation of hydrolases 
in the Golgi (Mazzulli et al., 2016).  
The presence of mono-, di- and tri-ubiquitinated α-syn in LBs of patients with PD, 
highlight the dysfunction of the UPS in disease (McNaught and Jenner, 2001; 
McNaught et al., 2003; Walden and Muqit, 2017). The UPS is a proteolytic complex 
responsible for maintenance of cellular protein homeostasis through cleavage of 
ubiquitinated polypeptide chains into short peptides to aid in cellular clearance. 
Impairment of the proteasome prevents degradation of proteins, resulting in the 
formation of intracellular protein aggregates (Lindersson et al., 2004). α-Syn is 
degraded by the proteasome when the protein is in its monomeric form (Webb et al., 
2003; Mo et al., 2012). In contrast, aggregated forms of α-syn have a longer half-life, 
which is degraded by the lysosomal pathway (Mo et al., 2012). Alterations in either of 
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these pathways could lead to dysfunction of the other, leading to the accumulation of 
α-syn ultimately leading to degeneration and death of dopaminergic neurons (Wang 
et al., 2015). 
Triggering of the unfolded protein response and persistent endoplasmic reticulum 
stress by the accumulation of misfolded proteins, including α-syn, has been 
demonstrated to lead to activation of the cell death cascade and subsequent 
apoptosis (Smith et al., 2005; Ogen-Shtern, Ben David and Lederkremer, 2016). 
Proteasomal impairment and oxidative stress are continuing themes in 
neurodegeneration, attributing to altered biochemical functions within cells. 
Overexpression of A53T α-syn in PC12 cells increased cell death through the 
inhibition of proteasome function as well as producing a significant increase in the 
intracellular level of ROS (Smith et al., 2005).  
1.5 α-Synuclein is a prion-like protein 
1.5.1 Prion hypothesis 
Transmissible spongiform encephalopathies (TSEs), or prion disorders, are a curious 
class of fatal neurodegenerative disorders caused by infectious prion protein. TSEs 
are characterised by the accumulation of β-sheet-rich protein aggregates and 
substantial neurodegeneration (Aguzzi and Lakkaraju, 2016). In humans, prions are 
associated with Creutzfeldt-Jakob disease (CJD), Gerstmann-Straüssler-Scheinker 
(GSS) disease, familial fatal insomnia (FFI), Kuru and variant CJD (vCJD). In 
animals, prions are associated with bovine spongiform encephalopathy (BSE), 
commonly known as 'mad cow disease' in cattle, scrapie in sheep and goats and 
chronic wasting disease of the Cervidae family in nonhumans (Collinge, 2001). 
Pathological features of TSEs include brain vacuolation, astrogliosis, neuronal 
apoptosis and accumulation of abnormal PrP isoforms in the CNS, a feature 
common to prion disorders in other mammalian species, including scrapie in sheep. 
Attempts to classify the infective agent associated with TSEs led scientists to 
conclude a slow virus was responsible for the disease following epidemiological 
evidence of a long lag phase of over 30 years in some cases (Alper et al., 1967; 
Rudge et al., 2015). Experimental attempts to inactivate the scrapie agent using 
formalin, UV and ionising radiation, extreme heat and high pressure suggested a 
virus substantially different from any previously discovered (Pattison, 1965; Alper et 
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al., 1967; Prusiner, 1982). The controversial 'protein-only' hypothesis, first indicated 
by Alper and Griffith in 1967, and later expanded upon by Prusiner in 1982 describes 
prions as infectious protein particles devoid of nucleic acids, instead able to encipher 
infectivity through the propagation of misfolded protein (Alper et al., 1967; Prusiner et 
al., 1982).  
The normal cellular prion protein (PrPC) is a natively unfolded 
glycosylphosphatidylinositol- variably N-glycosylated anchored membrane 
glycoprotein encoded by the highly conserved PRNP gene (Bolton, Meyer and 
Prusiner, 1985; Basler et al., 1986; Stahl et al., 1987). Conversion of the mainly α-
helical PrPC to the β-sheet rich disease-associated isoform, PrPSC, is the key 
pathogenic event associated with prion disorders although this is mechanism is not 
completely understood. Spectroscopic studies demonstrated PrPSC is biochemically 
distinct to PrPC, with specific differences in the biophysical structure associated with 
the change in conformation from α-helices to β-sheets (Pan et al., 1993; Riek et al., 
1996; Vázquez-Fernández et al., 2016). The PrPSC conformation was originally 
determined to be resistant to proteinase K (PK) digestion, denoted as PrPRES, 
although it should be noted that PK resistance is a relative concept that depends 
critically on various factors including PK concentration and the prion strain (McKinley 
et al., 1991; Weissmann, 2004). Classically, identification of PrPSC involves removal 
of PrPC by PK digestion and subsequent characterisation of electrophoretic bands 
indicative of the prion strain detected by anti-PrP antibodies (Kuczius and Groschup, 
1999; Shan et al., 2016); however, it has become apparent PK-sensitive PrPSC is 
related to infectivity and conversion of PrPC, therefore, PK digestion does not always 





Figure 1.9. Secondary nucleation events associated with continued generation of seed in PrPSC. (A) Secondary 
nucleation events associated with continued generation of seed in PrPSC (and other amyloidogenic proteins). 
Fragmentation of fibrils allows for secondary nucleation points for the interaction of monomeric protein and 
subsequent oligomer/fibril formation. (B) Representative ThT fluorescence kinetics of fibril formation following the 
addition of an oligomeric/fibrillar seed. Lag phase is shortened due to the presence of nucleation surface for the 
recruitment of monomer. Time taken to reach stationary phase is reduced as fibrils are produced quicker in the 
presence of seeds. Co-factors may aid in the propagation of prions by a) catalyst for induction of PrPSC from 
interaction with PrPC; b) interact to stabilise PrPSC; c) interaction with oligomeric structure to produce alternative 
strains; d) generation of infective seed through fragmentation of fibrillar structures. Image adapted from (Ghosh et 
al., 2017). 
In vitro conversion of PrPC to PrPSC has been demonstrated in cell-free systems and 
the few permissive cell lines which maintain PrPSC infectivity over several passages, 
including the murine neuroblastoma line (N2a), the rat adrenal phaeochromocytoma 
(PC12) and hypothalamic neuronal line (GT1) (Supattapone, 2004; Weber et al., 
2006; Castilla et al., 2008). From these models, it is understood PrPSC catalyses the 
accumulation of misfolded protein in a nucleation-polymerisation reaction akin to 
crystal growth and fragmentation (Jarrett and Lansbury, 1993; Knowles et al., 2009). 
In this sense, PrPSC acts as a seed that enciphers its structure onto the natively 
expressed PrPC based on the stoichiometry of the molecule, allowing for the growth 
of oligomeric/protofibrillar structures present in the plaques associated with TSEs 
29 
 
including Kuru, consistent with the observation that PRNPo/o knockout mice do not 
propagate PrPSC (Bueler et al., 1992; Nishina et al., 2006). A secondary nucleation 
event, aggregate fragmentation, is crucial to the propagation and infectivity 
associated with prion infections (Fig. 1.6), thus enabling the production of seeds for 
PrPSC to elongate and multiply, demonstrated in non-Mendelian heritability of the 
yeast prions URE3 and PSI+ and protein misfolded cyclic amplification (PMCA) 
reactions (Wickner, 1994; Saborio, Permanne and Soto, 2001; Bieschke et al., 2004; 
Liebman and Chernoff, 2012).  
1.4.1.1 Cell-to-cell propagation of PrPSC 
PrPSC molecules can spread in vitro and in vivo vertically, to progeny, and 
horizontally, to neighbouring cells, providing production of prions overcomes protein 
quality control mechanisms (Deriziotis et al., 2011). Vertical transmission of prions in 
mammalian cells is modulated by cell division (Ghaemmaghami et al., 2007) and is 
hypothesised to aid in prion propagation through the production of secondary 
nucleation events which occur following mechanical sheering during cell division 
(Knowles et al., 2009). Vertical transmission may be important in the spreading of 
prions in the periphery, where PrPSC replicates in the lymphoreticular system 
(McCulloch et al., 2011; Srivastava et al., 2015), in contrast to the post-mitotic cells 
of the CNS which may impede vertical transmission. The most common laboratory 
method to administer PrPSC into experimental animals is intracerebral inoculation, 
however, ingestion of prions is the most common mechanism for the spread of the 
disease in nature. Speculatively, change in transmission from vertical to horizontal 
(which is generally less efficient) (Ghaemmaghami et al., 2007) may represent the 
long lag phase associated with neuroinvasion in the pathogenesis of natural prion 
diseases, which is partially circumvented using experimental animal models of prion 
diseases. Therefore, in the CNS, horizontal transmission of prions may be central to 
disease progression, resulting from PrPSC hijacking of methods of cell-to-cell to 
communication such as exosomes and tunnelling nanotubes (TNTs) to facilitate 
intercellular spread in conjunction with direct cell-to-cell contact (Kanu et al., 2002; 
Paquet et al., 2007; Victoria et al., 2016).  
Exosomal transmission of PrPSC is well documented as a method of pathogen 
transfer and stimulating release of exosomes increases the intracellular transfer of 
prions (Guo, Bellingham and Hill, 2016). These small (50-200 nm) membrane-bound 
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extracellular vesicles are found in most biological fluids and are determined to be 
generated by the trafficking of multivesicular bodies from the cytosol to the cell 
surface (Harding, Heuser and Stahl, 1983; Johnstone et al., 1987). Following 
secretion from cells, exosomes are taken up by other cells by one of three pathways: 
1) captured by neighbouring cells; 2) internalised by cells at a certain distance or; 3) 
taken up by cells of distant tissues by utilising the systemic circulation (Pant, Hilton 
and Burczynski, 2012; De Toro et al., 2015). Exosomes are reported to function in 
cell-to-cell communication and modulation of the immune response (Basso and 
Bonetto, 2016), however, these vesicles, along with other multivesicular bodies such 
as microvesicles and apoptotic cell bodies, are becoming increasingly linked to 
disease pathogenesis and progression in a variety of disorders, including 
neurodegeneration, cancer, HIV and others (Madison and Okeoma, 2015; Zhang et 
al., 2015). It is interesting to note over 11,000 proteins have been identified in 
exosomes along with mRNA, miRNA and lipids and most are not associated with 
disease (Mathivanan et al., 2012). Various cell types secrete PrPC and PrPSC, in 
association with exosome-like vesicles including glial cells (Fevrier et al., 2004); 
activated platelets (Robertson et al., 2006); primary cultured cortical neurons (Fauré 
et al., 2006); neuroblastoma cells (Alais et al., 2008; Veith et al., 2009) and 
monocytes (Wang et al., 2010). There is increasing evidence to suggest PrPSC 
transmission in the blood and plasma is associated with exosomes (Saá et al., 2014; 
Properzi et al., 2015). In addition to the transfer of PrP alone, evidence suggests that 
exosomes may be important in the transfer of cofactors required for prion 
conversion, in particular lipids and RNA (Wang et al., 2007, 2010; Deleault et al., 
2012; Srivastava and Baskakov, 2015) or by the association of PrP to lipid rafts in 
exosomal membranes are thought to play a role in PrPSC conversion (Taylor and 
Hooper, 2006; Marijanovic et al., 2009). Furthermore, exosomal packaging may 
represent alternative processing of PrP which may aid in infectivity following the 
observation of N-terminally distinct exosomal-derived PrP (Vella et al., 2007; Wik et 
al., 2012; Guo, Bellingham and Hill, 2015). Although the size and conformation of 
PrPSC have not consistently been identified, a study by Coleman et al. (2012) 
demonstrated prion infectivity in exosomes at a maximum of 150 nm in diameter, 
suggesting PrPSC or the infectious entity to be inherently small (Coleman et al., 
2012). Aβ neurotoxicity was reduced by exosomal PrPC enhancing Aβ fibrillisation, 
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highlighting a protective effect of exosomal PrP in molecular mechanisms of AD 
(Falker et al., 2016).  
TNTs represent another method of cell-to-cell communication that assists in 
intercellular transfer of PrPSC (Gousset et al., 2009). TNTs are F-actin-based 
structures with diameters of 50 to 200 nm and a length of several cell diameters 
observed in a variety of cell types, forming complex cellular networks that enable the 
transfer of organelles and other material between cell types (Rustom et al., 2004; 
Wang and Gerdes, 2015). Combining both vesicle transport and TNTs, these 
dynamic structures have been shown to traffic PrPSC aggregates through TNTs in 
endosomal vesicles (Zhu et al., 2015). Taken together, these data suggest prions 
utilise several routes for efficient intercellular spreading, but it is unclear whether 
these differences represent PrPSC strain types or potentially varying culture 
conditions.  
1.5.2 Insights into the prion-like nature of α-synuclein from in vitro cell culture 
models 
Although there are several mechanistic similarities between the proteins involved in 
neurodegeneration such as α-syn (in PD), tau and A-β (in AD), huntingtin (in 
Huntingtin's disease) and superoxide dismutase (SOD1 in ALS) and PrP, there is 
reluctance to use the term 'prion' to describe these diseases. There is no evidence of 
transmissibility of disease between individuals in contrast to the highly infective 
nature of prion diseases (Cersosimo, 2015; Jaunmuktane et al., 2015; Abbott, 2016). 
Instead, a series of terms including 'prion-like', 'propagon', 'prionoid' has been used 
to describe the proteins related to these protein-misfolding diseases where some, 
but not all, of the molecular features of prion diseases exist (Harbi and Harrison, 
2014; Aguzzi and Lakkaraju, 2016). Recent research, utilising in vitro cell culture 
models of α-syn aggregation and propagation highlight intriguing similarities of PrP, 
these are listed below. 
1.4.5.1 Seeding and cell-to-cell propagation of α-synuclein 
The staging of α-syn-immunopositive pathology through post-mortem observations 
by Braak and colleagues suggested a predictable pattern of disease propagation 
following long unmyelinated axons of known anatomical pathways (Fig. 1.7) (Heiko 
Braak, Del Tredici, et al., 2003; Hawkes and Braak, 2007). The 'dual-hit' hypothesis 
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suggests the spread of pathology initiated by an unknown neurotrophic 
pathogen/virus via olfactory and gastric routes of entry (Hawkes and Braak, 2007; 
Manfredsson et al., 2018; Uemura et al., 2018). The neurotrophic agent was 
speculated to 'possess unconventional prion-like properties' and potentially consist of 
misfolded α-syn fragments that induce the spread of PD  pathology (H. Braak et al., 
2003; Dagher and Zeighami, 2018). The discovery of LBs immunopositive for α-syn 
and ubiquitin in graft neurons 11-18 years following the transplantation of 
dopaminergic neurons in the striatum of individuals with PD, has propelled the idea 
of α-syn as a 'prion-like' protein (Jeffrey H Kordower et al., 2008; Jeffrey H. Kordower 
et al., 2008; Li et al., 2008). In this context, the 'prion-like' capacity of α-syn enabled 
the spread of α-syn from diseased neurons to the relatively young, newly implanted 
graft neurons (Jeffrey H Kordower et al., 2008; Jeffrey H. Kordower et al., 2008; Li et 
al., 2008). The development of LB pathology was shown to be a progressive process 
(e.g. whole LBs do not move from cell to cell) suggesting the transfer of a seed that 
could initiate the development of pathology in transplanted neurons (Chu and 
Kordower, 2010; J.-Y. Li et al., 2010). Application of oligomeric/fibrillar species to 
both cultured cells and animal models provide a 'seed' or nucleation site for the 
recruitment of monomeric protein in the process of nucleation-dependent fibrillisation 
leading to the development of cellular inclusions reminiscent of LB pathology (Paula 
Desplats et al., 2009; Iljina et al., 2016). 
Although α-syn does not contain a classical secretory signal for extracellular release, 
both soluble and aggregated forms of the protein have been detected in culture 
media (secreted by living neurons), brain interstitial fluid, CSF, saliva and plasma 
(Lee, 2005; Paleologou et al., 2009; Emmanouilidou et al., 2010; Hansson et al., 
2014). Given the detection of a normally cytoplasmic protein found in the 
extracellular milieu, mechanisms of cellular clearance of α-syn are important 
mediators of seeding and propagation (Lee, 2005). Extracellular α-syn release 
depends on several factors including rate of proteasomal degradation (Bennett et al., 
1999; Webb et al., 2003; Zondler et al., 2017); the rate of lysosomal degradation 
(Paxinou et al., 2001b; Alvarez-Erviti et al., 2011; Wong and Krainc, 2016); post-
translational modifications of the protein (e.g. phosphorylation, ubiquitination, 
SUMOylation); intracellular levels of α-syn (Reyes et al., 2015); the mutated form of 
the protein (e.g. A30P, A53T etc.) (Conway et al., 2006; Lázaro et al., 2014); 
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potential release of α-syn upon the death of neurons (Omar M.A. El-Agnaf et al., 
1998; Ulusoy et al., 2015); accumulation of misfolded/damaged proteins (Jang et al., 
2010) and export in exosomes (Emmanouilidou et al., 2010; Danzer et al., 2012; 
Marie et al., 2015). In an inducible pluripotent stem cell (iPSC)-derived neuronal 
model, high levels of intracellular α-syn through the expression of an SNCA gene 
triplication results in high levels of secreted α-syn (Reyes et al., 2015). This is 
important when considering aging is the greatest risk factor for the development of 
disease and presumed to be associated with higher levels of α-syn (Tyson, Steiner 
and Brundin, 2016). In addition, an increase in oligomeric species is associated with 
an aging brain (Chen et al., 2015). Mechanisms to degrade released α-syn can 
potentially prevent the transmission of pathology, through the removal of the 
pathological conformation of the protein. However, in the aging brain, these 
mechanisms may have declined in the natural aging process leading to the 
accumulation of aggregated species that evade clearance and subsequently spread 
pathology to neighbouring cells. 
The uptake of α-syn by recipient cells allows for the perpetuation of pathological 
spread and can occur through several mechanisms. Extracellular α-syn can be taken 
up by neighbouring cells by various mechanisms including passive diffusion through 
the plasma membrane (Jiang et al., 2017); internalisation by endocytic processes 
(pinocytosis and phagocytosis) (Lee, 2005; Paula Desplats et al., 2009); interaction 
through TNTs (Gousset et al., 2009; Nath et al., 2012; Abounit et al., 2016) and 
exposure of cells to exosomes containing α-syn as cargo (Guo, Bellingham and Hill, 
2016). Uptake of extracellular α-syn by passive diffusion through the plasma 
membrane was shown to occur by monomeric protein but not oligomeric or 
aggregated structures (Grozdanov and Danzer, 2018).  In contrast, aggregated α-
syn is preferentially taken up by receptor-mediated endocytosis through the 
interaction of surface receptors such as the α3+-subunit of Na+/K+ - ATPase, LAG3 
and neurexin-1 (Shrivastava et al., 2015; Mao et al., 2016). Following endocytosis 
aggregated α-syn species can induce lysosomal membrane rupture and subsequent 




degradation mechanisms of the endo-lysosomal vesicles by aggregated α-syn allows 
for access of the pathological protein to the cytoplasm of cells and acts as a seed to 
recruit normal cellular protein (Victoria and Zurzolo, 2015). Exosomes have been 
demonstrated to efficiently transport oligomeric species into recipient cells (Danzer et 
al., 2012; Stuendl et al., 2016). Delenclos et al. (2017) demonstrate the preparation 
of cell-produced α-syn oligomers results in a small proportion of exosome-associated 
α-syn, in contrast to free α-syn oligomers that are not efficiently internalised by the 
cells. However, exosomes were readily internalised inside recipient cells in contrast 
to free α-syn oligomers (Bliederhaeuser et al., 2016; Delenclos et al., 2017). The 
increased propensity of α-syn to aggregate by exosomes could provide an 
environment favourable for the oligomerisation process and subsequent spreading of 
pathology (Delenclos et al., 2017).  
  
Figure 1.10. Progression of α-syn-
immunopositive pathology as described 
in the Braak hypothesis of α-syn spread 
of pathology. (A) Stage 1-2: In the 
presymptomatic phase of disease 
progression, the earliest lesions are 
associated with the olfactory bulb and 
dorsal IX/X motor nucleus (stage 1), 
followed by lesions appearing in the 
caudal raphe nuclei, reticular nucleus 
and locus coeruleus (stage 2). (B) Stage 
3-4: Pathology steadily moves upwards 
into the mesencephalic tegmentum and 
portions of the prosencephalon, with 
lesions in the substantia nigra pars 
compacta. Cortical involvement is 
evident with lesions in the temporal 
mesocortex and allocortex. (C) Stage 5-
6: Areas of high order sensory 
association in areas of the neocortex and 
prefrontal neocortex develop lesions plus 
pathology of previous stages (stage 5). In 
the final stage (stage 6) pathology 
extends further into first order sensory 
association areas and occasionally 
primary sensory and motor fields. 
Impaired cognition is commonly 
associated with this final phase of PD 
progression, related to the damage in the 
neocortex (Heiko Braak, Tredici, et al., 
2003; Watson and Leverenz, 2010). 




1.6 Aims and objectives 
Overall aim: 
The hypothesis was that 3D cell culture can be used to model the templated 
propagation of α-syn. Building on the recent publications describing a specific 
species of oligomeric α-syn able to induce aggregation of intracellular α-syn in a 
traditional 2D cell culture model and the demonstration that 3D cell culture increases 
development of aggregate formation in an AD disease model, we sought to develop 
a PD-relevant 3D culture system to investigate the propagation of these previously 
described species (Danzer et al., 2007; Choi et al., 2014, 2016; Illes-Toth et al., 
2015).  
The specific goals were: 
• To develop a human-relevant cell culture model of PD, utilising the human 
neuroblastoma SH-SY5Y cell line.  
• To develop methods for assessing the intracellular aggregation of α-syn in the 
3D model. 
• Characterise the formation of α-syn aggregates in the 3D model and 
determine whether these aggregates recapitulate traditional 2D cell culture 
systems. 
• Investigate the impact of the newly discovered cell death pathway, ferroptosis, 
on the intracellular aggregation of α-syn in the 3D model. 











Chapter 2 : Materials and Methods 
 
2.1 Cell culture 
2.1.1 SH-SY5Y cell culture 
All cell manipulations were undertaken in sterile conditions in a Grade II laminar flow 
hood. SH-SY5Y human dopaminergic neuroblastoma cells (Cat. No. 94030304, 
ECACC, Public Health England, Salisbury, UK) were maintained at 37oC, 5% CO2 in 
high glucose Dulbecco's modified Eagle's GLUTAMAXTM medium (DMEM; Cat. No. 
61965026, Gibco, ThermoFisher Scientific, Warrington, UK) supplemented with 10% 
(v/v) foetal bovine serum (FBS, batched, Cat. No. 10500-064, Gibco) and 1% (v/v) 
penicillin-streptomycin (P/S, Gibco). To subculture, the culture medium was 
removed, and cells were washed in phosphate-buffered saline (PBS, Gibco) to 
remove traces of serum before incubation with trypsin. 3 mL trypsin-EDTA (0.05% 
(v/v), Gibco) per 75 cm2 flask was incubated with the cells for approximately 2-3 mins 
at 37oC, or until cells were visibly detached from the culture flask. Trypsin-EDTA was 
inactivated following the addition of an equal volume of culture medium with 10% 
(v/v) FBS added. The resulting cell suspension was counted using a 
haemocytometer and the cell density was adjusted for use in experiments or 
subculture. Cells were purchased at passage 11 and used until passage 21, to 
prevent loss of neuronal characteristics as per ECACC culture guidelines.  
2.1.1.1 Cryopreservation of SH-SY5Y cells 
Cells were grown in culture flasks until 70-80% confluency before cryopreservation. 
Cells were trypsinised and resuspended in 3 mL DMEM supplemented with 10% 
(v/v) FBS and 1% P/S (v/v). Cell viability was determined by counting cells using a 
haemocytometer and trypan blue cell stain (0.4%, Gibco). Only cell populations with 
a percentage viability >90% were frozen to achieve a good recovery after freezing. 
Cells were centrifuged at 1,000 rpm for 5 mins before resuspension in freezing 
medium (90% FBS: 10% DMSO) at a concentration of 2 x 106 cells/mL. One mL 
aliquots of freezing medium and cells in cryoprotective ampules were placed inside a 
Nalgene Mr Frosty™ container filled with isopropyl alcohol and placed in a -80oC 
freezer to gradually freeze at 1oC/minute overnight. Frozen ampules were 
transferred to the vapour phase of liquid nitrogen. 
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2.1.1.2 Differentiation of SH-SY5Y cells  
Differentiation of SH-SY5Y cells into a more neuronal phenotype was undertaken 
using three different protocols and their suitability for adaptation into a 3D culture 
system was assessed. The following protocols were used: all-trans-retinoic acid (RA; 
Cat. No. R2625, Sigma-Aldrich, Dorset, UK) alone, sequential treatment with RA and 
aphidicolin (Cat. No. 10583155 Fisher Scientific, Leicestershire, UK) and sequential 
treatment with RA and brain-derived neurotrophic factor (BDNF; Cat. No. 450-02, 
Peprotech, London, UK). For differentiation with RA alone, cells were cultured in 10 
μM RA for 5-14 days in DMEM supplemented with either 1% (v/v) or 10% (v/v) FBS. 
For differentiation with RA and aphidicolin (0.1 μM, 0.3 μM or 0.5 μM aphidicolin), 
cells were cultured in 10 μM RA for 5 days. After 5 days, the culture medium was 
replaced with aphidicolin-containing culture medium and incubated for a further 9 
days. For differentiation with RA and BDNF, Cells were seeded at an initial density of 
15,000/cm2 in DMEM media supplemented with 10% (v/v) FBS, 1% (v/v) P/S and the 
addition of 10 μM RA. After 5 days in the presence of RA, cells were washed with 
serum-free DMEM, trypsinised and transferred to Matrigel-coated (Matrigel™ 
growth-factor-reduced phenol-red free, Cat. No. 356231, Lot: 7086009, Corning, UK) 
8-well chamber slides (Nunc Lab-Tek® Chamber Slide™, ThermoFisher) in serum-
free DMEM with 50 ng/mL BDNF. After 7 days in BDNF-supplemented serum-free 
DMEM cells were ready for experimentation (Encinas et al., 2000). 
2.1.1.3 3D cell culture 
Cells were pre-differentiated with RA in uncoated T75 flasks for 5 days before 
seeding into 3D Matrigel™ cultures. Matrigel™ was diluted to 6 mg/mL total protein 
with ice-cold serum-free DMEM and vortexed with cell pellets for 10 s, to a final cell 
concentration of approximately 7.5 x 106 cells per mL of diluted Matrigel™. Using 
pre-chilled pipettes, Matrigel™/cell mixtures were transferred to either pre-warmed 8-
well chamber slides or tissue culture inserts (ThinCerts, 0.4 µm pore size, Cat. No. 
662641, Greiner Bio-One, Gloucestershire, UK), at 100 µL and 300 µL volumes 
respectively, and incubated at 37oC for 1 h to form a gel. Following solidification of 
the 3D gels, pre-warmed serum-free DMEM supplemented with 50 ng/mL BDNF was 
added to the cultures and cells differentiated for a further 7 days. Media was 
changed every 3-4 days. After 7 days in 3D, cultures were treated with either 
oligomers or metals for 24 h.  
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2.1.1.4 Treatment with oligomers/iron (II) chloride 
When treating with oligomers, 10% (v/v) oligomers were added alongside cultures 
treated with 10% (v/v) solvent (sodium phosphate buffer + 20% ethanol), 10% (v/v) 
monomeric α-syn and media-only control for 24 hrs. Preparation of oligomers is 
stated in section 2.10.3. For metal treatments, 1000 µM iron (II) chloride was added 
to 3D cultures alongside 200 µM (II) chloride, solvent-only control (NTA only) and 
media-only control for either 24 or 72 hrs (Fig. 2.1). The “continual stress” group was 
subjected to fresh treatments of iron (II) chloride (and controls) every 24 hrs for a 
total of 72 hrs before cellular analysis, in contrast to a singular treatment of iron (II) 
chloride (and controls) (Fig. 2.1). 
 
Figure 2.1. Schematic representation of cell culture treatments. (A) Cells were treated with either media only, 
solvent control, 200 µM iron (II) chloride and 1000 µM iron (II) chloride once for the duration of the experiment at 
time 0, followed by analysis at either 24 or 72 hrs. (B) Cells were treated with either media only, solvent control, 
200 µM iron (II) chloride and 1000 µM iron (II) chloride three times during the course of the experiment (at 0, 24 
and 48 hrs), followed by analysis at 72 hrs from initial iron treatment. 
2.1.2 LUHMES cell culture 
The Lund human mesencephalic cell line (LUHMES) was purchased from ATCC® 
(Cat. No. CRL-2927, Virginia, USA). For LUHMES culture, cell culture flasks and 
multi-well plates pre-coated with 50 μg/mL poly-L-ornithine and 1μg/mL fibronectin 
(Cat. Nos. P3655 and F0895, Sigma-Aldrich) dH2O were used, to aid in adhesion of 
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neuronal cells to culture surfaces. Flasks were coated with 50 μg/mL poly-L-ornithine 
overnight at room temperature (RT). After removal of the coating solution, culture 
vessels were washed twice in dH2O and left to air dry prior to coating with 1μg/mL 
fibronectin for 3 hrs at RT. Removal of the coating was followed by a further wash 
with dH2O and air-dried before cell seeding.  
LUHMES cells were grown at 37oC in a humidified 95% air, 5% CO2 atmosphere. 
Proliferating LUHMES cells were grown in proliferation medium consisting of 
Advanced Dulbecco's modified Eagle's medium/F12 without L-glutamine 
(DMEM/F12; Cat. No. 10-090-CV, Corning), 1x N-2 supplement (Cat. No. 17502048, 
Invitrogen), 1x GlutaMAX™ (Cat. No. 35050061, Gibco), 40 ng/mL recombinant 
basic fibroblast growth factor (bFGF; Cat. No. 100-18B, Peprotech) and 1% (v/v) 
P/S. For passaging (at 85% confluency), cells were washed with PBS and incubated 
with 4 mL trypsin (0.05% trypsin-EDTA) for approximately 5 mins at 37oC, whilst 
monitoring cell detachment under an inverted microscope. Twelve mL of pre-warmed 
wash medium (DMEM/F12 + 1% (v/v) P/S) was added to each flask and cells 
aspirated by pipetting over the flask. The cell suspension was centrifuged at 300 x g 
for 5 mins at 18oC and the supernatant was discarded. Cell pellets were 
resuspended in 3 mL wash media and counted before seeding into pre-coated T75 
flasks. Three million cells were seeded for 2-day maintenance. Two million cells 
were seeded for 3-day maintenance. Ten mL of proliferation media was used per 
flask.   
2.1.2.1 Cryopreservation of LUHMES 
Cells were grown in culture flasks until 80-90% confluency prior to cryopreservation. 
Cells were trypsinised and resuspended in 3 mL DMEM/F12 supplemented with 20% 
(v/v) FBS and 1% (v/v) P/S. Cell viability was determined by counting cells using a 
haemocytometer and trypan blue cell stain. Only cell populations with a percentage 
viability >90% were frozen in order to achieve a good recovery after freezing. Cells 
were centrifuged at 300 x g for 5 mins at 18oC before resuspension in freezing 
medium (proliferation media supplemented with 20% (v/v) FBS and 10% (v/v) 
DMSO) at a concentration of 3 x 106 cells/mL. One mL aliquots of freezing medium 
and cells in cryoprotective ampules were placed inside a Nalgene Mr Frosty 
container filled with isopropyl alcohol and placed in a -80oC freezer to gradually 
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freeze at 1oC/minute overnight. Frozen ampules were transferred to the vapour 
phase of liquid nitrogen. 
2.1.2.2 Differentiation of LUHMES 
For differentiation, LUHMES were seeded at 2x106 cells per T75 flask and left to 
adhere and expanded for 2 days in proliferation media. After 48 hrs of proliferation 
(on Wednesday), media was changed to differentiation media (Day 0) consisting of 
Advanced Dulbecco's modified Eagle's medium/F12 without L-glutamine, 1x N-2 
supplement, 1x GlutaMAX™, 1 mM di-butyryl adenosine 3′, 5′-cyclic monophosphate 
sodium salt (cAMP; Cat. No. SC-201567B, Santa Cruz Biotechnology, Germany), 1 
µg/mL tetracycline hydrochloride (Cat. No. T7660, Sigma-Aldrich), 20 ng/mL glial-
derived neurotrophic factor (GDNF; Cat. No. 450-10, Peprotech) and 1% (v/v) P/S. 
At Day 2 of differentiation, cells were harvested and seeded into pre-coated 
plates/flasks in differentiation media. Cells were left to differentiate for 72 hrs. 
2.2 Neurite length analysis 
For neurite length analysis, phase-contrast images of undifferentiated SH-SY5Y or 
differentiated SH-SY5Y with 10 μM RA or sequential treatment with 10 μM RA and 
BDNF were analysed using ImageJ (Fig. 2.2) (US National Institutes of Health, 
Bethesda, MD, USA). This was performed by first setting the scale using the image 
scale bar in ImageJ then manually measuring randomly picked neurites. Two 
hundred neurites were measured per biological repeat and all data is displayed.  
 
Figure 2.2. Example neurite length analysis using ImageJ. Neurite length is indicated by the table on the right 




2D cultures were fixed with ice-cold methanol for 15 mins at -20oC followed by 
washing with PBS solution containing 0.1% (v/v) Tween-20 (PBS-T). After washing, 
unspecific binding sites were blocked with a solution containing PBS and 1% (w/v) 
bovine serum albumin (BSA, Sigma-Aldrich) for 1 hr at RT under gentle continuous 
shaking. After blocking, cells were washed in PBS-T before incubation with the 
primary antibody in blocking solution for 1 hr at RT under gentle continuous shaking. 
Following primary antibody incubation, cells were washed with PBS-T and incubated 
with secondary antibodies for 1 hr at RT in the dark (Table 2.1). Nuclei were 
counterstained with 0.1 µg/mL 4', 6-diamidino-2-phenylindole, dihydrochloride (DAPI, 
Sigma-Aldrich) for 5 mins, followed by 3 x washes with PBS-T. Slides were mounted 
with immersion oil, sealed with nail varnish and left to cure overnight at 4oC in the 
dark prior to image capture using an Olympus BX60 bright field/fluorescence 
microscope. Evaluation of immunofluorescence staining was performed by counting 
200 cells per repeat, with immunopositive cells expressed as a percentage of the 
total count.  
2.3.1 Corrected Total Cell Fluorescence Calculations 
To quantify total fluorescence per cell, fluorescent images were analysed using the 
image analysis software ImageJ using the corrected total cell fluorescence (CTCF) 
calculation were the background fluorescence in a selected area is subtracted from 
the fluorescence value of a measured area, using the calculation:  
𝐶𝑇𝐶𝐹 =  
(𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 − (𝑀𝑒𝑎𝑛 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑅𝑒𝑎𝑑𝑖𝑛𝑔 𝑜𝑓 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑋 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑜𝑛)
𝐶𝑒𝑙𝑙 𝑁𝑢𝑚𝑏𝑒𝑟
 
Three independent biological repeats were performed in total. 
2.3.2 Quantification of inclusion area 
α-Syn-positive-inclusions were selected at random and quantification of inclusion 
area was performed in ImageJ. This was achieved by first setting the scale in 
ImageJ using the image scale bar and manually measuring randomly picked 
aggregates within the field of view. Measurements were obtained from three 















Mouse monoclonal 1:2000 Goat anti-mouse 
(Texas RedTM) 
Amyloid fibrils OC Millipore: AB2286  Rabbit monoclonal 1:1000 Goat anti-rabbit 
(Texas RedTM) 















Mouse monoclonal 1: 7500 Goat anti-mouse 
(Texas RedTM) 
NF200  Abcam: ab82259 Mouse monoclonal 1:100 Goat anti-mouse 
(Texas RedTM) 
Dopamine Abcam: ab6427 Rabbit polyclonal 1:200 Goat anti-rabbit 
(Texas RedTM) 
Ki67 Abcam: ab16667 Rabbit monoclonal 1:200 Goat anti-rabbit 
(Texas RedTM) 
Texas RedTM Goat 
anti-mouse 
secondary Ab 
Invitrogen: T6390 Goat polyclonal 1:1000 N/A 
Texas RedTM Goat 
anti-rabbit 
secondary Ab 




Abcam: ab150077 Goat polyclonal 1:1000 N/A 
Table 2.1. Antibody information used for immunofluorescence staining of 2D cultures. All antibodies diluted in 1% 
w/v BSA in 1 x TBS. 
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2.4 Staining and immunohistochemistry of 3D sections 
2.4.1 Processing, paraffin embedding and sectioning 
Three-dimensional cultures were fixed with 4% (w/v) PFA, 1% (v/v) glutaraldehyde 
(ThermoFisher) at RT overnight. The fixed Matrigel was then transferred to a plastic 
mould, pre-loaded with liquefied Histogel™ (Cat. No. HG-4000-012, ThermoFisher). 
The fixed Matrigel was positioned in the centre of the mould and encapsulated with 
liquefied Histogel. The Matrigel/Histogel complex was fixed with 4% (w/v) PFA, 1% 
(v/v) glutaraldehyde overnight before being processed in sequential changes of 50% 
IMS, 70% IMS, 100% IMS 3x and Sub-X followed by infiltration by paraffin wax 
(Leica TP1020 semi-enclose benchtop tissue processor, Milton Keynes, UK). The 
paraffin blocks were cut into 10 µm sections (Leica microtome), mounted onto X-tra 
adhesive glass slides (Leica) and incubated at 45oC overnight for Haematoxylin and 
Eosin (H+E) staining and 1 week for immunohistochemistry (IHC) staining. 
2.4.2 Cryosectioning of 3D cultures 
For cryostat sectioning, 3D cultures were fixed by snap-freezing in isopentane over 
liquid nitrogen and stored at -80oC before sectioning. Ten μm Matrigel sections were 
cut using Leica CM3050S cryostat at -25oC and mounted on X-tra adhesive glass 
slides. Sections were stored at -80oC until stained. 
2.4.3 Haematoxylin and Eosin staining 
Following sectioning, the 10 µm sections were oven-dried for 24 hrs before staining 
with H + E (Leica). For the H + E stain, dried slides were subjected to three changes 
of Sub-X for 5 mins, three changes of IMS for 5 mins, stained in Haematoxylin for 5 
mins, blued in running tap water for 5 mins, stained in Eosin for 5 mins, three 
changes of IMS for 5 mins, three changes of Sub-X for 5 mins before mounting in 
Pertex (Leica). Slides were viewed using an Olympus BX60 bright field/fluorescent 
microscope. 
2.4.4 Immunohistochemistry for 3D cultures 
For IHC, 10 µm frozen sections from 3D thick-layer cultures were fixed with 1:1 
methanol and ice-cold acetone. Staining with anti-α-syn monoclonal antibody was 
performed using the Mouse on Mouse Polymer IHC Kit according to the 
manufacturer's protocols (Cat. No. ab127055; Abcam, Cambridge, UK). Briefly, 














Abcam: ab59264 Rabbit polyclonal *1:10, 1:25, 1:50, 
1:100 
Goat anti-rabbit 




Mouse monoclonal 1: 500 Goat anti-rabbit  
NF200 
Abcam: ab82259 Mouse monoclonal 1:100 Goat anti-
mouse  
Dopamine Abcam: ab6427 Rabbit polyclonal 1:200 Goat anti-rabbit  








Abcam: ab6788 Goat polyclonal 1:500 N/A 
Table 2.2. Antibody information used for immunohistochemistry protocols on 3D sections. All antibodies diluted in 
1% BSA in 1 x TBS. *Unable to detect any staining at the following dilutions, therefore no optimal dilution was 
determined.  
Peroxide Block (provided in the kit) for 10-15 mins at RT. Slides were washed in 
TBS-T and subsequently incubated in Rodent Block for 30 mins. After blocking, 
slides were washed in TBS-T and primary antibody added for overnight incubation at 
4oC (Table 2.2). Slides were washed in TBS-T and Mouse on Mouse HRP Polymer 
was incubated for 15 mins at RT. 0.08 % (v/v) hydrogen peroxide in 0.65 mg/ml 3, 3-
diaminobenzidine tetrahydrochloride (DAB; Cat. No. D5905, Sigma-Aldrich) in TBS 
was added to sections prior to counterstaining with Mayer's haematoxylin (section 
2.4.3). 
Staining with anti-ubiquitin rabbit primary antibodies was performed using the 
following method. Following blocking, endogenous peroxidases were blocked with 
0.3% H2O2 in methanol for 30 mins at RT. Slides were washed with TBS-T and non-
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specific binding sites were blocked at RT for 2 hrs with 25% (v/v) normal goat serum 
(Fisher Scientific) and 1% (w/v) BSA in TBS. Sections were incubated with primary 
antibody overnight at 4oC (Table 2.2). Slides were washed in TBS before incubation 
with secondary antibodies for 30 min at RT (Table 2.2). Binding of the secondary 
antibody was detected using a streptavidin–biotin complex (Vector Laboratories, 
Peterborough, UK) technique with. Sections were counterstained with Mayer's 
haematoxylin (section 2.4.3). 
2.4.4.1 Antigen Retrieval Methods 
To unmask antigens in α-syn S129 IHC, both heat-mediated and enzymatic antigen 
retrieval methods were undertaken on sections. For enzyme-mediated antigen 
retrieval, sections were incubated in α-chymotrypsin from bovine pancreas (Sigma; 
0.1% (w/v) α-chymotrypsin in TBS, 46.8 mM calcium chloride dihydrate, pH 7.5) for 
30 min at 37oC. For heat-mediated antigen retrieval, sections were incubated in 
sodium citrate buffer (10 mM sodium citrate, 0.05% (v/v) Tween-20, pH 6.0) in a 
water bath at 60oC overnight.  
2.4.5 Immunocytochemistry for 3D cultures 
For immunofluorescence staining of thin-layer 3D cultures in 8-well glass-bottomed 
chamber slides, cultures were fixed with 4% PFA at RT overnight. The fixed cells 
were washed with TBS-T (TBS buffer containing 0.1% (v/v) Tween-20) three times 
before permeabilisation and blocking. For permeabilisation and blocking, 3D cultures 
were incubated in permeabilisation buffer (TBS-T containing 0.5% (v/v) Triton X-100 
and 4% (v/v) goat IgG) for 1 hr at RT followed by incubation with blocking solution 
(TBS-T containing 1% (v/v) BSA, 0.1% (w/v) gelatin, 0.3 M glycine and 4% (v/v) goat 
IgG) for 12 hrs at 4oC with gentle shaking.  After washing with TBS-T once for 10 
mins, the 3D cultures were incubated with the primary antibody in the blocking 
solution for 24 hrs at 4oC with gentle shaking. Following primary antibody incubation, 
3D cultures were washed with TBS-T three times for 10 mins, followed by overnight 
incubation in TBS-T at 4oC and final 10 min TSB-T incubation. After washing, 
cultures were incubated with Alexa Fluor secondary antibodies for 5 hrs at RT. A 
drop of ProLong™ Gold Antifade (Cat. No. P10144, ThermoFisher) was added to 
each well to prevent fluorescence quenching. Stained 3D cultures were imaged 
immediately using an Olympus IX51 inverted microscope. The following antibody 
dilutions were used in this study: anti-βIII tubulin antibody (1:500, Cat. No. SDL3D10, 
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Sigma-Aldrich,) and goat anti-mouse AlexaFluor488 secondary antibody (1:500, Cat. 
No. AB150113, Abcam). 
For immunofluorescence staining of sections, sections were processed as per 
section 2.4.4. Fluorescent secondary antibodies were used in the place of HRP-
conjugated antibody. Nuclei were counterstained with 0.1 µg/mL DAPI for 5 mins at 
RT, with immersion oil, sealed with nail varnish and left to cure overnight at 4oC in 
the dark. Image capture was undertaken using an LSM 800 confocal microscope 
with Zen Blue software. All samples were imaged using a 40 X plan-apochromat oil 
objective. To image DAPI staining a 405 nm diode laser with a maximum output of 5 
mW was used. For imaging of fluorophores excited to 488 nm, a diode laser with a 
maximum output of 10 mW was used.  
2.5 Cell viability assays 
2.5.1 Resazurin reduction assay 
A 3 mg/mL stock solution of resazurin (Cat. No. R7017, Sigma-Aldrich) was 
prepared in cell culture media and further diluted to 10 µg/mL. Following treatment 
with oligomeric or monomeric species and appropriate solvent controls, media was 
removed and 100 µL of culture media with 10 µg/mL resazurin was incubated with 
the cells for 2 hrs. Fluorescence (Ex530 nm /Em590 nm) was measured on a 
CLARIOstar® plate reader (BMG LABTECH, Buckinghamshire, UK). Culture media 
was incubated with resazurin in parallel as a blank control. As a positive control, cells 
were incubated with 1% (v/v) Triton X-100. Cell viability was calculated as a 
percentage of live cells normalised to negative controls minus relative fluorescence 
intensity (RFU) of blank wells. 
2.5.2 Lactate dehydrogenase assay 
Lactate dehydrogenase (LDH) assay was undertaken to quantitatively measure LDH 
released from damaged cells as a biomarker for cell viability to determine cell 
viabilities of 3D cultures at various cell densities (1 x 106 to 2 x 107 cells/mL) within 
the 3D matrix. LDH released was assayed by measuring extracellular LDH in culture 
media by using the PierceTM LDH Cytotoxicity Assay Kit according to the 
manufacturer's protocols (Cat. No. 88953, Pierce, ThermoFisher). Briefly, 50 μL 
media from 3D cultures was transferred to a 96-well plate in duplicate and incubated 
with 50 μL of the reaction mixture (0.6 mL Assay Buffer with 11.4 mL Substrate Mix) 
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for 30 mins at RT. 50 μL of stop reaction was added to each well and the plate was 
read at 490 nm (background) and 680 nm. Data were analysed by subtracting 
media-only control and background from the instrument (value at 490 nm) from 
average values of each duplicate. Percentage live cells were calculated by 
normalising to positive controls (same cell density treated with 0.1% (v/v) Triton-X-
100).  
2.5.3 LIVE/DEAD viability/cytotoxicity assay 
LIVE/DEAD assay was undertaken to determine cell viability and distribution of cells 
with the 3D matrix. The LIVE/DEAD viability/cytotoxicity assay kit for mammalian 
cells was undertaken according to the manufacturer's instructions (Cat. No.: L3224, 
Invitrogen, ThermoFisher). Stock solutions of 2 µM calcein AM and 4 µM EthD-1 
were made up in sterile PBS prior to addition to differentiated 3D cultures. Three 
hundred µL of calcein/EthD-1 solution was added per well of thin layer 3D cultures 
and incubated for 45 mins at RT. Cultures were visualised immediately using an 
IX51Inverted fluorescence microscope (Olympus). 
2.6 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and western blotting 
2.6.1 Protein extraction 
2.6.1.1 Protein extraction from 2D cultures 
Culture medium was removed from monolayer cultures and cells washed twice with 
sterile PBS. Protein was extracted using lysis buffer (CellLytic MTM, 1 mM 
phenylmethylsulphonyl fluoride (PMSF) and 1x protease inhibitor cocktail) at 4oC 
under gentle shaking for 15 mins. Following lysis, cells were scraped and centrifuged 
at 15,000 x g for 10 mins to separate protein from cellular debris. The resultant 
supernatant containing protein was frozen at -80oC until further use.  
2.6.1.2 Protein extraction from 3D cultures  
For general protein extraction, 3D cultures were harvested from cell culture inserts 
by cutting round (but not completely) the ThinCert membrane, placing onto a 
centrifuge tube and spinning at 1,000 x g to collect Matrigel™-cell pellet. Samples 
were frozen at this point at -80oC for future analysis. For protein extraction, 
Matrigel™-cell pellet was thawed on ice for 10 mins. An equal volume of 2x 
extraction buffer (1 x TBS, pH 7.4, 2 x protease inhibitor tablets, 100 mM sodium 
48 
 
orthovanadate, 100 mM sodium fluoride and 20 mM PMSF) was added to 
Matrigel™-cell pellet and homogenised using a rotor-driven homogenizer before 
sonication. The homogenised solution was centrifuged at 15, 000 x g for 10 mins to 
separate cellular debris. The resultant supernatant containing protein was frozen at -
80oC until further use. 
2.6.1.3 TBS/SDS/Formic acid extraction of thick-layer 3D cultures 
For TBS/SDS/Formic acid extraction of thick-layer 3D cultures, the protein was 
harvested from Matrigel™-cell pellets as section 2.6.1.2, prior to centrifugation. 
Following sonication, centrifugation was performed at 100,000 x g (~48,000 rpm 
using a TLA-55 fixed angle rotor) for 1 hr at 4oC using a benchtop Beckman Coulter 
Optima™ MAX ultracentrifuge (Beckman Coulter, UK). The supernatant was then 
TBS-soluble fraction and was frozen at -20oC. The cell pellet remaining was 
homogenised with 50 µL of 1 x SDS extraction buffer (2% (w/v) SDS, 1% (v/v) Triton 
X-100, 1 x TBS/EDTA, pH 7.4, 2 x protease inhibitor tablets, 100 mM sodium 
orthovanadate, 100 mM sodium fluoride and 20 mM PMSF) then sonicated before 
centrifugation at 100,000 x g for 1 hr at 4oC. The supernatant was saved as the TBS-
insoluble/2% SDS-soluble fractions and stored at -20oC. The cell pellet was washed 
with 100 µL 1x SDS extraction buffer and 10 µL of 70% (v/v) formic acid were added 
before centrifugation at 100,000 x g for 1 hr at 4oC. The supernatant was the TBS-
insoluble/2% SDS-insoluble/formic-acid-soluble fraction. Fractions were used for 
western blotting or ELISA analysis. 
2.6.2 BCA assay for protein determination 
Protein concentration was determined using the manufacturer's protocols for the 
Bicinchoninic Acid Protein Assay Kit (BCA, Sigma-Aldrich). Briefly, 25 μL sample or 
standard was added to 200 μL of working BCA reagent (19 mL BCA and 0.38 mL 4% 
(w/v) copper sulphate) in a 96-well plate incubated at 37oC for 30 mins. In order to 
produce a standard curve, protein standards were made using bovine serum albumin 
(BSA) in distilled water (dH2O) at concentrations of 0, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 and 
2.0 mg/mL. The absorbance at 570 nm was measured and protein concentration 
was determined using the equation of the standard curve.  
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2.6.3 SDS-PAGE electrophoresis 
Glass plates were used to cast gels according to the manufacturer's protocols (1.5 
mm thickness, Bio-Rad). The resolving gel was cast first and allowed to polymerise 
with the addition of 200 µL isopropanol to the top of the gel (Table 2.3). Following 
polymerisation, isopropanol was removed and stacking gel added on top of the 
resolving gel. A well-comb was added (10 or 15 wells) for the formation of wells.  
For electrophoresis, cell lysates were prepared to known protein concentrations 
(from BCA assay) at 30-50 µg protein in 20 µL samples followed by the addition of 
4x loading buffer. 10 mL of 4x loading buffer contained: 2 mL 1M Tris-HCl pH 6.8, 
0.8g SDS, 4 mL 100% glycerol, 0.4 mL 14.7 M β-mercaptoethanol, 1 mL 0.5 M 
EDTA and 8 mg bromophenol blue. 10x running buffer (5 mM Tris-HCl, 250 mM 
glycine, pH 8.3, 0.1% (w/v) SDS) in 1 L ultrapure water) was diluted 1:10 in ultrapure 
water prior to addition to gels. Samples were loaded into wells in addition to a broad 
molecular weight prestained protein ladder (10-245 kDa, Cat. No.: ab116028, 
Abcam). Proteins were resolved at 120 V for 1-2 hrs before either staining gels with 
Instant Blue (Cat. No.: 1SB1L, Expedeon, Cambridge, UK) to visualise proteins or 
proceeded with western blotting. 
 Gel component 
Volume added 
for resolving gel  
Volume added 
for stacking gel  
12% gel 
1.5 M Tris-HCl, pH 8.8 2 mL - 
0.5 M Tris-HCl, pH 6.8 - 1.25 mL 
Ultrapure water 3.4 mL 2.9 mL 
40% acrylamide 2.4 mL 0.75 mL 
10% (w/v) SDS 80 µL 50 µL 
10% (w/v) APS 80 µL 50 µL 
TEMED 8 µL 5 µL 
15% gel 
1.5 M Tris-HCl, pH 8.8 2 mL - 
0.5 M Tris-HCl, pH 6.8 - 1.25 mL 
Ultrapure water 2.8 mL 2.9 mL 
40% acrylamide 3 mL 0.75 mL 
10% (w/v) SDS 80 µL 50 µL 
10% (w/v) APS 80 µL 50 µL 
TEMED 8 µL 5 µL 
Table 2.2-1. Components for 12% and 15% SDS-PAGE gel recipes. 
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2.6.4 Western blotting 
Resolved protein was transferred onto a 0.45 μm polyvinylidene fluoride (PVDF) 
membrane (Amersham Hybond 0.45 µm, Cat. No.: 10600023, GE Healthcare Life 
Sciences, Buckinghamshire, UK) for either 90 mins at 75 volts (GPX4) or 120 mins 
at 100 volts (α-syn/phosphorylated α-syn). For improved immunodetection of α-
syn/phosphorylated α-syn on membranes, the membrane was fixed using 4% (w/v) 
PFA/0.1% (v/v) glutaraldehyde for 30 mins at RT (Lee and Kamitani, 2011; Sasaki et 
al., 2015). Membranes were rinsed briefly in water before proceeding with staining of 
total protein with REVERT™ Total Protein Stain Kit (P/N 926-11010; LI-COR 
Biosciences, UK) and subsequent immunodetection. 
As an alternative for housekeeping proteins to normalise target proteins, 
normalisation of the target protein to loaded sample was undertaken using the 
REVERT™ Total Protein Stain Kit. For total protein staining, membranes were 
washed following transfer with dH2O and incubated in 5 mL of REVERT™ Total 
Protein Stain solution for 5 mins with gentle shaking. After staining, the membrane 
was rinsed two times for 30 seconds with 5 mL wash solution and rinsed briefly in 
dH2O before imaging immediately in the 700 nm channel using an Odyssey® Imaging 
System. For single colour western blotting, membranes were immediately placed in 
blocking solution. For two-colour western blots, the membrane was incubated in 5 
mL of REVERT™ Reversal solution after imaging the membrane. Membranes were 
incubated in REVERT™ Reversal solution until the stain was no longer visible by 
eye, after 5-10 mins. The membrane was rinsed briefly in water and immediately 
followed with blocking.  
The membrane was blocked in either TBS-T with 5% (w/v) non-fat milk (NFM) for 
non-phosphorylated proteins or in Odyssey Blocking Buffer (TBS, Cat. No.: P/N 927-
50100, LI-COR Biosciences) for the detection of phosphorylated proteins. The blots 
were incubated for 1 hr at RT, followed by overnight incubation with primary 
antibodies in TBS-T with 2% (w/v) NFM at 4oC under gentle shaking. For the 
detection of phosphorylated proteins, NFM was omitted in antibody solutions. 
Membranes were washed 3 times for 10 mins with TBS-T and incubated with 
secondary antibody in TBS-T with 2% (w/v) NFM for 1 hr at RT. LI-COR secondary 






Clonality Optimal Dilution 
Secondary 
Antibody 
α-synuclein syn211 Fisher: AFMA112874  Mouse monoclonal 1:2000 Goat anti-mouse  
Phosphorylated α-
synuclein (S129) 
Abcam: AB59264 Rabbit polyclonal 1:2000 Goat anti-rabbit 
GPX4 Abcam: AB125066 Rabbit polyclonal 1:1000 Goat anti-rabbit 
Tyrosine 
hydroxylase 
Sigma: T1299 Mouse monoclonal 1:7500 Goat anti-mouse 
IRDye® 680LT Goat 
anti-mouse IgG 
(H+L) 
Licor: 925-68070 Goat polyclonal 1:15000 N/A 
IRDye® 680RD Goat 
anti-rabbit IgG 
(H+L) 
Licor: 925-68071 Goat polyclonal 1:15000 N/A 
Table 2.2-2. Antibody information for western blotting. All antibodies were diluted in 1 x TBS. 
2.6.5 Total protein quantification using REVERT Total Protein Stain  
REVERT™ Total Stain analysis was used to monitor protein transfer across the 
entire blot and to normalise proteins levels of target proteins. In order to quantify 
target proteins in each lane, Total Protein Stain (TPS) levels (700 nm) were first 
quantified before analysing target proteins in either the 700 nm or 800 nm channels 
(see section 2.6.4 for two-colour detection after TPS). To quantify target proteins, the 
lane normalisation factor was calculated from each lane of the Total Protein Stain 
image, using the following calculation: 
𝐿𝑎𝑛𝑒 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 =
𝑇𝑃𝑆
𝑇𝑃𝑆 𝑠𝑖𝑔𝑛𝑎𝑙 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑙𝑎𝑛𝑒 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 ℎ𝑖𝑔ℎ𝑒𝑠𝑡 𝑠𝑖𝑔𝑛𝑎𝑙
  
To calculate the normalised signal for target quantification, the normalised signal for 
each band was divided by the signal for each band by the Lane Normalisation Factor 
for the lane the band is in, using the following calculation:  








Figure 2.3. Example of REVERT™ Total Protein Stain Lane Normalisation. (A) Visualisation of REVERT™ Total 
Protein Stain at 700 nm. Lanes highlighted to represent the highest signal (lane 12) on the blot and an example 
lane used for normalisation (lane 6). (B) Visualisation of GPX4-positive bands in the 800 nm channels. Lanes 6 
and 12 shown as an example of normalisation. (C) Lane normalisation factor was calculated by dividing the 
signal at 700 nm by the highest signal (at 700 nm). In this example, lane 12 has the highest signal of 8240000, 
therefore the other lanes are divided by this value to give the lane normalisation factor. (D) Lane normalisation 
factor is used to calculate the relative signal intensity of the band of interest (GPX4, B). The signal at 800 nm in 
this example is divided by the lane normalisation factor to give the normalised signal. 
2.7 Dot blotting 
Nitrocellulose membranes (0.45 µm, GE Healthcare) were spotted with 1 µL of 
sample and allowed to air dry. Samples were blocked for 1 hr in 5% (w/v) NFM in 
TBS-T. Primary antibody was diluted in 1% (w/v) NFM in TBS-T and incubated for 1 
hr at RT under gentle shaking. Three wash steps were performed with TBS-T before 
the addition of secondary antibodies. Secondary antibodies were diluted in 1% (w/v) 
NFM in TBS-T and incubated with membranes for 1 hr at RT under gentle shaking. 
Visualisation was performed using the LI-COR Odyssey and Odyssey Imaging 
software (LI-COR Biosciences, UK). 
2.8 α-Syn ELISA 
Human α-syn ELISA was performed using the Abcam Human Alpha-Synuclein 
SimpleStep ELISA® kit according to manufacturer's protocols (Cat. No. AB210973, 
Abcam). Briefly, protein samples were normalised using protein concentrations 
calculated from BSA assay and diluted either 1:5, 1:10 or 1:50 in 1x Cell Extraction 
Buffer PTR. A standard curve was prepared first by the addition of 1 mL of 1x Cell 
Extraction Buffer PTR to the human α-syn lyophilised recombinant protein provided 
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in the kit (stock standard, 5,000 pg/mL). 140.4 µL of 1x Cell Extraction Buffer PTR 
was added to tube number 1 and 130 µL was added tubes numbered 2-8. A serial 
dilution was prepared by transferring 249.6 µL from the stock standard to tube 
number 1, then 260 µL from tubes 1-7. Standard 8 was classed as no protein control 
(blank). 50 µL of sample or standards were added to wells with 50 µL Antibody 
Cocktail. The plate was sealed and incubated for 1 hr at RT on a plate shaker at 400 
rpm. Each well was subsequently washed 3x 350 µL with 1x Wash Buffer PT. 
Following wash steps, 100 µL TMB substrate was added to each well and incubated 
for 10 mins in the dark on a plate shaker at 400 rpm. For an endpoint reading, 100 
µL of Stop Solution was added to each well for 1 minute on a plate shaker. The plate 
was scanned at 450 nm using a CLARIOstar® plate reader. α-Syn concentrations of 
samples were calculated by using the equation of the α-syn standard curve and 
multiplying by the dilution factor used for each sample. 
2.9 RNA Extraction and qPCR 
2.9.1 RNA extraction from 2D cell cultures 
Total RNA was extracted from 1 x 106 cells using either the ReliaPrepTM RNA Cell 
Miniprep System (Cat. No. Z6011, Promega, UK) or using TRIzol® reagent (Cat. No. 
15596026, Invitrogen). Total RNAs were prepared using the ReliaPrepTM RNA Cell 
Miniprep System according to the manufacturer's protocols. Briefly, cell pellets were 
washed once with ice-cold, sterile 1x PBS and centrifuged at 300 x g for 5 mins to 
collect the cells. 250 µL BL + TG buffer (for 1 x 106 cells) was added to the cell pellet 
and mixed by vortexing and pipetting. 85 µL isopropanol (for 1 x 106 cells) was 
added to cells in BL + TG buffer and vortexed for 5 seconds. Lysates were 
transferred to a ReliaPrep™ Minicolumn and centrifuged at 13,000 x g for 30 
seconds at RT. 500 µL RNA Wash Solution was added to the ReliaPrep™ 
Minicolumn with bound nucleic acids, and centrifuged at 13, 000 x g for 30 seconds. 
DNase I enzyme (24 µL Yellow Core Buffer, 3 µL 0.09 M MnCl2 and 3 µL DNase I 
enzyme/sample) was incubated on the column membrane for 15 mins at RT. After 
incubation, 200 µL of Column Wash Solution was added to the column, followed by 
centrifugation at 13,000 x g for 15 seconds. 500 µL RNA Wash Solution was added 
and centrifuged at 13,000 x g for 30 seconds, followed by another wash step with 
300 µL RNA Wash Solution and centrifuged for 2 mins at 13,000 x g. Isolated RNAs 
were eluted using nuclease-free water by adding 30 µL of nuclease-free water (for 1 
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x 106 cells) to membranes and centrifuged at 13,000 x g for 1 minute. RNA was 
subsequently used for cDNA synthesis or stored at -80oC for future work. 
For RNA extraction using TRIzol® reagent, cells were harvested and washed with 
ice-cold PBS before extraction. Cells were lysed with 1 mL of TRIzol® reagent at RT 
for 10 mins. 0.2 mL of chloroform was added per 1 mL of TRIzol® reagent, vortexed 
for 15 seconds and incubated at RT for 10 mins for phase separation of RNA 
(aqueous phase, colourless, top), DNA (interphase, white, middle) and proteins/lipids 
(organic phase, red/pink, bottom). The aqueous phase was transferred to a new tube 
and RNA precipitated with the addition of 0.5 mL isopropanol per 1 mL of TRIzol® 
reagent. Samples were transferred to -80oC to precipitate RNA for at least an hr, or 
for greater yields, overnight. RNA was harvested by centrifugation at 12,000 x g for 
15 mins at 4oC. The resultant RNA pellet was washed with 75% ethanol and 
centrifuged at 7,500 x g for 10 mins at 4oC. RNA pellets were air-dried on ice for 10-
15 mins prior to solubilisation in nuclease-free water. Isolated RNA was used for 
subsequent cDNA synthesis or stored at -80oC for future work. 
2.9.2 RNA extraction from 3D cell cultures 
2.9.2.1 Extraction using Corning® Cell Recovery Solution 
Cells were recovered from the Matrigel following the dissolution of the matrix using 
Corning® Cell Recovery Solution (Corning, UK). The medium was removed from 3D 
cultures and washed with ice-cold PBS 3 times. Three hundred µL Matrigel gel 
culture was added to 3 mL of ice-cold Corning® Cell Recovery Solution in an ice-
cold falcon tube and left on ice for 1 hr. The tube containing the Matrigel and 
Corning® Cell Recovery Solution was inverted and left on ice until dissolved before 
centrifugation at 1000 rpm at 4oC for 5 mins. To completely release from the gel, 
cells were washed with ice-cold PBS before centrifugation 2 more times. Total RNAs 
were prepared using the ReliaPrepTM RNA Cell Miniprep System (Promega, UK) 
according to the manufacturer's protocols.  
2.9.2.2 Extraction using TRIzol® 
For extraction of RNA from 3D cultures using TRIzol® reagent, Matrigel™ cultures 
were incubated in 1 mL TRIzol® reagent for 10 mins to lyse cells. RNA isolation was 
subsequently carried out according to section 2.8.1. 
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2.9.3 RNA Yield and Quality 
RNA concentration and quality were determined using the NanoDrop 
spectrophotometer and RNA integrity was determined using agarose gel 
electrophoresis. Good quality and intact RNA was determined to be samples with an 
A260/A280 ratio of 2.0-2.1 and A260/A230 ratio >2.0 and the presence of distinct 
28s and 18s subunits following electrophoresis, with the absence of any genomic 
contamination or smearing. 
2.9.4 cDNA synthesis 
Complementary DNAs (cDNA) were synthesised by the nanoScript 2 Reverse 
Transcriptase kit (Cat. No. RT-NanoScript2, Primerdesign Ltd, UK). For the 
annealing step, 2 µg RNA template was incubated with oligo-dT, random nonamer 
primers and RNase/DNase free water (in 10 µL reaction volume) for 5 mins at 65oC 
before immediately cooling on ice. For the extension step, a 10 µL mixture of 
nanoScript2 4x Buffer (5 µL), sNTP mix 10 mM (1 µL), RNase/DNase free water (3 
µL) and nanoScript2 enzyme (1 µL) was added to each reaction from the annealing 
step on ice. Tubes were mixed briefly by vortexing and incubated at 25oC for 5 mins 
then at 42oC for 20 mins. The reaction was inactivated by incubation at 75oC for 10 
mins. cDNA samples were subsequently used for qPCR either straightaway or 
stored at -20oC for short term storage or at -80oC for long-term storage.  
2.9.5 qPCR 
Quantitative real-time polymerase chain reaction (qPCR) was undertaken using 
Precision®PLUS qPCR Master Mix formulated for Applied Biosystems 
StepOnePLUS or LifeTechnologies QuantStudio (Cat. Nos. PPLUS-LR and PPLUS-
R, Primerdesign) and pre-validated primer sets purchased from Primerdesign (Cat. 
No. SY-HU for TH, DAT, NES, MAP2, VMAT2 or TUBB3) or Sigma-Aldrich 
(KiCqStart® SYBR® Green Primers, Cat. No. KSPQ12012 for SLC7A11, SLC3A2, 
SLC7A5, VDAC 1, VDAC2 and VDAC3). For the qPCR reaction, cDNA samples 
were diluted to 5 ng/mL in nuclease-free water and 5 µL of sample added to in 
duplicate to the wells of a Bright White qPCR plate (Cat. No. BW-FAST, 
Primerdesign). A master mix was prepared to contain 10 µL PrecisionPLUS qPCR 
Master Mix, 1 µL primer/probe and 4 µL RNase/DNase free water per sample and 
added to each well containing diluted cDNA. Plates were sealed and centrifuged to 
collect samples at the bottom of the wells. The amplification was performed in a final 
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volume of 20 µL under the following conditions: 2 min at 95oC and then 50 cycles at 
95oC for 15 sec and 60oC for 60 sec followed by a post PCR melt curve analysis. 
The sizes of PCR products were confirmed using agarose gel electrophoresis. Gene 
expression levels were normalised against reference genes for each sample and fold 
changes were calculated using the 2-ΔΔCt method (Schmittgen and Livak, 2008) by 
setting the expression levels of each gene in undifferentiated SH-SY5Y/untreated 
cells as 1. Data collected from at least three independent biological replicates was 
calculated and plotted as mean log10-fold changes ±SEM. 
2.9.5.1 GeNorm Analysis 
Reference gene analysis was undertaken using the geNormPLUS kit (Primerdesign) 
and Qbase+ software to identify inherently stable reference genes for RT-PCR 
between different treatment groups following differentiation of SH-SY5Y with RA and 
BDNF. A reference gene mixture was made up with 1 µL primer, 10 µL Primerdesign 
2x PrecisionPLUS™ master mix and 4 µL of RNase/DNase free water per well, 
according to the plate set up. Five µL of diluted cDNA samples were added to wells 
for a final well volume of 20 µL. The amplification was done in a final volume of 20 
µL under the following conditions: 2 min at 95oC and then 40 cycles at 95oC for 10 
sec and 60oC for 60 sec followed by a post PCR melt curve analysis. Optimal 
reference genes were calculated using Qbase+ software (Biogazelle). 
2.9.6 Agarose gel electrophoresis 
PCR products and isolated RNA were separated on a 1% (w/v) agarose gel to check 
RNA quality and confirm the size of PCR products. 50x tris-acetate-EDTA (TAE) 
buffer (40 mM Tris, 20 mM acetate and 1 mM EDTA, pH 8.6) and diluted 1:50 for use 
in electrophoresis. A 1% (w/v) agarose gel UltraPure™ Agarose (Cat. No.: 
16500500, ThermoFisher) in 1x tris-acetate-EDTA (TAE) buffer and heating in 30 
sec bursts in a microwave until all agarose was dissolved. The solution was allowed 
to cool before the addition of 0.5 µg/mL ethidium bromide (Cat. No.: 15585011, 
ThermoFisher). Gels were poured into a Bio-Rad gel tray sealed with a Bio-Rad gel 
caster with the addition of a well-comb then allowed to set at RT. Agarose gels were 
placed in a Bio-Rad horizontal electrophoresis tank (Mini-Sub® Cell GT Cell) and 
submerged in 1x TAE buffer. DNA or RNA samples were mixed with 10x gel loading 
buffer (Cat. No.: A3481.0010, VWR, Leicestershire, UK) and loaded into wells (2 µL 
of loading buffer per 20 µL DNA/RNA). A 100 base pair (bp) to 2,000 bp ladder (Cat. 
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No.: 15628050, Invitrogen) was added alongside DNA/RNA samples to aid in size 
estimation.  Samples were resolved at 100 volts for 1-1.5 hrs and viewed on a 
NuGenius/NuGenius+ gel imaging system.   
2.10 Expression of WT recombinant α-synuclein and production of oligomers 
2.10.1 Transformation of competent E. coli  
BL21 (DE3) E. coli competent cells (Agilent Technologies, 200121) were thawed on 
ice and incubated with a pET 23a+ vector containing the human WT α-syn sequence 
or negative control (BL21 (DE3) competent cells with no plasmid added) for 30 mins 
at RT with periodic gentle agitation. Cells were exposed to heat shock at 42oC for 45 
seconds and returned to ice for 5 mins. Five hundred μL LB broth (1% (w/v) tryptone, 
1% (w/v) sodium chloride and 0.5% (w/v) yeast extract) was added to each tube and 
incubated in a shaking incubator at 200 rpm, 37oC for 1 hr to allow cells to express 
antibiotic resistance genes. One hundred µL of the reaction was spread onto LB agar 
plates containing the selectable marker ampicillin (100 mg/mL) and incubated 
overnight at 37oC. Colonies were observed 24 h after transformation apart from 
plates inoculated with negative control cells (no plasmid added).  
2.10.2 Expression and purification of recombinant protein 
Single colonies were inoculated into starter cultures containing 100 mL LB media 
and 100 μL of 100 mg/mL ampicillin solution and incubated in a shaking incubator at 
200 rpm, 37oC overnight. Ten mL starter cultures were added to auto-induction 
medium (Formedium, UK) and incubated in a shaking incubator at 200 rpm, 37oC for 
24 hrs to induce expression of WT α-syn. Bacterial cells were harvested by 
centrifugation at 4oC, 8,000 rpm. The resulting pellet was resuspended in lysis buffer 
(10 mM Tris-HCl, pH 8, 100 µg/mL lysozyme, 20 µg/mL DNase, 20 µg/mL RNase, 1 
mM PMSF and 1x protease inhibitor mini-tablet EDTA free) and incubated for 30 
mins before the addition of 1 mM EDTA and sonication of the cell pellet to enhance 
cell lysis. Following lysis, the cell lysate was centrifuged at 10,000 x g for 40 mins to 
remove cellular debris. The supernatant was acidified to pH 4.5 and centrifuged 
again at 10,000 x g for 40 mins to remove any aggregated protein. The pH of the 
resulting supernatant was adjusted to pH 8 before the crude lysate was subjected to 
further purification by anion exchange and size exclusion chromatography using the 




For anion exchange, a 50 mL Q-Sepharose column (Q1126; Q-Sepharose Fast 
Flow, Sigma-Aldrich) was equilibrated with two column volumes of buffer A (25 mM 
Tris-HCl, pH 8) followed by loading of the column with crude lysate. Bound protein 
was eluted with a 0-100% linear gradient of buffer B (25 mM Tris-HCL, 1 M NaCl, pH 
8) in 5 mL fractions. After elution, the protein was dialysed overnight at 4oC with at 
least 6 changes of water prior to freeze-drying. The resultant lyophilised protein was 
subject to size exclusion chromatography. For size exclusion chromatography, a Hi-
Load 26/200 Superdex 200 pg column (28989336; GE Healthcare) was equilibrated 
with three column volumes of buffer A. Lyophilised protein was dissolved in 3 mL 
buffer A before injection. Protein was eluted in 5 mL fractions before being subjected 
Figure 2.4. 
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to dialysis and freeze-drying. Lyophilised purified α-syn was stored at -20oC. Protein 
concentration was measured using a UV/vis spectrophotometer (Jenway 6715) at 
absorbance 214 nm with an extinction coefficient of 5960 M-1 cm-1. 
2.10.3 Production of α-synuclein oligomers 
Seeding oligomers were prepared as previously described by Danzer et al. (2009), 
omitting the addition of 10 µM FeCl2. Briefly, lyophilised α-syn was dissolved in 50 
mM sodium phosphate buffer (pH 7.0) containing 20% (v/v) ethanol to a final 
concentration of 7 µM.  Following overnight incubation at 21oC with continuous 
shaking, oligomers were concentrated 1:14 using ultracentrifugation (VivaSpin 500 
columns, MWCO 30 kDa, GE Healthcare), allowing the separation of oligomeric 
species from monomeric protein. Each batch of oligomers was used immediately for 
experiments. Oligomers were determined to be present by size exclusion 
chromatography and mass spectrometry analysis (Fig. 2.4).  
2.11 Detection of lipid peroxidation using BODIPY C11 581/591  
2.11.1 Fluorescent microscopy 
For 2D SH-SY5Y cell culture, cells were plated at a density of 1.875 x 105 cells/cm2 
in a 6-well plate containing 2 mL DMEM containing 10% (v/v) FBS and 1% (v/v) P/S. 
Cells were left to adhere and expand to 70% of the culture surface prior to treatment 
with test agents. For the detection of lipid peroxidation after iron (II) chloride 
treatment, cells were incubated with either: media only control, solvent control 
(highest amount of nitrilotriacetic acid trisodium salt (NTA) used), 200 μM or 1000 
μM iron (II) chloride (with 1:2 ratio of iron (II) chloride to NTA) for 12, 24 or 72 hrs at 
37oC. 30 mins before the end of the treatment, 5 μM C11-BODIPY581/591 (Cat. No. 
D3861, ThermoFisher Scientific, UK) was added to the cultures. The medium was 
removed after 30 mins and cells washed three times with PBS before imaging. 
Oxidation of C11-BODIPY581/591 was indicated by the change of BODIPY 
fluorescence from red (non-oxidised) to green (oxidised). Fluorescent microscopy 
was undertaken using an IX51Inverted fluorescence microscope (Olympus). 
Quantification of red and green signals was performed using ImageJ software (US 
National Institutes of Health, Bethesda, MD, USA). Data was analysed by counting 
cells positive for lipid peroxidation (oxidised, green) and calculating the percentage 
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lipid peroxidation as a percentage of the total number of cells per field of view (non-
oxidised, red) using the formula ((green/ (green+red)) x 100(%)).  
2.11.2 Flow cytometry 
Two dimensional SH-SY5Y were cultured until 70% confluent in T75 flasks before 
treatment with media, solvent (NTA only), 200 μM or 1000 μM iron (II) chloride (with 
1:2 ratio of iron (II) chloride to NTA) for 24 hrs or 72 hrs. 24 hr treatment with 10 µM 
menadione was used as a positive control. Following treatment, cells were washed 
with warmed PBS and incubated in 2 µM C11-BODIPY581/591 in PBS for 30 mins at 
37oC. Cells were harvested, pelleted and resuspended in 5mL PBS and subjected to 
flow cytometric analysis. C11-BODIPY581/591 exhibits a shift in fluorescence 
emission from ~590 nm to ~510 nm as detected by flow cytometry. Dyes were 
excited using a 488 nm Ar laser and detected with the FL1 and FL4 detectors on a 
FACSCalibur flow cytometer (BD Biosciences, Berkshire, UK). Ten thousand cells 
were counted for each measurement. For every assay, unstained cells were used to 
set a gating strategy. Data was analysed using FlowJo® software (BD Bioscience) 
with the median fluorescent intensity used for subsequent data analysis, including 
the calculation of percentage lipid peroxidation ((green/ (green+red)) *100(%). 
2.12 Glutathione quantification 
Glutathione quantification was undertaken using the GSH/GSSG-GloTM Glutathione 
Assay according to the manufacturer’s instructions (V6611, Promega). Briefly, 2 x 
104 cells/well were cultured and treated in white-opaque walled 96-well plates. Test 
compounds (media-only, solvent control (NTA only), 200 µM iron (II) chloride and 
1000 µM iron (II) chloride and 10 µM menadione as a positive control) were 
incubated for 24 hrs. Test compounds were removed from cells and replaced with 50 
μL of Total Glutathione Lysis Reagent or Oxidised Glutathione Lysis Reagent as 
appropriate. 50 μL of Total Glutathione Lysis Reagent was also added to no-cell 
controls and wells containing a range of glutathione concentrations (0-16 µM) to 
produce a standard curve. The plate was then shaken at 5 mins at RT before the 
addition of 50 µL/well of Luciferin Generation Reagent and incubated for 30 mins at 
RT. One hundred µL of Luciferin Detection Reagent was added per well and 
incubated for 15 mins at RT. Luminescence was recorded using a CLARIOStar® 
plate reader. The concentration of total and oxidised glutathione in treated cells was 
determined using the equation of the standard curve. 
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2.13 CellROX™ Assay 
Oxidative stress was measured using CellROX™ Green reagent following the 
manufacturer's guidelines (Cat. No's: C10444, ThermoFisher). SH-SY5Y cells were 
cultured on coverslips in 6-well plates and treated with oligomers or iron (II) chloride 
at 70% confluent for 2, 24 or 72 hrs. The CellROX™ Green reagent was added to 
treated cells at a final concentration of 5 µM and the cells incubated for 30 mins at 
37oC. Nuclei were counterstained using Hoechst 33342 (Cat. No. H3570, 
ThermoFisher) diluted 1:2,000 to each well. The medium was then removed, and 
cells washed with PBS, followed by fixing with 10% formalin before mounting and 
curing overnight at 4oC in the dark prior to image capture using an Olympus BX60 
bright field/fluorescent microscope. Corrected total cell fluorescence was calculated 
as described in section 2.3.1. 
2.14 ICP-MS analysis of cultures 
Cells (2D and 3D cultures) were harvested following treatment with media, solvent 
(NTA only), 200 μM or 1000 μM iron (II) chloride (with 1:2 ratio of iron (II) chloride to 
NTA) for 24 hrs. Cell lysates were prepared by removal of culture medium and cells 
washed twice with sterile PBS. Protein was extracted using lysis buffer (CellLytic TM, 
1 mM PMSF and 1x protease inhibitor cocktail) at 4oC under gentle shaking for 15 
mins. Following lysis, cells were scraped and centrifuged at high speed for 10 mins 
to separate protein from cellular debris. The resulting supernatant containing protein 
was frozen at -80oC until further use. A BCA assay was conducted to determine 
protein concentrations. Five hundred μg of each sample (3 biological repeats, 12 
samples total) was freeze-dried. Samples were digested with nitric acid by incubating 
with 150 μL nitric acid at 90oC on a hot block, followed by hydrogen peroxide 
incubation at 90oC. Standards were prepared by diluting trace metals in dH2O to final 
concentrations of 0, 0.5, 1, 5, 10, 50 and 100 nM iron. Iron concentrations of 
samples were calculated using the equation of the standard curve.  
2.15 Statistical analysis 
Statistical analysis was undertaken using StatsDirect version 3.0.126. Data were 
unpaired and determined to be non-parametric following the Shapiro–Wilk test of 
normality; therefore, a Kruskal–Wallis test was undertaken with post hoc analysis. 
Post hoc analysis was only undertaken if the initial significance test was at P<0.05. 
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Dwass-Steel-Chritchlow-Fligner was used for data points >6 and Conover-Inman 





























Aggregation of α-syn into intracellular LB-inclusions represents one of the major 
neuropathological hallmarks of PD. The mechanisms underlying LB formation and 
the influence of α-syn pathology on disease pathogenesis remain poorly understood, 
largely due to the lack of whole-animal or cell-based models that recapitulate the 
development of these inclusions. One of the significant barriers in PD research 
surrounds the difficulty in obtaining cultures of the A9 dopamine-producing neuronal 
population that are specifically affected in the disease (Arenas, Denham and 
Villaescusa, 2015). To address this animal and cell culture systems have been 
developed to model the complex pathogenesis of the disorder (Arenas, Denham and 
Villaescusa, 2015; Xicoy, Wieringa and Martens, 2017). The cost incurred, time 
constraints and ethical framework required for animal-based research are inhibitory 
for many laboratories making cell culture-based systems attractive (Barré-Sinoussi 
and Montagutelli, 2015). The recent development of 3D culture models and 
organoids represent feasible alternatives to animal models (Choi et al., 2014; 
Hoarau-Véchot et al., 2018). In the following sections, popular cellular models used 
in PD research will be highlighted and the limitations/advantages associated with 
each discussed.  
3.1.1 Cell models used in Parkinson's disease research  
3.1.1.1 SK-N-SH and SH-SY5Y cell line 
An in vitro model popular for use in PD research is the SH-SY5Y neuroblastoma cell 
line, a subline of SK-N-SH (Xicoy, Wieringa and Martens, 2017). Due to the difficulty 
in obtaining and maintaining primary neurons, most PD research is performed using 
immortalised cell lines, with the most popular choice being the neuroblastoma SH-
SY5Y cell line. The popularity of the cell line is attributed to both the dopaminergic 
characteristics and ease of culture (Forster et al., 2016). The SK-N-SH cell line is 
originally derived from a bone marrow metastasis of a 4-year-old patient suffering 
from neuroblastoma and established in vitro in the 1970s (Biedler, Helson and 
Spengler, 1973). SK-N-SH comprised of two morphologically distinct cell 
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populations, a small neuritic cell and a large epithelioid cell (Biedler et al., 1978; 
Deinum et al., 2004). SH-SY5Y is a more commonly used neuroblast-like subclone 
of the SK-N-SH used in PD research. SK-N-SH was subcloned three times, first to 
the neuroblast-line SH-SY, then to SH-SY5 and finally SH-SY5Y (Kovalevich et al., 
2013). SH-SY5Y share morphological features of the parental SK-N-SH line 
including the presence of distinct phenotypes of neuroblast-like cells and epithelial-
like cells, corresponding to 'N' and 'S' subtypes, respectively (Encinas et al., 2000; 
Kovalevich et al., 2013). SH-SY5Y also displays a catecholaminergic phenotype, 
with the machinery to synthesise both dopamine and noradrenaline (TH and 
dopamine β-hydroxylase, respectively) (Kovalevich et al., 2013). Using whole-
genome analysis of SH-SY5Y, most of the genes belonging to major PD pathways 
were intact in the SH-SY5Y, including those related to dopamine metabolism 
(Krishna et al., 2014).  
SH-SY5Y can be differentiated into a more neuronal phenotype using a variety of 
chemical agents, including RA, phorbol esters such as 12-O-tetradecanoyl-phorbol-
13 acetate (TPA), cAMP, nerve growth factor, and BDNF, amongst others (Encinas 
et al., 2000; Constantinescu et al., 2007; Dwane, Durack and Kiely, 2013; Teppola et 
al., 2016; Xicoy, Wieringa and Martens, 2017). A review of SH-SY5Y culture 
conditions by Xicoy et al. (2017) reveals only 17% of papers utilising the SH-SY5Y 
cell line in PD research report using a differentiation protocol. Among the papers that 
used differentiated cells, the differentiation treatments were: 10 µM RA with or 
without reduced serum media (~10% of studies overall), other concentrations of RA 
(~3% of studies), 10 µM RA and 80 nM TPA (~2% studies), 10 µM RA and 50 ng/mL 
BDNF (~1% studies) and other (~1% of studies) (Xicoy, Wieringa and Martens, 
2017). Upon differentiation, cells express dopamine receptors (D2 and D3), DAT and 
VMAT2 (Kovalevich et al., 2013).  
Although more studies are utilising the differentiation of SH-SY5Y in PD research, 
the phenotypic outcome can give contradicting outcomes (Xicoy, Wieringa and 
Martens, 2017). Some studies report the development of a dopaminergic or 
cholinergic phenotype following differentiation (Hashemi et al., 2003; Korecka et al., 
2013; Ito et al., 2017). The original source of cells either from the American Type 
Culture Collection (ATCC) or European Collection of Authenticated Cell Cultures 
(ECACC) can also have a huge influence in the phenotype of SH-SY5Y and logically 
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this would affect the ability of cells to differentiate (Donato et al., 2007; Nishida et al., 
2008; Xicoy, Wieringa and Martens, 2017). Due to the cancerous properties of the 
cell line, SH-SY5Y does not wholly represent the cell type post-mitotic nature of 
neurons affected in PD. The cancerous properties influence differentiation fate, 
viability, metabolic properties and genomic instability. However, genes associated 
with major PD pathways are expressed in SH-SY5Y (Krishna et al., 2014). However, 
the importance of differentiation of SH-SY5Y is apparent given the increased 
susceptibility to neuronal toxins such as MPP+ and 6-OHDA when compared to 
undifferentiated counterparts (Presgraves et al., 2004). Increased expression of the 
MPP+ transporter, DAT, in differentiated cells compared to undifferentiated explains 
the differences in susceptibility to neuronal toxins (Presgraves et al., 2004; 
Schildknecht et al., 2009). LUHMES cells following differentiation into a 
dopaminergic phenotype also show increased susceptibility to MPP+ (Schildknecht et 
al., 2009). The differences between mitotically active and post-mitotic cells should 
not be underestimated, given continually dividing cells can be influenced by agents 
that inhibit cell proliferation which MPP+ is known to do (Soldner et al., 1999).  
Treatment with α-syn oligomers has been shown to induce the formation of α-syn-
positive intracellular inclusions with different morphologies in differentiated and 
undifferentiated cells, with differentiated cultures showing greater resemblance to in 
vivo morphologies and is the subject of this chapter (Taylor-Whiteley et al., 2019).  
3.1.1.2 Immortalised human embryonic mesencephalic cells (LUHMES and 
ReNcell) 
LUHMES is a clone of the MESC2.10 (derived from eight-week-old human 
mesencephalic cells) and immortalised by use of a retroviral vector containing the 
tetracycline controlled v-myc-oncogene (Hoshimaru et al., 1996; Lotharius et al., 
2002; Lotharius, 2005). In the absence of tetracycline, v-myc is constitutively 
expressed allowing cells to proliferate continuously in culture (Lee and Reddy, 1999). 
Addition of low, non-toxic, levels of tetracycline abolishes v-myc expression, allowing 
cells to exit the cell cycle and differentiate in a post-mitotic state (Hoshimaru et al., 
1996). LUHMES cells can undergo differentiation using tetracycline, cAMP and glial-
derived neurotrophic factor (GDNF), resulting in the development of mature 
electrically active dopaminergic-like neurons that express TH, DAT, VMAT2, βIII-
tubulin and increased levels of α-syn (Lotharius et al., 2002; Schildknecht et al., 
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2009; Scholz et al., 2011; Smirnova et al., 2016). In regards to PD, LUHMES have 
been used to investigate MPP+/rotenone associated neurodegeneration 
(Schildknecht et al., 2009; Pöltl et al., 2012; Krug et al., 2014; Smirnova et al., 2016; 
Harris et al., 2018), neuroprotection (e.g. upregulation of hypoxia-inducible factor 
(HIF) genes) (Johansen et al., 2010), lysosomal dysfunction (Gan et al., 2015), cell 
death mechanisms (e.g. apoptosis/ferroptosis) (Do Van et al., 2016). With regards to 
α-syn aggregation in LUHMES, there isn't the wealth of data available as with the 
more commonly used cell line SH-SY5Y, due to the number of studies using 
LUHMES cells being limited. However, as the use of the cell line is becoming more 
popular, the number of studies will increase.  
Although LUHMES represent a promising cellular model for modelling PD in vitro, 
the use of the cell line does have its negatives. For example, LUHMES need to be 
cultured on poly-L-lysine and fibronectin-coated culture surfaces but this support 
matrix is degraded by the growing/differentiating cultures. Monolayer cultures tend to 
detach from culture vessels as early as 72 hrs after differentiation (Smirnova et al., 
2016). This has been circumvented by culturing in 3D spheroid culture, allowing for 
prolonged survival of the differentiated cells and suitability of the 3D model for long-
term neurotoxicity studies (Smirnova et al., 2016; Harris et al., 2018).   
3.1.1.3 Non-neuronal cell lines 
HEK-293 is a cell line originally derived from normal embryonic kidney cells from the 
kidney of an aborted human embryo (Graham et al., 1977). Transfection of the cell 
line was achieved following exposure and incorporation of mechanically sheared 
adenovirus type 5 DNA into chromosome 19 of the host genome (Graham et al., 
1977; Louis, Evelegh and Graham, 1997; Thomas and Smart, 2005). HEK-293 is 
widely used in cell biology and biotechnology mainly due to the ease of growth in 
culture and as an excellent cell line to use in transfection experiments (Thomas and 
Smart, 2005). Although derived from kidney cells, HEK-293 display some properties 
associated with cells of a neuronal lineage, as demonstrated by the strong 
immunoreactivity to neurofilaments (NF-M, NF-L and a small amount of NF-H) and 
mRNAs normally expressed in early differentiating neurons (Shaw et al., 2002; 
Thomas and Smart, 2005). Several other adenoviral transformed cells derived from 
human embryonic kidney cells also express a similar expression of intermediate 
filaments indicative of an early differentiating neuronal phenotype (Shaw et al., 
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2002). Later analysis indicated the adenovirus transformed the small percentage of 
cells of neuronal lineage in the original HEK-293 culture, explaining the difficulty in 
establishing the original cell line (Shaw et al., 2002). In PD research, the cell line is 
mainly used for stably expressing mutant or normal α-syn typically in conjunction 
with other proteins of interest e.g. DAT (Lehmensiek et al., 2006; Shavali et al., 
2008; Luk et al., 2009). Of interest, the addition of a fibrillar seed to α-syn 
overexpressing HEK-293 was shown to induce the formation of LB-like inclusions by 
actively recruiting endogenous α-syn (Luk et al., 2009). Importantly, these LB-like 
aggregates underwent several modifications characteristic of LBs in vivo including 
phosphorylation and ubiquitination, demonstrating the potential role of fibrillar seeds 
in the pathogenesis of PD (Luk et al., 2009). 
3.1.1.4 PC12 and Neuro-2a 
The rat-derived PC12 pheochromocytoma cell line exists as a mixture of neuroblastic 
cells and eosinophilic cells that are able to synthesize, release, take up and store 
catecholamines (Greene and Tischler, 1976). PC12 differentiate in response to 
serum-free media and nerve growth factor (NGF) (Greene, 1978). Upon 
differentiation, cells cease to be mitotically active, extend neuronal-like processes 
and are classed as sympathetic-neuron-like cells (Greene and Rein, 1977; Greene, 
1978). PC12 cells are sensitive to several toxins that mimic PD and therefore are 
used as a cell model to study neurodegeneration and neuroprotection in relation to 
mitochondrial toxins 6-OHDA (Walkinshaw and Waters, 1994; Ryu et al., 2002), 
MPP+ (Ryu et al., 2002; Chakraborty et al., 2017), rotenone (Mirzaei et al., 2006; Jing 
et al., 2014) and paraquat (Yang and Sun, 1998). Iron and paraquat treatment in 
PC12 cells was shown to exacerbate lipid peroxidation and subsequent cell death 
(when compared to paraquat treatment alone), therefore indicating the importance of 
iron in PD (Yang and Sun, 1998). This is especially interesting as in recent years the 
iron-dependent cell death pathway, ferroptosis, has been linked to pathology in PD 
(Do Van et al., 2016).  
N2a is a mouse neural crest-derived cell line able to differentiate into either 
cholinergic or dopaminergic cells depending on culture conditions (Kojima et al., 
1994; Tremblay et al., 2009). Differentiation of N2a with dibutyryl cAMP (dbcAMP) 
was shown to increase expression of TH and dopamine in contrast to other cultures 
additives of GDNF, RA, transforming growth factor and bone morphogenic protein 4 
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(Wu et al., 1998; Tremblay et al., 2009). Use of N2a in PA research is not particularly 
widespread but have been used to investigate neurotoxicity of MPP+ due to the high 
affinity for MPP+ uptake and vulnerability which exceeds other cell lines of PC12 and 
SH-SY5Y (Mazzio and Soliman, 2003; Deguil et al., 2007; Soliman et al., 2009). 
3.1.1.5 Induced pluripotent stem cells  
Embryonic stem cells (ESCs), derived from the inner cell mass of mammalian 
blastocysts, are able to differentiate into any cell type while maintaining the ability to 
grow indefinitely (Evans and Kaufman, 1981). Induced pluripotent stem cells (iPSCs) 
are pluripotent stem cells that can be generated from adult cells whilst maintaining 
the ability to differentiate into any tissue type (Takahashi and Yamanaka, 2006). The 
programming of mouse fibroblasts into iPSCs was achieved by exposing cells to four 
transcription factors Octamer binding transcription factor-4 (Oct4), Sex determining 
region Y (Sox2), Kruppel-like factor 4 (Klf4) and c-Myc (Takahashi and Yamanaka, 
2006). iPSCs reprogrammed from adult human fibroblasts was subsequently 
reported using the same transcription factors (K. Takahashi et al., 2007; Park et al., 
2008). Disease modelling can be achieved by harvesting skin fibroblasts or blood 
cells from patients and reprogrammed into the cell type to be investigated (i.e. A9-
like dopaminergic neurons) or by introducing specific mutations into wild-type (WT) 
iPSCs (Caiazzo et al., 2011; Devine et al., 2011). 
Culture of ESCs and iPSCs is time-consuming and associated with high cost, with 
the need for expensive reagents for reprogramming and labour costs during clonal 
selection and expansion (Beers et al., 2015). During the expansion stage of iPSC 
samples (where colonies are selected, expanded and frozen), colonies may appear 
at different time points requiring researchers to juggle several samples at different 
stages of reprogramming. For this reason, researchers are limited to 2-4 
reprogramming samples per person (Beers et al., 2015). Beers et al. (2015) quote as 
much as $10,000 in reagents for a full-time researcher to generate a six sample 
iPSC project (3 controls and 3 patients) before characterisation and clonal selection. 
However, optimised methods of iPSC generation have recently reduced the cost 
associated with reprogramming (from ~$1,300/ sample to $150-200/sample) and 
have reduced the need for labour-intensive cell culture (from 2 samples/person to 
20-40 samples/person) meaning iPSCs are becoming more accessible to smaller 
laboratories (Beers et al., 2015). 
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3.1.1.6 Primary cell lines  
Primary cells isolated from rat or murine tissue provides an alternative to the use of 
immortalised cell lines in scientific research. Cultures prepared from the midbrain of 
rats are not solely dopaminergic neuronal preparations, but rather a mixture of 
different kinds of neurons and glia (Falkenburger, Saridaki and Dinter, 2016). 
Approximately 5-10% of neurons cultured are dopaminergic, with only 1-2% positive 
for TH (Visanji et al., 2008; Schüle, Pera and Langston, 2009; Falkenburger, Saridaki 
and Dinter, 2016). Dissociated rodent superior cervical sympathetic ganglia are the 
primary neuronal counterpart to the PC12 immortalised cell line and succumb to 6-
OHDA and MPP+ (Grau and Greene, 2012).  
3.1.2 Three dimensional cell culture 
Recent progress in 3D cell culture systems has facilitated the development of human 
cellular disease models to study the pathogenesis of disease in a more 
physiologically relevant context when compared to traditional 2D culture models. 
Much of our understanding of cell biology processes is based on studies of cells 
grown in 2D monolayer cultures on flat polystyrene or glass surfaces whereby cells 
are in contact with homogenous amounts of nutrients and growth factors (Breslin and 
O’Driscoll, 2013). However, cells in vivo exist in complex tissues with cells interacting 
with multiple extracellular matrix (ECM) components, other cell populations and 
various cell-secreted factors. The limitation in the interaction between other cells and 
or/ECM has an enormous impact both on cellular structure and cellular function, 
including survival, differentiation, proliferation and migration (Abbott, 2003). 3D 
cultures have been shown to more closely mimic cellular in vivo characteristics when 
compared to 2D counterparts, including the development of a more mature neuronal 
phenotype when cultured in 3D (Jo et al., 2016; Marchini et al., 2019).  
There are several formats and materials suitable for use in 3D culture. Cells can be 
cultured in scaffold-based or scaffold-free systems (Vinci et al., 2012). Scaffold-
based cultures involve culturing cells either on synthetic/biologically-derived 
scaffolds (Breslin and O’Driscoll, 2013; Eglen and Klein, 2017). Synthetic scaffolds 
include the cultivation of cells grown on a hard material based support such as 3D-
printed structures (made metals, ceramics or other polymers), polystyrene-based 3D 
culture materials (e.g. 3D Biotek Inserts™), sponge-like structures (e.g. foams) or 
fibres (Caicedo-Carvajal et al., 2011; Accardo et al., 2017; Xu et al., 2018). 
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Biologically-derived scaffolds typically consist of hydrogel cultures which can be 
classified as ECM protein-based hydrogels (e.g. Matrigel™, laminin, and collagen), 
natural hydrogels (e.g. alginate beads and dextran) and synthetic hydrogels (e.g. 
polyethylene glycol, polyvinyl alcohol, polycaprolactone and polyhydroxyethyl 
methacrylate) (Lim F. and Sun A.M., 1980; Hughes, Postovit and Lajoie, 2010). 
Scaffold-free systems involve the formation of multi-cellular aggregates generally 
known as spheroids, whereby interactions between cells produce their own ECM 
components. Spheroid cultures can be produced by culturing cells on low adherence 
substrates, using hanging-drop methods and agitation-based approaches 




















3.2 Aims and objectives 
The purpose of this chapter was to develop a 3D cell culture model utilising 
differentiated SH-SY5Y and an extracellular matrix-based (Matrigel™-based) 3D 
culture system. The growth and maturation of a mesencephalic neuronal cell line in a 
Matrigel™-based 3D culture system demonstrated the development of key events in 
AD, including extracellular aggregation of amyloid-β (Aβ) and accumulation of 
hyperphosphorylated tau/aggregated tau as neurofibrillary tangles (Choi et al., 
2014). This culture system was shown to promote deposition of Aβ species; 
therefore, it was posited that a Matrigel™-based culture system would promote the 
aggregation of α-syn in SH-SY5Y.  
The specific aims of this chapter were: 
• To establish a differentiation protocol for SH-SY5Y, in 2D initially, that gives 
rise to a more neuronal phenotype for further development in 3D culture. 
• To determine the dopaminergic phenotype of differentiated cells cultured in 
2D prior to culture in 3D. 
• To develop 3D cell culture methods utilising the differentiation protocol used in 
2D cultures, including optimisation of cell densities, Matrigel™ concentrations 
and methods for downstream analysis of cultures. 















3.3.1 Differentiation of SH-SY5Y with retinoic acid and aphidicolin results in 
the development of a ‘neuron-like’ phenotype contaminated with mitotically 
active non-differentiating ‘S-type’ cell population 
Prior to developing the 3D model, cells were differentiated in 2D to determine a 
protocol that could yield post-mitotic neuron-like cells. Initially, cells differentiated in 
2D were monitored for development of neuron-like characteristics by evaluation of 
cell morphology by phase-contrast microscopy. Undifferentiated SH-SY5Y cells 
display characteristic morphology of two distinct phenotypes: neuroblastic (‘N-type’); 
and substrate adherent (‘S-type’) (Fig. 3.1 and 3.4). In agreement with others 
(Korecka et al., 2013; Forster et al., 2016; Ito et al., 2017), upon treatment with 10 
μM RA, for 4 days the neuroblastic SH-SY5Y cells differentiated into a more neuron-
like phenotype as judged by the development of extended neurites (Fig. 3.1) in both 
1% and 10% FBS groups. Continued treatment with 10 μM RA at day 7, 10 and 14 
lead to the death of the ‘neuron-like’ cells with extended neurites and the growth of 
the substrate-adherent, non-neuronal ‘S-type’ cells. As RA promotes exit from the 
cell cycle, ‘neuron-like’ cells become post-mitotic and do not go through cell division. 
The ‘S-type’ cells do not differentiate into neurons and are not affected by RA, 
therefore are able to continue cell division and can progressively overgrow the 
culture flask. For long term culture in 3D, the ‘S-type’ cell could potentially overgrow 
the culture and lose the neuronal population. To address the issue of the mitotically 
active ‘S’ type from overgrowing the neuronal population, the mitotic inhibitor 
aphidicolin was added to RA-differentiated cultures (Poluha et al., 1996). Aphidicolin 
is a reversible inhibitor of nuclear DNA replication and blocks the cell cycle in S 
phase (Jensen, 1987). Addition of aphidicolin to pre-differentiated SH-SY5Y resulted 
in a lot of cell death and did not prevent the growth of the ‘S’ type cells, as they were 
still detectable at day 14 (Fig. 3.2). To conclude, differentiation of SH-SY5Y with 10 
µM RA ± aphidicolin resulted in the extension of neurites of the 'N-type' population, 







Figure 3.1.  Effects of RA treatment in SH-SH5Y cells shown in phase-contrast micrographs growing in 
complete medium (DMEM with 10% FBS), reduced-serum media (DMEM with 1% FBS), and in medium 
containing 10 μM RA (DMEM with either 1% or 10% FBS) for 4, 7, 10 and 14 days. Treatment with RA 
resulted in neurite outgrowth by day 7 in both RA groups (1% or 10% FBS added to DMEM) when 
compared to solvent control and 1%/10% FBS groups without FBS. White arrow highlights a ‘N-type’ cell 
with extended neurites. As culture time increased, ‘N-type’ cells with neurites are still detectable, however, 
‘S-type’ non-neuronal cells progressively overgrow the culture. Scale bar represents 100 µm. 
Abbreviations: FBS, foetal bovine serum; RA, retinoic acid. 
 
Figure 3.2. Effects of RA and aphidicolin treatment in SH-SH5Y cells shown in phase-contrast 
micrographs growing in medium with or without 10 μM RA initially followed by sequential treatment of 
aphidicolin (either 0.1, 0.3, 0.5 μm) for 10 or 14 days. Addition of the mitotic inhibitor aphidicolin to RA-
differentiated SH-SY5Y resulted in extensive cell death in all groups examined as demonstrated by large 
clumps of cells detaching from the culture surface. Scale bar represents 100 µm. Abbreviations: RA, 
retinoic acid. 
3.3.2 Differentiation of SH-SY5Y with retinoic acid and brain-derived 
neurotrophic factor yields ‘neuron-like’ phenotype and suppression of 
growth of mitotically active ‘S-type’ cells 
In order to fully differentiate the SH-SY5Y cell line and remove the residual S-
































and brain-derived neurotrophic factor (BDNF) was investigated as a potential 
differentiation protocol for use in 3D cultures. Initial treatment with 10 μM RA 
induced the development of cells with extended neurites (Fig. 3.1). Subsequent 
addition of BDNF in serum-free media further promoted the development of a 
neuronal phenotype as determined by extensive neurite outgrowth, neurite 
extension and development of complex neurite networks in response to the 
neurotrophic factor (Fig. 3.3 and 3.4 A). The removal of serum prevented the 
growth of the mitotically active ‘S-type’ cells (Encinas et al., 2000). Pre-
differentiation with 10 μM RA in 1% FBS (in contrast to 10% FBS) followed by 
sequential treatment with 50 ng/mL BDNF was not chosen for further 
experiments due to the death of all cells at day 12 (Fig. 3.3, left column). 
Quantification of neurite length in undifferentiated, RA and RA + BDNF-
differentiated SH-SY5Y reveals an average neurite length and standard 
deviation of 51.22 ± 22.87 μm (undifferentiated), 64.91 ± 33.07 μm (RA) and 
130.50 ± 77.91 μm (RA+BDNF). There was deemed to be a significant change 
in neurite length between all group (<P=0.0001; Fig. 3.4B).
Figure 3.3. Effects of RA and BDNF treatment in SH-SH5Y cells shown in phase-contrast micrographs growing in medium with 10 μM 
RA initially followed by sequential treatment of 50 ng/mL BDNF for 7 or 12 days. Addition of 50 ng/mL BDNF to cultures previously 
differentiated in culture medium with either 10% FBS, 1% FBS + 10 μM RA, or 10% FBS + 10 μM RA demonstrate the development of 
neurites in all groups at day 7. The 1% FBS + 10 μM RA group has extensive neurites when compared to 10% FBS alone and 10% FBS 
+ 10 μM RA. However, at day 12, cells have detached from the culture vessel due to cell death in the 1% FBS + 10 μM RA group. 
Neuronal-like cells with long neurites and cell bodies are detected in both 10% FBS and 10% FBS + 10 μM RA, with extended neurites in 
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Figure 3.4. Phase contrast analysis of SH-SY5Y differentiation with retinoic acid and brain-derived 
neurotrophic factor.  (A) Representative phase contrast images of SH-SY5Y differentiated with RA alone 
or sequential treatment with RA and BDNF. Neuroblastic ('N-type'; arrow) and substrate adherent ('S-type'; 
asterisk) cells are shown. Scale bar represents 100 µm. (B) Neurite length analysis of undifferentiated, RA 
only and sequential treatment with RA and BDNF SH-SY5Y. 200 neurites were measured per repeat 
treatment group, with three independent biological repeats. All data is presented with the mean shown as 
a straight line (in red). Statistical significance determined by Kruskal-Wallis test with post-hoc Dwass-Steel-
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3.3.3 SH-SY5Y differentiated with sequential treatment of RA and BDNF in 
2D culture express markers of dopaminergic neurons as evaluated by 
qPCR and immunocytochemistry 
 
Figure 3.5. qPCR analysis of dopaminergic and neuronal markers in undifferentiated, retinoic acid only 
and retinoic and brain derived neurotrophic factor SH-SY5Y.Undifferentiated (blue), RA treatment group 
(red) and RA+BDNF treatment group (green). Relative gene expression normalised to reference genes 
(ACTB and YWHAZ) and undifferentiated SH-SY5Y. Neuronal (TUBB3 and MAP2) and dopaminergic 
markers showed increased expression in the RA+BDNF (green). Data presented as all data points and 
mean (straight line) of at least three independent experiments. Statistical significance determined by 
Kruskal-Wallis test with post-hoc Conover-Inman. Results of initial Kruskal-Wallis test P= 0.0321. P-values 
are displayed on the figure. Abbreviations: DAT, dopamine transporter; DRD2, dopamine receptor 2; 
MAP2, microtubule-associated protein 2; NES, nestin; TUBB3, βIII-tubulin; VMAT2, vesicular monoamine 
transporter 2. 
Key to the development of an effective cell culture model of PD is the 
expression of relevant neuronal markers. Evaluation of mRNA levels by 
quantitative real-time PCR (qPCR) after each differentiation protocol was used 
to determine the transcriptional levels of genes specifically associated with 
dopaminergic neurons (Fig. 3.5). Increased expression of neuronal markers βIII-
tubulin (TUBB3) and microtubule-associated protein 2 (MAP2) upon 
differentiation with RA + BDNF confirmed the development of a more neuronal 
phenotype than was observed with RA or undifferentiated SH-SY5Y. Nestin 
(NES), an immature neuronal marker, was not significantly changed by 
differentiation with either RA alone of RA + BDNF treatment. A greater 
dopaminergic phenotype in RA + BDNF cultures was observed, indicated by 
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Figure 3.6. Immunocytochemistry analysis of undifferentiated, retinoic acid only, and retinoic and brain derived neurotrophic factor SH-SY5Y. (A) 
NF200. (B) Dopamine. (C) Ki67. Cultures stained for neurofilament 200 (NF200), dopamine and Ki67 (red). Nuclei were visualised using DAPI 




Figure 3.7. Corrected total cell fluorescence and percentage cells positive for staining analysis of  undifferentiated, retinoic acid, and retinoic acid and brain-
derived neurotrophic factor of immunocytochemistry  images in Fig. 3.6. (A-C) Corrected total cell fluorescence image analysis of NF200 (A), dopamine (B), and 
Ki67 (C). (D-F) Percentage of cells positive for immunostaining with NF200 (D), dopamine (E), and Ki67 (F). (A-F) Individual data points presented with straight line 
(median). Statistical significance determined by Kruskal-Wallis test with post-hoc Dwass-Steel-Chritchlow-Fligner. Results of initial Kruskal-Wallis test P= 0.0001 (A), 




Figure 3.8. Immunocytochemistry analysis of undifferentiated, retinoic acid only and retinoic and brain 
derived neurotrophic factor SH-SY5Y with tyrosine hydroxylase (TH) antibody. Representative images of 
three independent biological repeats. Scale bars represent 50 μm.  
(DRD2) and vesicular monoamine transported member-2 (VMAT2) when 
compared to the other two cell populations (Fig. 3.5). 
Cells at all stages of differentiation were stained with antibodies for the neuronal 
marker neurofilament 200 (NF200), presence of dopamine, proliferation marker 
(Ki67) and tyrosine hydroxylase (TH) (Fig. 3.6 and 3.7). NF200 staining was 
reduced following differentiation with RA (7±3%) compared to undifferentiated 
SH-SY5Y (43±21%). NF200 immunopositivity was increased in RA + BDNF 
(64±17%) compared to undifferentiated and RA groups (Fig. 3.7 A, D).  
Dopamine is the neurotransmitter produced by dopaminergic neurons of the 
SNPc and therefore an antibody for dopamine was used to determine the 
presence of the neurotransmitter in all stages of differentiation (Fig. 3.7 B, E). 
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The anti-dopamine antibody used here has previously been demonstrated to be 
specific for dopamine through cross-reactivity studies (Banks et al., 2017). 
Dopamine immunoreactivity was significantly increased in RA + BDNF cultures 
[21,800±7126 corrected total cell fluorescence (CTCF)/cell] compared to 
undifferentiated cells (19,800±6371 CTCF/cell) or RA (10,216±5823 CTCF/cell) 
(Fig. 3.7 B). 
Ki67 is a protein associated with cell proliferation and is present in the G1, S 
and G2 phases of cell cycling and mitosis but absent in the G0 resting state. 
Undifferentiated cultures expressed this marker, typically associated with the 
nucleus (591,943±171,477 CTCF/cell). A significant reduction in expression 
seen in the RA (193,629±160,908 CTCF/cell) and RA + BDNF 
(180,465±105,445 CTCF/cell) cells indicate that they are terminally 
differentiated (Fig. 3.7 C, F). 
Tyrosine hydroxylase (TH) is a key enzyme in the production and homeostasis 
of dopamine within catecholamine neuronal cell types (Daubner, Le and Wang, 
2011) and is expressed in all three cell types (Fig. 3.8). 
Overall, these observations are in line with previously published work on 
differentiated SH-SY5Y cell lines in which RA + BDNF was utilised and 
demonstrate that these conditions result in terminally differentiated cells 
expressing many of the key markers of a dopaminergic neuron (Agholme et al., 
2010; Ito et al., 2017; Xicoy, Wieringa and Martens, 2017). Importantly, for use 
in 3D cultures, the addition of BDNF in serum-free media reduces the 
proliferation of the non-differentiating ‘S-type’ cell population preventing 
overgrowth within the cultures.  
3.3.4 Cell number optimisation of 3D cultures 
To achieve the tissue-like structural integrity of in vivo organs the cell number 
density is important to ensure cellular communication. In addition, the 
concentration of ECM used for 3D cultures can impact cellular health and 
differentiation of cultures. Therefore, a variety of cell densities and Matrigel™ 
concentrations were used to evaluate the optimal cell conditions for 
differentiation in 3D. Initially, in ‘thin-layer’ cultures (100 μL matrix volumes in 8 
well chamber slides), incremental increases in cell densities from 5x105 cells/mL 
to 1x107 cells/mL were investigated by LIVE/DEAD staining to determine overall 
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culture health and distribution of cells throughout the cultures (Fig. 3.9 A). At 
low cell densities, cells clumped together and were not distributed evenly 
throughout the 3D matrix (Fig. 3.9 A).  
LDH assay was also undertaken to assess the health of 3D cultures (Fig. 3.9 
B). Increasing culture density from 7.5x106 cells/mL to 2x107 cells/mL with 
increments of 2.5x105 cells/mL steadily decreased the viability of cells within the 
matrix (Fig. 3.9 B). The lower cell densities 1x106 cells/mL to 7.5 x106 cells/mL 
were investigated further for the expression of neuronal and dopaminergic 
markers by qPCR. 
 
Figure 3.9. Cell number optimisation of 3D cultures using LIVE/DEAD staining and lactate dehydrogenase 
(LDH) assay. (A) LIVE (green)/DEAD (red) imaging analysis of RA+BDNF-differentiated cultures in 3D.  
Representative images of two independent biological repeats. (B) LDH assay of 3D cultures. Data 









































































Figure 3.10. Optimisation of Matrigel concentrations for 3D cultures as analysed by qPCR. (A) Dopamine 
transporter (DAT). (B) β-III tubulin (TUBB3). (C) Microtubule-associated protein 2 (MAP2). Data points 
presented as individual points and median (straight line) of three independent biological repeats. Relative 
gene expression normalised to reference genes (RPL13A and SDHA) and undifferentiated SH-SY5Y. 
Statistical significance determined by Kruskal-Wallis test with post-hoc Conover-Inman. Results of initial 
Kruskal-Wallis test P= 0.0276 (A), P=0.0113 (B), P= 0.0164 (C). P-values are displayed on the figure. 
Matrigel™ as a 3D matrix can be diluted from a stock concentration to a variety 
of working concentrations. Previous studies (Choi et al., 2014) that employed 
the use of this matrix did so by diluting the stock solution 1:1, 1:3 etc. However, 
because stocks of Matrigel™ can differ in protein concentration, working 
concentrations were employed using protein concentrations in mg/mL allowing 
for differences in protein concentrations in different batches. To determine 
which protein concentration to use in 3D cultures, qPCR was employed to 
determine gene expression of DAT, TUBB3 and MAP2 in Matrigel™ 
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TUBB3 and MAP2 were observed in concentrations of 4, 5 and 6 mg/mL. 
TUBB3 and MAP2 were significantly increased in the 7 mg/mL 
Matrigel™ concentration. The 6 mg/mL protein concentration of Matrigel™ was 
used for future experiments due to the greatest increase in expression of all 
three genes investigated when compared to other the protein concentrations of 
4, 5 and 7 mg/mL.  
To further investigate optimal cell densities to use in future 3D experiments, 
LDH assay was undertaken to determine the cell viability of 3D cultures at 
various cell densities (Fig. 3.11 A). Following on from the dramatic reduction of 
cell viability in cultures with high cell numbers (Fig. 3.9 B), the cell viabilities of 
lower cell concentrations of 1x106 to 1.25x107 cells/mL were determined in 
‘thick-layer’ cultures of 300 μL (in 24-well inserts) (Fig. 3.11 A). Incremental 
increases in densities from 1x106 to 1.25x107 cells/mL by 2.5x105 cells/mL 
steadily decreased the viability of cells within the matrix (~17% decrease) as 
measured by LDH concentration (Fig. 3.11 A).  
In 300 μL matrix volumes, expression of genes associated with dopaminergic 
and neuronal markers in 3D cultures was undertaken using qPCR (Fig. 3.11 B, 
C). Like in 2D-differentiated cultures, expression levels of DAT, DRD2, MAP2, 
NES, TUBB3 and VMAT2 were determined. Upon differentiation in the 3D 
matrix, gene expression of DRD2, MAP2 and VMAT2 was increased (compared 
to undifferentiated SH-SY5Y) in the 7.5x106 cells/mL group (Fig. 3.11 B). A 
substantial increase in VMAT2 expression within the same cells differentiated in 
3D compared to 2D indicated the development of a more neuronal phenotype 
(Fig. 3.11 B). Gene expression data of cell densities 1x107 cells/mL and 
1.25x107 cells/mL were not included due to the decrease in cell viability 
(Fig.3.11 A) and great variability in gene expression between biological repeats. 
Comparing expression of DAT, DRD2, MAP2, NES, TUBB3 and VMAT2 in 3D-
differentiated cultures with 2D-differentiated cultures reveals no significant 
difference in gene expression but reveals a much higher increase in VMAT2 
expression in 3D cultures (Fig. 3.11 C). 
Based on these observations, a cell density of 7.5x106 cells/mL was selected 




Figure 3.11. Cell number optimisation of 3D cultures SH-SY5Y analysed by LDH assay and qPCR. (A) Cell number optimisation of thick-layer 3D-differentiated SH-
SY5Y using LDH cell viability assay. An incremental increase in cell density is associated with decreased cell viability (~17% decrease from 1 x 106 cells/mL to 1.25 x 
106 cells/mL. LDH cell viability was normalised to cell-density-matched positive controls. All data points are presented with median (straight line) of at least four 
independent biological repeats. (B) mRNA levels of genes specifically associated with dopaminergic neurons were evaluated by qPCR. Relative gene expression 
normalised to reference genes (ACTB and YWHAZ) and undifferentiated SH-SY5Y. Data presented as mean ± SEM of at least three independent experiments. (C) 
Comparison of mRNA levels of genes specifically associated with dopaminergic neurons in 2D-differentiated and 3D-differentiated SH-SY5Y cultures as evaluated by 
qPCR. Relative gene expression normalised to reference genes (ACTB and YWHAZ) and undifferentiated SH-SY5Y. Data presented as mean ± SEM of at least 




MAP2, TUBB3 and VMAT2 were all increased in relation to undifferentiated SH-
SY5Y, and expression of NES was decreased in comparison to other cell 
densities. Cells displayed a homogenous distribution within the matrix, in 
contrast to lower densities where clusters of cells were observed (Fig. 3.9 A). In 
addition, this was the highest cell density at which cell viability was unaffected. 
Hence, 7.5x106 cells/mL was the optimal balance between cell viability and 
homogeneity within the matrix.  
3.3.5 SH-SY5Y differentiation in 3D culture retains a dopaminergic 
phenotype 
Using qPCR, 3D-differentiated cultures revealed the expression of both 
neuronal and dopaminergic markers. Immunohistochemistry was used to 
confirm the expression of proteins related to neurons (NF200 and βIII-tubulin), 
the mitotic status of cells (Ki67) and presence of the neurotransmitter 
dopamine. Prior to this, optimisation of staining techniques was investigated in 
order to carry out immunohistochemistry protocols. Initially, 3D-cultures of 300 
μL matrix volumes (in 24-well inserts) were fixed and sectioned using paraffin-
embedded sectioning and subsequent staining of cultures using Haematoxylin 
and Eosin (H + E) (Fig. 3.12 A). Visualisation of these cultures revealed 
shrinking of the 3D cultures that were difficult to section and subsequently stain. 
Cryostat sectioning was determined to provide a viable method of fixing, 
sectioning and staining of the 3D cultures (Fig. 3.12 B). In contrast to paraffin-
embedded sectioning, cryostat sections were not subjected to shrinking and 
nuclei were easily identified following H + E staining (Fig. 3.12 A, B). Therefore, 
cryostat sectioning was used to prepare sections for further 
immunohistochemical staining.  
βIII-tubulin staining was used to develop an immunofluorescence-based 
immunohistochemistry protocol and confirmed the expression of neuron-specific 
proteins (Fig. 3.13 A). Due to difficulty observing the fluorescence on the 
microscopes available at the time of the study, DAB staining was chosen over 
immunofluorescence staining. Staining with NF200 again confirmed the 
neuronal phenotype of cells differentiated in 3D cultures (Fig. 3.13 B).  Anti-
dopamine staining revealed the presence of the neurotransmitter within these 
cultures (Fig. 3.13 B). Ki67 staining was also undertaken to determine the 




Figure 3.12. Optimisation of staining techniques for 3D cultures. Cultures stained using H + E staining 
where nuclei are stained purple and proteins in the cytoplasm are stained pink. (A) Paraffin-embedded 
sectioning of 3D cultures reveals shrinking of cultures. Cultures stained using H + E staining where nuclei 
are stained purple and proteins in the cytoplasm are stained pink. (B) Cryostat sectioning of 3D cultures 
allows for identification of cells in contrast to paraffin-embedded sectioning. Scale bar represents 2000 µm. 


















Figure 3.13. Neuron-like cells cultured in 3D retain a dopaminergic phenotype. (A) Immunofluorescence staining of β-III tubulin staining 
(AlexaFluor; green). Nuclei were visualised using DAPI (blue). Scale bar represents 100 μm. (B) 3D-differentiated SH-SY5Y cultures retain a 
post-mitotic neuronal dopaminergic phenotype in 3D as determined by the absence of Ki67 staining and positive staining for NF200 and 
dopamine. Haematoxylin was used as a counter stain for nuclei (purple). Positive control for Ki67 staining is undifferentiated SH-SY5Y cultured 
in 3D. Scale bar represents 100 µm. 
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Absence of Ki67staining in 3D-differentiated cultures demonstrated the post-
mitotic phenotype of these neuron-like cells (Fig. 3.13 B). A positive control for 
Ki67 staining was included, undifferentiated SH-SY5Y cells were grown in the 
3D matrix for 24 hrs before subjected to cryostat sectioning and staining.  
Undifferentiated SH-SY5Y was determined to be positive for Ki67 expression as 
shown by the nuclear associated brown DAB staining (Fig. 3.13 B). Isotype 
controls demonstrate no non-specific staining for Ki67, NF200 or dopamine. 
This body of work establishes a 3D cell culture model in which fully 
differentiated neuronal SH-SY5Y cells have been encapsulated within a 
Matrigel™ scaffold. 
3.4 Discussion 
The objective of this chapter was to develop a 3D cell culture model utilising the 
easily accessible SH-SY5Y neuroblastoma cell line, to be used to further model 
the aggregation of α-syn in a more physiologically-relevant cell culture model. 
SH-SY5Y have long since been used in PD research for several reasons, 
including the expression of genes associated with a dopaminergic phenotype 
(DAT, DRD2, VMAT2 and TH), ease of culture and induction of differentiation 
into a more neuronal phenotype (Smidt and Burbach, 2007). Importantly for this 
study, α-syn has been shown to form aggregates in SH-SY5Y (Danzer et al., 
2007; Illes-Toth et al., 2015). At present, there are relatively few cell culture 
models that model the development of LB-like α-syn aggregates that faithfully 
recapitulate in vivo phenotypes. Therefore, the primary aim of this work was to 
adapt a differentiated SH-SY5Y model to 3D, with the hypothesis that culturing 
in 3D would promote α-syn-cell interaction and enhance aggregate formation 
(Choi et al., 2014). 
Although relatively few papers have employed the use of this protocol (1-2%), 
differentiation of SH-SY5Y with the sequential treatment of RA and BDNF leads 
to the development of a homogenous neuronal population with the expression 
of neuronal markers and reduction of cell proliferation (Encinas et al., 2000; 
Goldie, Barnett and Cairns, 2014; Xicoy, Wieringa and Martens, 2017). Pre-
differentiation for at least 5 days with RA coincides with peak expression of the 
tropomyosin receptor kinase B (TRKB) required for biological responsiveness of 
BDNF (Kaplan et al., 1993; Encinas et al., 2000; Nishida et al., 2008). BDNF 
stimulates the phosphorylation of TRKB and subsequent activation of PI3K/AKT 
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and Ras/MAPK pathways, resulting in the promotion of cell survival and neurite 
outgrowth (Kaplan et al., 1993; Encinas et al., 1999, 2000). Removal of serum 
in media when culturing with BDNF results in the ablation of ‘S’ type cell growth 
due to the lack of expression of neuron-specific markers and failure to induce 
TRKB (Encinas et al., 2000).  
Controversy remains as to whether RA or RA + BDNF promotes SH-SY5Y cell 
differentiation and the development of a terminal dopaminergic phenotype 
(Lopes et al., 2010; Korecka et al., 2013; Xicoy, Wieringa and Martens, 2017). 
Induction of neurite growth, expression of dopaminergic markers and exit from 
the cell cycle was explored in RA + BDNF differentiation cultures prior to culture 
in 3D. In addition, the above was also explored in RA-only differentiated SH-
SY5Y, as this represents the most commonly used differentiation protocol for 
use in PD research (Xicoy, Wieringa and Martens, 2017). In agreement with 
previous publications, RA and RA + BDNF promoted the differentiation of SH-
SY5Y as demonstrated by the formation of extended neurites. RA + BDNF 
demonstrated the most marked extension of neurites that form complex 
networks (Encinas et al., 2000; Mastroeni et al., 2009). NF200 (neurofilament 
heavy polypeptide, neurofilament H), exclusively localised in neurons, is a key 
constituent of the neuronal cytoskeleton with an important function in mature 
axons (Yuan Aidong, Rao Mala V. , Veeranna, 2017). Presence of NF200 was 
observed in both undifferentiated and RA + BDNF SH-SY5Y, with little staining 
detectable in RA SH-SY5Y. The reduction in NF200 staining in RA compared to 
undifferentiated SH-SY5Y could be related to the continued presence of the ‘S’ 
type non-neuronal cell type within the RA population (Constantinescu et al., 
2007). All cultures stained positive for dopamine and TH, demonstrating the 
ability for cells to synthesis DA, critical for a dopaminergic phenotype. DA 
uptake and release have previously been shown in RA + BDNF cultures 
(Mastroeni et al., 2009). Ki67, a protein associated with cell proliferation was 
used to determine the post-mitotic status of each stage of differentiation 
(Gerdes et al., 1983; Bullwinkel et al., 2006). Reduction of Ki67 staining was 
observed in RA and RA + BDNF, indicating the removal of cells from the cell 
cycle. Using other methods, such as BrdU/EdU and propidium iodide staining 
and flow cytometry analysis also indicate withdrawal from the cell cycle 
(Encinas et al., 2000; Ito et al., 2017). However, not all studies confirm the 
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inhibition of cell growth following differentiation (Teppola et al., 2016). In the 
previous study, cell growth was monitored by counting cell nuclei in contrast to 
the assessment of the stage of the cell cycle (either by staining with 
BrdU/EdU/PI or presence of proteins associated with the cell cycle e.g. Ki67), 
meaning cell number could be affected by the death of cells that have not 
responded to differentiation, or if treatment has stabilised cell populations 
(Encinas et al., 2000).  
All SH-SY5Y cultures expressed markers of a dopaminergic phenotype as 
determined by qPCR, including DRD2, DAT and VMAT2, independent of 
differentiation (Cheung et al., 2009; Mastroeni et al., 2009; Korecka et al., 
2013). In conjunction, dopamine and TH immunostaining indicates a 
dopaminergic phenotype. When compared to undifferentiated and RA SH-
SY5Y, RA + BDNF treated cultures show increased expression of DAT, DRD2 
and VMAT2. This may again be due to the presence of ‘S’ type cells in the 
undifferentiated and RA populations. Expression of neuronal proteins MAP2 
and TUBB3 were also upregulated following treatment with RA + BDNF, 
indicating the development of a neuronal phenotype following differentiation. 
Expression of the neural stem/progenitor cell marker NES was increased 
(although not significantly) in both RA and RA + BDNF cultures, compared to 
undifferentiated cultures. Following differentiation, this would be expected to be 
downregulated as NES is replaced by tissue-specific intermediate filament 
proteins, e.g. neurofilaments (Lendahl, Zimmerman and McKay, 1990; 
Hendrickson et al., 2011). NES plays an important role in the remodelling of the 
cell’s cytoskeleton by assisting in the assembly and disassembly of intermediate 
filament proteins (Hendrickson et al., 2011). NES expression may be related to 
the development of axons in differentiating cells, therefore increased expression 
is indicative of neuronal development and remodelling of the cytoskeleton 
during differentiation. Similarly, NES expression was still observed to form 
cytoskeletal structures in fully post-mitotic LUHMES (Scholz et al., 2011). Other 
reasons could be that SH-SY5Y have a limited maturation capacity under the 
culture conditions presented here, or the downregulation of NES could require a 
longer differentiation time. 
It is important to note that the differentiation of cells in 2D was difficult due to 
cells detaching from the culture vessel before the end of differentiation with 
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BDNF. Culturing in 3D circumvented this issue by preventing cells washing 
away, therefore allowing for more robust handling methods and analysis. 
Adaptation of the culturing and differentiation method for SH-SY5Y to 3D was 
achieved by culturing RA pre-differentiated SH-SY5Y in a 3D matrix for further 
differentiation in serum-free media with the addition of BDNF. Matrigel™, a 
basement protein preparation, was chosen as a 3D support due to the previous 
observation that culturing cells within this matrix allowed for enhanced Aβ 
deposition in a model of AD (Choi et al., 2014). Moreover, encapsulation of cells 
can be achieved through moderate thermal changes and provides a brain-like 
environment rich in laminin, entactin, collagen and heparan sulphate 
proteoglycans (Hughes, Postovit and Lajoie, 2010; Choi et al., 2014; Kim et al., 
2016).  
Following encapsulation in 3D and further differentiation, cells were 
demonstrated to retain a dopaminergic phenotype as indicated by expression of 
DAT, DRD2 and VMAT2 and immunostaining with dopamine. Immunostaining 
of 3D cultures with Ki67, dopamine and NF200 showed a similar phenotype to 
2D-differentiated cells. Optimisation of various techniques such as qPCR and 
immunostaining of the 3D model demonstrated the adaptability of the culture 
system to general laboratory techniques widely used by scientists. One 
particular advantage of the 3D-differentiated SH-SY5Y model is the ability to 
expand and bulk up cell numbers relatively cheaply and easily (no expensive 
culture additives) prior to culture in 3D. A point to note is that as Matrigel™ is a 
biological product, batch-to-batch variation is an important factor that could lead 
to a disparity between experiments (Hughes, Postovit and Lajoie, 2010). These 
differences include protein and growth factor concentration between batches, 
therefore, using the same the batch and reduced growth-factor Matrigel™ is a 
viable option and was used in this study.   
In conclusion, culturing differentiated SH-SY5Y in both 2D and 3D formats 
produced cells displaying features of neurons relevant to PD. These features 
include the development of extended neurites (mature neurons) and expression 
of key proteins associated with dopaminergic neurons (DAT, DRD2, VMAT2), in 
addition to positive immunostaining for dopamine. Culture of SH-SY5Y cells 
was easily adapted to 3D culture conditions, providing an easily accessible 
culture model that has the potential to be used in diverse areas of PD research.  
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Chapter 4 : Characterisation of the effect of α-




The mechanisms underlying LB formation and the influence of α-syn pathology on 
disease pathogenesis remain poorly understood, largely due to the lack of whole-
animal or cell-based models that recapitulate the development of these inclusions. 
Relatively few studies have observed the development of LB pathology without 
overexpressing high levels of human versions of α-syn (Volpicelli-Daley et al., 2011; 
Falkenburger, Saridaki and Dinter, 2016). In addition, a predominant number of 
studies rely on the introduction of a familial mutation into α-syn (e.g. A53T) to 
increase aggregation propensity (Uversky, Li and Fink, 2001; Koprich, Kalia and 
Brotchie, 2017). α-Syn in Drosophila mirrors the formation of LB-like structures and 
neuronal loss, but this has unfortunately not been replicated in higher-order 
organisms or human-cell-based models (Feany and Bender, 2000). Interestingly, 
rodent models of PD that overexpress human α-syn by mutations in the SNCA gene 
(e.g. the M83 strain, overexpressing mutant human A53T α-syn) do develop 
inclusions but the anatomical distribution is widely variable among animals and often 
coincides with areas of substantial neuroinflammation (Lee et al., 2002; Dawson, Ko 
and Dawson, 2011; Sacino et al., 2014; Fares et al., 2016). Impaired human α-syn 
fibrillisation can occur in rodent models due to an interaction with endogenously 
expressed murine α-syn (Fares et al., 2016). Such interactions highlight a 
fundamental experimental caveat when investigating LB formation in murine models 
or rodent-derived primary neuronal cultures (Fares et al., 2016). Species differences 
between rodent models (including primary rodent cell culture systems) make it 
difficult to model and extrapolate findings to human subjects (Ioannidis, 2012; 
Goldie, Barnett and Cairns, 2014; Pound and Bracken, 2014).  
 
In previous human-cell-based models, limitations have also arisen from the use of 
traditional 2D monolayer cultures. Intracellular α-syn aggregates are often observed 
as multiple cytoplasmic punctate inclusions rather than recapitulating the typical 
large singular inclusions associated with human pathology (Desplats et al., 2009; 
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Danzer et al., 2009). Formation of LB-like pathology in human cell culture models 
has only been achieved through overexpression of α-syn, either driven from viral 
promoters or in cell lines not associated with the disease, such as those from human 
embryonic kidney lines (HEK-293)  (Luk et al., 2009; Volpicelli-Daley et al., 2011; 
Sacino et al., 2013). Such viral promotors do not allow the study of transcriptional 
and translational modulations brought about during the disease pathogenesis. To 
address these issues, in vitro 3D culture systems are increasingly being utilised for a 
multitude of disease models, with the aim of more closely mimicking an in vivo 
environment with tissue-like cell density and cell-to-cell as well as cell-to-
extracellular-matrix contacts (Griffith and Swartz, 2006; Tang-Schomer et al., 2014; 
Kim et al., 2016; Smirnova et al., 2016). Taken together, the current limitations of 
both in vitro and in vivo models demonstrate a greater need to develop a human-





















4.2 Aims and Objectives 
The purpose of this chapter was to investigate the neurotoxicity of α-syn seeding 
oligomers using 3D SH-SY5Y cell culture as a model of PD and identify whether 
exogenously added forms of α-syn in the 3D model recapitulate traditional 2D 
systems. Numerous in vitro preparations of α-syn oligomers and fibrils have been 
reported with two main gain-of-function mechanisms of neurotoxicity in 2D cell 
culture: Ca2+ influx and prion-like seeding (Danzer et al., 2007). A specific population 
of α-syn oligomer, identifiable by mass spectrometry, have been shown to induce 
intracellular aggregation in a 2D culture system (Illes-Toth et al., 2015). Using these 
compact, high order ring-like oligomers, the neurotoxicity and seeding effects were to 
be investigated in both 2D and 3D SH-SY5Y cultures.  
The specific aims of this chapter were: 
• To determine neurotoxicity of seeding oligomers in SH-SY5Y cell populations. 
• To determine whether seeding oligomers induced the intracellular aggregation 
of α-syn in SH-SY5Y cell populations. 
• To identify whether seeding oligomers induced the intracellular aggregation of 












4.3.1 Production of recombinant α-syn  
 
Figure 4.1. Typical column chromatography UV chromatograms and SDS-PAGE analysis of recombinant α-syn 
during purification. (A) Crude lysate prepared from E. coli overexpressing α-syn was subjected to anion 
exchange chromatography through a 50 mL Q-Sepharose anion exchange column. A sodium chloride gradient 
eluted the bound proteins from the column and fractions were subjected to SDS-PAGE electrophoresis. (B) SDS-
PAGE gel of fractions eluted from anion exchange column. Lanes 1-3 show samples from the crude purification 
process prior to anion exchange. Lanes 9-13 show fractions with high levels of α-syn, corresponding to MW of 
~15 kDa. (C) Following selection of fractions containing α-syn from anion exchange, samples were lyophilised 
before being subjected to size exclusion chromatography using a HiLoad® 26/600 Superdex™ 200 size 
exclusion column. (D) SDS-PAGE gel of fractions eluted from size exclusion column. Lanes 1-7 show the 
presence of α-syn in these fractions. (E) Mass spectrometric analysis of recombinant α-syn shows intact protein 
of the expected mass. 
Certain species of α-syn have the ability to be internalised from the extracellular 
environment and induce the aggregation of endogenous α-syn (Danzer et al., 2007; 
Luk et al., 2009; Aulic et al., 2014). This mechanism of seeding and subsequent 
propagation has the potential to explain the spread of α-syn species throughout the 
PD brain. To investigate whether the oligomers produced here were capable of 
seeding the intracellular aggregation of α-syn, undifferentiated and differentiated SH- 
SY5Y in 2D and 3D cultures were exposed to exogenous α-syn oligomeric species, 
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monomeric and solvent controls. Recombinant α-syn was produced in E. coli and 
seeding oligomers were produced by incubation overnight in 50 mM sodium 
phosphate buffer, with 20% ethanol at pH 7, followed by ultracentrifugation (Fig. 4.1).  
4.3.2 Application of α-syn oligomers are not associated with toxicity in 2D SH-
SY5Y cultures 
Seeding oligomers are capable of inducing the intracellular aggregation of α-syn 
without necessarily being neurotoxic to cell preparations, in contrast to treatment 
with pore-forming oligomers (Danzer et al., 2007; Illes-Toth et al., 2015). Prior to 
investigating the intracellular aggregation of α-syn in all SH-SY5Y differentiation 
protocols, cell viability was investigated using the resazurin reduction assay (Fig. 
4.2). Treatment with 10% v/v solvent, 10% v/v monomer and 10% v/v oligomer for 24 
hrs did not induce any significant changes in cell viability in undifferentiated or RA-
differentiated SH-SY5Y (Fig. 4.2 A, B). In contrast, the same treatments to RA + 
BDNF-differentiated cultures induced large amounts of cell death (Fig. 4.2 C).  
 
Figure 4.2. Resazurin cell viability assays of 2D undifferentiated and differentiated SH-SY5Y following 24 hr 
treatment with solvent, monomeric and oligomeric preparations.  (A) Undifferentiated SH-SY5Y. (B) RA-
differentiated SH-SY5Y. (C) RA + BDNF-differentiated SH-SY5Y. (A-C) Data presented as median with all data 






















































































































































































































4.3.3 Intracellular aggregation properties of ‘seeding’ oligomers
 
Figure 4.3. Exogenous addition of oligomers induces intracellular aggregation of α-syn in 2D undifferentiated SH-
SY5Y cultures. Double immunostaining with α-syn (Texas Red, red) and nuclei (DAPI, blue) reveals the presence 
of multiple, small inclusions throughout the cytoplasm in 10% v/v oligomer-treated cultures when compared to 
diffuse staining in 10% v/v solvent control (sodium phosphate buffer + 20% ethanol) and 10% v/v monomer 
control. Scale bar represents 20 µm. 
Application of seeding oligomers to 2D undifferentiated SH-SY5Y cell populations 
was demonstrated to be non-toxic (Fig. 4.2), therefore the intracellular aggregation of 
α-syn was investigated (Fig. 4.3, 4.4). Treatment with seeding oligomers to 
undifferentiated SH-SY5Y resulted in a reduction in the homogenous cytoplasmic 
staining of α-syn and development intracellular α-syn-immunopositive aggregates, 
consistent with Danzer et al. 2007 (Fig. 4.3). This is in contrast to both solvent and 
monomeric treatments that did not induce the development of intracellular inclusions 
(Fig. 4.3). Western blotting analysis revealed an increase in intracellular levels of α-
syn following treatment with oligomers and monomer when compared to media only 





Figure 4.4. Western blot analysis of α-syn levels in 2D undifferentiated SH-SY5Y treated with oligomers and 
controls. (A) α-syn blot. (B) Loading control. (A, B) All biological repeats were run on the same blot. Lanes 1-3 
represent media samples, lanes 4-6 represent 10% v/v solvent, lanes 7-9 represent 10% v/v monomer and lanes 
10-12 represent 10% v/v oligomer treatments. (C) Fold change of α-syn levels. Data presented as median with all 
data points present. Statistical analysis was undertaken using Kruskal-Wallis with post-hoc Conover-Inman with 
all P values presented on the graph. Results of initial statistical test P= 0.0237. 
Within the PD brain, LB pathology is only observed in a discrete cell population 
within ex vivo material (Braak et al., 2003). As demonstrated above, all cells of  
undifferentiated SH-SY5Y treated with oligomeric α-syn developed inclusions 
(Danzer et al., 2009; Illes-Toth et al., 2015). Here, it was investigated whether the 
extent of cellular differentiation resulted in alterations in the intracellular aggregation 
propensity of the cell line. Following the addition of oligomeric α-syn to 
undifferentiated SH-SY5Y cells, the presence of multiple punctate α-syn-positive 
cytoplasmic inclusions with an average inclusion size of 0.28 μm2 was confirmed in 
our model (Fig. 4.5 A, B). The addition of the same oligomer treatment on RA-
differentiated cultures also produced several small cytoplasmic inclusions within 
each cell, but the average inclusion size was significantly (P<0.0001) larger (0.82 
μm2) than in the undifferentiated SH-SY5Y cells (Fig. 4.5 A, B). In both 
undifferentiated and RA-differentiated SH-SY5Y cells, all surviving cells developed 
the punctate inclusions (Fig. 4.5 C). In contrast, the addition of the same soluble 
oligomeric α-syn preparation to RA+BDNF-differentiated culture media demonstrated 
the development of a single perinuclear inclusion, consistent with a large LB-like 
aggregate (Fig. 4.5 A, asterisks and arrows, bottom panel), with an average inclusion 
size of 8.95 μm2. Cellular inclusions could be detected 24 h after treatment, but only 
31% of the cell population developed these structures (Fig. 4.5 C). To our 
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knowledge, this is the first observation of single large inclusions within a genetically 
unmodified cell culture model. 
 
Figure 4.5. Exogenous addition of α-syn oligomers induces the intracellular aggregation of α-syn in 2D SH-SY5Y 
cultures. (A) Double immunostaining of undifferentiated and differentiated SH-SY5Y cells reveals intracellular 
aggregation of α-syn following 24 h incubation with seeding oligomers. α-syn inclusions in undifferentiated cells 
display several distinct, punctate accumulations dispersed throughout the cytoplasm, consistent with aggregates. 
In contrast, the RA+BDNF cell lines show a single prominent accumulation (red; arrows) and obscure the nucleus 
(asterisks). Scale bars: 50 μm. (B) Quantification of inclusion area (reflected as μm2) shows inclusions that are 
present in differentiated cells to be much larger than those in undifferentiated cells (measurements obtained from 
three independent experiments; n=50). All data points are present, with mean shown as a straight line (red). (C) 
The percentage of cells containing inclusions was determined by counting 100 cells per repeat. Cells were 
deemed to contain inclusions if aggregation matched that in reference images when compared to controls. Data 
points are presented from three independent biological repeats. (B, C) Differences between treatments were 
tested for significance using Kruskal–Wallis test with post-hoc Dwass-Steel-Chritchlow-Fligner for >6 data points 
and Conover-Inman for <6 data points. P-values are displayed in the figures. 
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4.3.4 Application of exogenous oligomers induce the development of α-syn-
immunopositive inclusions reminiscent of in vivo Lewy body pathology in 3D-
differentiated SH-SY5Y 
Using the 3D model described in Chapter 3, oligomeric α-syn was added to RA + 
BDNF-differentiated 3D cultures to determine whether the intracellular inclusions 
developed in these cells following the addition of the oligomeric seed. Cell viability 
was investigated in both thin-layer and thick-layer 3D cultures following 24 hr 
treatment with 10% v/v solvent, 10% v/v monomer and 10% v/v oligomer using LDH 
assay (Fig. 4.6). Addition of oligomeric preparations to cells differentiated in either 
thin-layer or thick-layer cultures did not induce cell death (Fig. 4.6). This is in contrast 
to the same preparations when added to 2D RA + BDNF-differentiated SH-SY5Y 
whereby treatment of oligomers caused significant cell death (Fig. 4.7). As such cells 
grown in 3D appear resilient to oligomer-induced cell death. 
 
Figure 4.6. Lactate dehydrogenase assay of 3D thin layer and 3D thick layer cultures following 24 hr treatment 
with solvent, monomeric and oligomeric preparations. Data presented as median with all data points shown. No 
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Figure 4.7. Resazurin assay of 2D-differentiated and 3D-differentiated SH-SY5Y cultures following treatment with 
solvent, monomeric and oligomeric preparations. Data presented as median with all data points shown. 
Differences between treatments were tested for significance using Kruskal–Wallis test with post-hoc Conover-
Inman. 
In vivo LBs are phenotypically more complex than the punctate aggregates of α-syn 
seen in 2D cell culture models. To determine the morphological changes in 
intracellular aggregates in 3D culture, fully differentiated cells within the matrix were 
treated with preformed α-syn oligomers. Similar to our observations in 2D cultures 
(Fig. 4.3 and 4.5); inclusions in our 3D cell culture model were detectable 24 h after 
α-syn oligomer treatment (Fig.  4.8, 4.9 and 4.10). Immunostaining of these nuclear-
associated inclusions in our 3D model confirmed that they were α-syn positive (Fig. 
4.9) and equivalent size to those seen in vivo (Fig. 4.10). Fig. 4.9 shows the 
percentage of α-syn immunopositivity in 3D cultures treated for 24 h with media, 10% 
v/v solvent or α-syn in 10% v/v monomeric or 10% v/v oligomeric preparations. The 
data demonstrate that oligomer-treated cells develop significantly more inclusions 
than control cells (media, solvent and monomeric preparations). The percentage of 
cells containing observable inclusions also significantly increased relative to controls 
(Fig. 4.10). Immunostaining for ubiquitin in the oligomer-treated 3D cell cultures 
demonstrated diffuse nuclear-associated staining that co-localised with the LB-like 
aggregates (Fig. 4.10 B). Co-staining using both anti-α-syn and anti-ubiquitin 
antibodies demonstrates co-localisation of both proteins within the same inclusion 






Figure 4.8. Exogenous α-syn oligomers seed the development of intracellular inclusions in 3D SH-SY5Y 
cultures.  Representative images of α-syn staining with syn211 monoclonal antibody (brown) with nuclei 
visualised using DAPI staining (blue/purple). α-Syn oligomer treatment to cells leads to strong immunoreactivity 
for α-syn compared to isotype controls, media only, or treatment with solvent or α-syn monomer. Arrows indicate 
the location of the intracellular inclusions. Scale bars: 100 μm. 
 
Figure 4.9. Cell counts of 3D cultures following treatment with media, solvent, monomeric and oligomeric 
preparations. (A) Percentage of α-syn immunopositivity in 3D cultures treated for 24 h with media, solvent or α-
syn in monomeric or oligomeric preparations. Cells were deemed to contain inclusions if aggregation matched 
that in reference images when compared to controls. Data presented as mean ± SEM. of three independent 
experiments. (B) Monomeric and oligomeric α-syn treatments resulted in an increase in the percentage of cells 
with inclusions. Statistical significance in the oligomer-treated cultures related to the increase in large inclusions 
compared with media and solvent controls. Data presented as mean± SEM. of three independent experiments. 
(*, compared to media; •, compared to solvent). Evaluation of immunohistochemical staining was performed by 
counting 200 cells per slide, with ten slides counted per repeat (2000 cells counted in each treatment group for 
three independent experiments). (A, B) Statistical differences were determined using the Kruskal–Wallis test with 
post hoc Conover-Inman (*/•P≤0.05, **/••P≤0.01). 
These inclusions are highly reminiscent of LBs in vivo (Shults, 2006), and completely 
absent in the isotype controls and untreated cultures (Fig. 4.10). 
Immunohistochemical detection of phosphorylated α-syn at S129 using a selective 
antibody was not able to show evidence of phosphorylation following 24 h treatment. 
This would indicate that the aggregates have either formed without the requirement 
for phosphorylation or that the S129 epitope is protected within these aggregates 
(Walker et al., 2013). To unmask antigenic sites within the 3D cultures antigen 
retrieval methods were used but did not show evidence of phosphorylation at S129. 
The antigen retrieval methods used included heat-mediated and enzymatic retrieval 
(described in Chapter 2 Section 2.4.4.1). The lack of observable phosphorylation 
within the inclusions would suggest that this post-translational modification may not 
be required for aggregate formation within this model or occurs within a timeframe 
exceeding that was investigated here. If so, then the LB-like inclusions observed 
here could represent an early aggregated morphology. Sequential extraction of 
aggregated species from cultures in 3D using TBS-soluble and TBS-insoluble/2% 
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Media and Solvent not significant
(0.666667 > 3.605373) P = 0.6811
Media and Monomer significant
(3.666667 > 3.605373) P = 0.047
Media and Oligomer significant
(7 > 3.605373) P = 0.0021
Solvent and Monomer significant
(4.333333 > 3.605373) P = 0.0242
Solvent and Oligomer significant
(7.666667 > 3.605373) P = 0.0012
Monomer and Oligomer not significant
(3.333333 > 3.605373) P = 0.0656
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cultures in both fractions when measured by α-syn ELISA (Fig. 4.11). Overall, the 3D 
differentiated SH-SY5Y culture model presented here can produce LB-like 
aggregates when treated with preformed oligomeric material that recapitulates 
characteristic in vivo LB. 
 
Figure 4.10. α-Syn-seeded inclusions in 3D are indicative of in vivo Lewy body inclusions. α-syn oligomer 
treatments to 3D-differentiated cultures develop α-syn positive inclusions that demonstrate the same morphology 
as in vivo Lewy bodies (LBs; A) and are positive for the marker ubiquitin (B). Dotted line in purple highlights cell 
nuclei, whereas brown dotted line highlights stained area. (C) Immunofluorescence shows co-localisation of α-
syn (red) and ubiquitin (green) staining. Nuclei were visualised using DAPI staining (blue). Scale bars: 50 μm 
(left) and 10 μm (right). In vivo pathology image displayed with permission from Springer Nature. This image is 
not published under the terms of the CC-BY license of this article. For permission to reuse, please see 
(Chesselet and Richter, 2012). 
 
Figure 4.11. α-Syn ELISA analysis of TBS-soluble and TBS-insoluble fractions from media, solvent, monomeric 
and oligomeric-treated 3D cultures. (A) TBS-soluble fraction. (B) TBS-insoluble fractions. Data presented as 





























































































































4.4 Discussion  
Previously, the Sheffield Hallam University group (Illes-Toth et al., 2015) and others 
(Danzer et al., 2007; Danzer et al., 2009) have reported the induction of punctate 
intracellular aggregates in 2D undifferentiated cells when specific preparations of 
oligomeric α-syn are added to the cell culture media. Findings presented here 
describe a human 3D cell culture model that recapitulates LB-like formation. 
Inclusions are initiated by oligomeric α-syn preparations when introduced to 
terminally differentiated post-mitotic, neuron-like SH-SY5Y cells within a 3D matrix. 
Importantly, although the LB-like structures present here do not show evidence of 
phosphorylation, they are positive for α-syn and ubiquitin, closely resembling the 
morphology of inclusions found within the human pathology (Goedert et al., 2013).  
 
Certain forms of α-syn located in the extracellular environment have recently been 
shown to be internalised by neurons through several receptor-mediated mechanisms 
and induce self-aggregation of endogenous α-syn (Bieri, Gitler and Brahic, 2018). 
Seeding oligomers, originally described by Danzer et al. (2007), were used in this 
study to determine the seeding effect upon the 3D-differentiated SH-SY5Y cell 
populations. The seeding oligomers were described as globular and protofibrillar 
structures between 4 and 10 nm in size capable of inducing the intracellular 
aggregation of α-syn as determined by immunocytochemistry. Co-localisation of 
endogenous α-syn with the exogenously added Alexa-Fluor-labelled oligomers 
provides evidence for recruitment of cellular forms of α-syn into inclusions, a key 
characteristic of seeding and propagation (Danzer et al., 2007; Grozdanov and 
Danzer, 2018). This prion-like propagation has been proposed to explain the spread 
of the disease through the neuronal network and justify the post-mortem 
observations of α-syn aggregates in a PD patient that had undergone midbrain 
embryonic neuronal transplants (Heiko Braak, Del Tredici, et al., 2003; Jeffrey H 
Kordower et al., 2008; Chu and Kordower, 2010). 
 
The results of this study demonstrate the addition of seeding oligomers to SH-SY5Y 
cultures are capable of inducing the same intracellular aggregation as previously 
described (Danzer et al., 2007; Illes-Toth et al., 2015). Homogenous, cytoplasmic 
staining of α-syn is apparent in the 10% v/v solvent and 10% v/v monomeric controls 
when added to SH-SY5Y in all stages of differentiation (undifferentiated, RA-
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differentiated, RA + BDNF-differentiated) (Fig. 4.3, 4.5 and Appendix Fig. 1 and 2). 
Upon treatment with the oligomeric seed, the development of aggregates is 
observed as punctate spots throughout the cell cytoplasm of all cells in both 
undifferentiated and RA-differentiated SH-SY5Y (Fig. 4.5). In contrast, treatment of 
oligomer preparations to RA + BDNF-differentiated SH-SY5Y in 2D resulted in the 
development of large, singular α-syn positive inclusions in a small subset of cells 
(~31%) (Fig. 4.5). Addition of solvent and monomeric controls to RA + BDNF-
differentiated SH-SY5Y in 2D did not result in the development of intracellular 
inclusions, but homogenous staining of cytoplasmic α-syn is evident (Appendix Fig. 
2.). These inclusions were reminiscent of LB-pathology given the size of inclusions, 
positive staining for α-syn and perinuclear location. One caveat of using the 2D RA + 
BDNF-differentiated cells was that cells easily detached from the culture surface 
following media changes after differentiation, similar to that which has been 
observed previously with LUHMES cell culture (Smirnova et al., 2016). This could 
account for the variation in inclusion size in these cultures (Fig. 4.5 C) and toxicity of 
10% v/v solvent, 10% v/v monomer and 10% v/v oligomer treatment (Fig. 4.2 C).  
 
Given that use of SH-SY5Y in PD research is generally undertaken using the 
undifferentiated cultures in 2D (83% of papers), the morphology of inclusions in 
these cells do not represent what is observed in vivo (Goldie, Barnett and Cairns, 
2014). Several small inclusions are apparent throughout the cell cytoplasm in both 
undifferentiated and RA-differentiated SH-SY5Y in contrast to the large, singular 
inclusion observed in vivo. One potential reason for the difference in morphology 
observed in undifferentiated SH-SY5Y is due to the fact that this is a continually 
dividing cell line, with a doubling time of ~27 hrs, and could potentially divide the 
protein load into daughter cells akin to yeast replication (Tuite and Cox, 2003; 
Kovalevich et al., 2013). Aulic et al. (2014) demonstrated the addition of short 
amyloid fibrils were capable of spreading pathology in subsequent cellular passages 
once inoculated at P0 and was detected at P6 (Aulic et al., 2014). However, the 
same inclusion morphology was observed in RA-differentiated SH-SY5Y cells which 
were previously demonstrated to have exited the cell cycle (Chapter 3) as indicated 
by the absence of Ki67 staining. Another explanation could be that oligomers are 
taken up by cells and processed by the cell to be degraded and exported to the 
extracellular space. Therefore, the morphology of inclusion formation would correlate 
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to the subcellular location of the ubiquitin-proteasome in cells (Bennett et al., 1999; 
Zhao, 2003). Cells with morphology as in undifferentiated and RA-differentiated SH-
SY5Y, with a nucleus surrounded by abundant amounts of cytoplasm in the absence 
of developed axons, would stain for the 26 S proteasome throughout the cytoplasm, 
in accordance with the pattern of aggregate formation (Zhao, 2003). This is 
supported by a time-course experiment whereby aggregate formation was induced 
by the addition of oligomeric seed (same oligomer preparation as used in this study) 
over 16 hrs. At 30 hrs, the presence of cellular inclusions was reduced but increased 
extracellular background staining was observed, suggesting the cell has attempted 
to decrease cellular protein load (Mason, 2018). Interestingly, in RA-differentiated 
cultures where cells are not actively undergoing mitosis, there is increased 
extracellular α-syn staining, suggesting increased clearance (Fig. 4.5 A). In contrast 
to the abundant cytoplasmic staining of α-syn aggregates in undifferentiated and RA-
differentiated SH-SY5Y, singular, large nuclear-associated inclusions were observed 
in RA + BDNF-differentiated 2D cultures where cellular morphology consists of the 
nucleus surrounded by scant cytoplasm and long, thin axons (Fig. 4.5). Staining with 
a proteasome antibody would demonstrate whether α-syn inclusion formation 
correlates to the cellular localisation of the proteasome.  
 
Addition of oligomers to 3D-differentiated cultures demonstrated the development of 
LB-like aggregates reminiscent of in vivo pathologies such as staining for α-syn and 
ubiquitin, size of inclusions and perinuclear location (Fig. 4.9 and 4.11). Importantly, 
these inclusions were apparent in a cell line with no genetic manipulation and in a 
more physiologically-relevant culture system where cells are in contact with the ECM 
and other cells in 3D. Inclusions were not observed in isotype, media, solvent and 
monomeric controls (Fig. 4.9). A major component of LBs is the presence of α-syn 
phosphorylated at S129 at <90% in synucleinopathies compared to normal 
conditions of >4% implicates this post-translational modification as important in the 
pathogenesis of PD (Fujiwara et al., 2002; Anderson et al., 2006). Staining with a 
phosphorylation-specific antibody (S129) revealed the absence of phosphorylated α-
syn within these inclusions due to either the antibody not binding due to epitope 
masking, phosphorylation not being required for inclusion formation or 
phosphorylation occurring in a time-frame outside what was used in this study (24 
hrs) (Walker et al., 2013). Indeed, a previous study by Luk et al. (2009) 
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demonstrated phosphorylation was not required for the development of LB-like 
aggregates in a cell culture model stably expressing α-syn (Luk et al., 2009). 
Phosphorylation of α-syn at S129 is associated with clearance, toxicity and stability 
of α-syn in addition to being associated with cellular stress (Machiya et al., 2010; 
Oueslati, 2016). Phosphorylation at S129 is selectively targeted for degradation by 
the proteasome and extensively aggregated forms are unable to be degraded by the 
proteasome and accumulate as LBs (Machiya et al., 2010; Arawaka et al., 2017). 
This could mean that phosphorylated α-syn that has already been degraded and 
processed by the cell to the extracellular space (by ubiquitin-proteasome and 
autophagy-lysosomal pathways) and therefore not detectable in inclusions (Chau et 
al., 2009; Machiya et al., 2010; Lashuel, Overk, A. Oueslati, et al., 2013). 
Interestingly, previous work in our group has demonstrated the ability of seeding 
oligomers to induce the release of phosphorylated α-syn species to cell culture 
media (Mason, 2018). The late-stage disease could then be associated with 
accumulation of p-α-syn, therefore, the lack of phosphorylated presented here would 
represent an early aggregated model of PD (Beach et al., 2009; Walker et al., 2013).  
 
Following internalisation, the ability of α-syn to trigger oligomerisation of endogenous 
α-syn potentially occurs through the induction of oxidative or other stress responses 
(Deas et al., 2016; Di Maio et al., 2016). Although the precise series of events 
surrounding the development of these inclusions remains to be established, a model 
system such as the one described here opens the opportunity to investigate these 
mechanisms within a controlled environment, without the need to genetically modify 
or overexpress α-syn. In multifactorial disorders such as PD, dissecting the complex 
pathological processes into simpler molecular events may allow us to better interpret 
disease progression. Using the 3D cell culture model described here may allow us to 
identify therapeutic interventions and the pathways leading to LB development 
before translating them to more complex models of the brain (e.g. transgenic mouse 
models) in which confounders such as neuroinflammation and innate immunity could 






Chapter 5 : The role of ferroptosis to the 
aggregation and propagation of α-synuclein in 
in vitro models 
5.1 Introduction 
Medical management of PD has largely focussed on replacement of the dopamine 
deficit caused by loss of dopaminergic neurons in the disease, through the 
administration  of the dopamine precursor L-DOPA (Birkmayer and Hornykiewicz, 
1961; Cotzias, Papavasiliou and Gellene, 1969; Korczyn et al., 1999). Levodopa 
remains the gold standard therapy for PD patients and as such almost all patients 
are prescribed this particular treatment. L-DOPA (levodopa) therapies are generally 
administered in conjunction with other drugs to help the bioavailability of L-DOPA 
and reduce some side effects associated with L-DOPA. 3,4-dihydroxyphenylaline 
(DOPA) decarboxylase inhibitors, catechol-o-transferase (COMT) inhibitors and 
monoamine oxidase (MAO) inhibitors (Riederer and Laux, 2011; Nyholm, Klangemo 
and Johansson, 2012). For example, carbidopa, a DOPA decarboxylase inhibitor, is 
administered to patients alongside levodopa to prevent the breakdown of levodopa in 
the periphery, thereby increasing concentration of levodopa reaching the brain. By 
increasing the amount of levodopa reaching the brain, carbidopa allows for a lower 
dose of levodopa, which reduces the side effects of nausea and vomiting if levodopa 
was administered alone (Muddapu et al., 2020). Administration of 
levodopa/carbidopa shifts the peripheral pathway of levodopa to a secondary 
pathway involving COMT, subsequently reducing the bioavailability of levodopa 
(Nevrly et al., 2010). Therefore, triple therapy with added COMT inhibitors in the 
levodopa/carbidopa preparations inhibits this method of metabolism to increase the 
bioavailability and half-life of levodopa (Hinz, Stein and Uncini, 2011; Muddapu et al., 
2020). Importantly, the use of levodopa only provides symptomatic relief in the 
management of PD and does not treat the underlying pathology. Moreover, long-
term levodopa therapy loses its efficacy and is associated with a range of adverse 
side effects (Hinz, Stein and Uncini, 2011). Symptoms of late-stage disease respond 
poorly to levodopa therapy due to degeneration in other brain regions. Loss of 
neurons from these regions ensure deficits in the non-dopaminergic transmission of 
involving acetylcholine, glutamate, norepinephrine, and serotonin neurotransmitters. 
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Degeneration of cholinergic neurons, and subsequent depletion of acetylcholine, can 
cause dementia, gait abnormalities, and falls (Perez-lloret and Barrantes, 2016).  
As a consequence of no disease-modifying therapies available to either slow down 
the progression of the disease or prevent neuronal cell death in the SNPc in patients 
of PD, there is an urgent need identify new molecular targets to be able to slow the 
progression of the disease and subsequent neurodegeneration (Smith et al., 2012). 
The various mechanisms of neuronal degeneration in PD are associated with 
multiple cell death pathways; however, it is currently not known how these contribute 
to disease. A newly discovered cell death pathway, ferroptosis, has recently been 
implicated in the pathogenesis of PD (Dixon et al., 2012; Do Van et al., 2016). 
Ferroptosis is characterised by the accumulation of iron-dependent ROS, depletion 
of cellular GSH/GPX4 and lipid peroxidation, leading to cell death (Dixon et al., 
2012). These features of ferroptosis are all pathogenic changes associated with PD. 
Chelation of iron and administration of ferroptosis inhibitors have shown to be 
promising therapeutic options in the treatment of PD (Devos et al., 2012, 2014). 
Deferiprone, an oral iron chelator, has shown promise in a recent phase III trial of 
early-stage PD patients whereby therapy was associated with reduced motor 
symptoms and slowing the progression of motor deficits (Devos et al., 2014). 
Replication of this result in a larger-scale clinical trial could lead to the first disease-
modifying therapy for PD. Although promising, only one paper has been published to 
date directly relating ferroptosis to cell death in PD and it is currently unknown if α-
syn is linked to ferroptotic cell death (Do Van et al., 2016). In this section, cell death 
pathways of apoptosis, autophagy and ferroptosis involved in PD are discussed.  
5.1.1 Cell death mechanisms 
Programmed cell death (PCD) plays a fundamental role in the development and 
tissue homeostasis in biological systems (Fuchs and Steller, 2011). Developing 
tissues rely on a balance between cellular proliferation and PCD to prevent the 
development of hyper-proliferative diseases through the regulation of cell numbers 
(Arya and White, 2015). Approximately half of the neurons generated in the central 
nervous system (CNS) are eventually eliminated by PCD to maintain appropriate cell 
numbers (Yamaguchi and Miura, 2015). An abundance of cells in tissue 
development allows for selection of the 'fittest' cells to optimise organ function. Cells 
that are deemed 'unfit' for tissue function are eliminated by PCD, preventing the 
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survival of cells that have developed differentiation defects (Baehrecke, 2002; 
Hanahan and Weinberg, 2011; Arya and White, 2015). The 'neurotrophic factor 
hypothesis' describes one method of regulating cell numbers of the peripheral 
nervous system (PNS) in which the overproduction of neurons is regulated by the 
competition for survival-promoting neurotrophic factors (Oppenheim et al., 1991; 
Yuen et al., 1996). PCD also serves as a 'quality control' mechanism to eliminate 
potentially dangerous cells in response to cellular defects such as DNA damage, 
response to viral infection and cell fate defects (Suzanne and Steller, 2013; Upton 
and Chan, 2014; Nagata and Tanaka, 2017). Abnormal regulation PCD processes 
are associated with human disease, including the development of cancer, 
developmental disorders and neurodegeneration (Hanahan and Weinberg, 2011).  
Exposure of cells to an instantaneous, catastrophic form of cellular stress (physical, 
chemical or mechanical) results in accidental cell death (ACD), a form of cell death 
not defined by a molecular mechanism of action in contrast to the forms of PCD 
discussed below (Galluzzi et al., 2015). PCD exhibits a molecular 'fingerprint' 
specifically initiated by the cell as a consequence of intracellular/extracellular stress 
(Vandenabeele et al., 2010; Galluzzi et al., 2015, 2018). As cell death progresses 
macroscopic morphological alterations and the mechanisms by which cells are 
disposed of, have been classified into three major mechanisms: type I cell death or 
apoptosis, type II cell death or autophagy and type III cell death or necrosis (Galluzzi 
et al., 2015, 2018). The discovery of more specific cell death mechanisms has 
challenged the mechanism of cell death in various disease states, including in 
neurodegeneration (Table 5.1) (Agostini, Tucci, & Melino, 2011). Pharmacological 
intervention has the potential to modify these cell death modalities therefore it is 









• packaging of apoptotic bodies 




Activation of caspases p53, BAX, BAK, 
BCL-2, initiator 
caspases- 2, 8, 9, 
10 and effector 
caspases- 3, 6, 7  
Inducers: Staurosporine, apicidin, 
apoptosis activator 2, cisplatin, 
cyclophosphamide, rifaximin 
Inhibitors: Z-VAD, QVD-OPh 
(Jorgensen and 







•in chaperone mediated autophagy, 
selective degradation of cytosolic 
proteins 
•in microautophagy, double 
membrane structures to sequester 
cell material for degradation 




Inducers: MG-132, SAHA, trichostatin-A, 
Z-VAD-FMK 
Inhibitors: metformin, perifosine, 
rapamycin, everolimus, resveratrol 
(Todde, Veenhuis 







•increased cell volume 
•swelling of organelles 
•plasma membrane 
permeabilisation 
•cellular collapse and subsequent 
release of cellular contents, 
triggering inflammatory response 
Activation of specific 
death receptors including 






Inducers: TNFα, FASL, TRAIL  
Inhibitors: Nec-1, necrosulfonamide, 
ponatinib, pazopanib, sorafenib, 
hydroxyanisole, diphenyleneiodonium, 
caspase-8, necrostatin-1, GSK’872, 
necrosulfonamide 
(Xie et al., 2016; Ito 









•intact cell membrane, no blebbing  
•mitochondrial alterations including 
dense, small mitochondria with 
vestigial cristae 
•normal size nucleus, no chromatin 
condensation 
Accumulation of toxic 
lipid peroxides as a result 
of ROS generated from 
iron metabolism  
GSH depletion and 






Inducer: Erastin, RSL3, sorafenib, 
sulfasalazine, DP17, buthionine 
sulfoximine (BSO), acetaminophen, 
artesunate, lanperisone, iron, ROS 
Inhibitors: Trolox, cycloheximide, 
ebselen, deferoxamine, ferrostatin-1, 
liproxstatin-1, vitamin E, n-acetylcysteine 
(NAC)   
Yang and 
Stockwell, 2008; 
Dixon et al., 2012, 
2014; Do Van et al., 
2016; Xie et al., 




•morphologically similar to 
ferroptosis 




Inducers: iron, aminoadipate, 
homocysteate, quisqualate, BSO, ROS 
(Tan, Schubert and 







•mitochondria appear swollen and 
degraded 
(LO) activation and lethal 
calcium influx 
factor (AIF) Inhibitors: NAC, deferoxamine, 
quercetin, vitamin E, vitamin C, 
ibdebenone, α-tocopherol 
and Schubert, 2009; 








•pore formation in the plasma 
membrane by gasdermin D 
(GSDMD) oligomerisation 
•water and ions rush into cells 
causing cell swelling and lysis 
•release of cellular contents 
•chromatin condensation but intact 
nuclei 
•DNA damage (lower intensity to 
that of apoptosis) 
Initiated by inflammatory 
caspases 
Proteolytic maturation of 
inflammatory cytokines 
interleukin-1β (IL-1β) and 
IL-18 following caspase 1 
activation 
Caspases – 1, 3, 4, 
5, 11, GSDMD 
Inducers: gram-negative bacteria, 
lipopolysaccharide, influenza A virus 
Inhibitors: ablation of caspase 1, 11, 4 
or 5, caspase 1 inhibitor z -YVAD-fmk 
(Cookson and 
Brennan, 2001; Fink 
and Cookson, 2006; 
Bergsbaken, Fink 
and Cookson, 2009; 
Jorgensen and 
Miao, 2016; Sborgi 







•large scale DNA fragmentation and 
chromatin condensation 
Hyperactivation of poly 
(ADP-ribose) polymerase 
1 (PARP1) 
NAD+ and ATP depletion 
resulting in bioenergetic 
and redox collapse 
Accumulation of poly 
(ADP-ribose) polymers at 







nitrosoguanidine, UV light, ionizing 
radiation, reactive nitrogen species 
Inhibitors: PARP inhibitors; 
isoquinolinones, quinazolinones, 
quinazoline diones, phthalazinones and 
phenanthridinones, 
 
(Yu et al., 2002; 
Curtin and Szabo, 
2013; Galluzzi et 
al., 2018) 
Table 5-1.1.  Morphological and biochemical features of distinct mechanisms of cell death. Listed are some examples of inducers and inhibitors specific to a mechanism 
of cell death but it is not an exhaustive list.
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5.1.2 Cell death mechanisms in Parkinson’s disease 
5.1.2.1 Apoptosis 
Apoptosis is a form of PCD characterised by a cascade of executioner caspases that 
ultimately leads to cell death through one of two pathways - intrinsic or extrinsic 
pathway (Table 5.1 and Fig. 5.1). Intrinsic apoptosis is initiated by several 
environmental perturbations including growth factor withdrawal, DNA damage, 
endoplasmic reticulum (ER) stress, ROS, mitotic defects, amongst others (Nuñez et 
al., 1990; Czabotar et al., 2014; Shim et al., 2014; Pihán, Carreras-Sureda and Hetz, 
2017; Galluzzi et al., 2018). Extrinsic apoptosis is defined as a modality initiated by 
perturbations of the extracellular environment, driven by the two types of membrane 
receptors: death receptors and dependence receptors (Wang and El-Deiry, 2003; 
Flusberg and Sorger, 2015; Galluzzi et al., 2018). Both result in the activation of 
executioner caspase proteins that irreversibly lead to cell death (Fig. 5.1) (Flusberg 
and Sorger, 2015). These executioner caspases are responsible for the 
morphological and biochemical features of apoptosis including: cell shrinkage, 
chromosome condensation, DNA fragmentation, formation of apoptotic bodies and 
phosphatidylserine exposure (Xu et al., 2002; Galluzzi et al., 2018).  
Apoptosis has been linked to PD in both humans and cell models. Several post-
mortem studies have identified apoptotic neurons in the SNPc of PD patients, either 
by detection of apoptosis by terminal deoxynucleotidyl transferase dUTP nick-end 
labelling (TUNEL) staining, morphological characterisation of neurons and 
immunostaining for caspase proteins (Mochizuki et al., 1996; Tatton and Kish, 1997; 
Tatton, 2000). Nigrostriatal dopaminergic neurons of late-onset PD patients 
expressed increased immunostaining for caspases 3, 8, 9 in addition to elevated 
activities of caspase 3 in the SNPc (Hartmann et al., 2001; Viswanath et al., 2001; 
Nazli et al., 2016). Models of PD using the toxins 1-methyl-4- phenyl-1,2,3,6-
tetrahydropyridine (MPTP), rotenone and 6-hydroxydopamine (6-OHDA) lead to the 
activation of caspase 8 in both the SNPc of animal models and cultured cells 
(Hartmann et al., 2001; Vila et al., 2001; Viswanath et al., 2001; Recasens et al., 
2014). MPTP-induced neurodegeneration in murine models can be rescued with the 
application of caspase inhibitors (Q-VD-OPH), highlighting the role of apoptosis in 




Figure 5.1. Intrinsic and extrinsic apoptotic signalling pathways. Extrinsic pathway: ligand binding to death 
receptors activates CASP8 and CASP10. Active CASP8 and CASP10 then cleave executioner caspases, CASP3 
and CASP7, leading to cell death. Intrinsic pathway: mitochondrial outer membrane permeabilisation (MOMP) 
initiated by the BCL2 apoptosis regulator family (Galluzzi, Kepp and Kroemer, 2016). In response to cellular 
stresses, members of the BCL2 family including BCL2 associated X (BAX) and/or BCL2 antagonist/ killer 1 
(BAK1), together with BCL2 family apoptosis regulator (BOK) mediate MOMP. BAX and BAK are activated by 
pro-apoptotic BH3 proteins (Gavathiotis et al., 2010; Czabotar et al., 2013; Zhang et al., 2016). Once activated, 
BAX and BAK can form rings or oligomers that perforate the outer mitochondrial membrane (OMM) (Kuwana et 
al., 2002; Schafer et al., 2009; Grosse et al., 2016). MOMP releases apoptotic factors that normally reside within 
the mitochondria into the cytosol, including cytochrome c somatic (CYCS) and secondary mitochondrial activator 
of caspases (SMAC). CYCS binds to apoptotic peptidase activating factor-1 (APAF1) and pro-caspase 9 
(CASP9) to form the apoptosome complex, activating CASP9 (Hu et al., 2014). Activated CASP9 catalyses the 
activation of executioner caspases (CASP3 and CASP7) and in turn, results in cell degradation in both intrinsic 
and extrinsic apoptosis. Reprinted by permission from Springer Nature: License Number 4658840206496, 
Springer Nature, Nature Reviews Cancer, A fate worse than death: apoptosis as an oncogenic process, Gabriel 
Ichim and Stephen W. G. Tait, Jul 1, 2016 (Ichim and Tait, 2016). 
Overexpression of WT α-syn or expression of mutant α-syn (e.g. A53T) in cultured 
cell lines and animal models leads to the activation of apoptosis, which can be 
rescued by caspase inhibitors or knockdown of caspase-12 (Saha et al., 2000; 
Stefanova et al., 2001; Tanaka et al., 2001; Martin, 2006). The association of α-syn 
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with apoptosis has been linked to; interaction of α-syn with pro-apoptotic BCL2 family 
members (e.g. BCL2-associated death promoter; BAD) (Saha et al., 2000), oxidative 
stress (Stefanova et al., 2001) and mitochondrial DNA damage (Stefanova et al., 
2001; Tanaka et al., 2001; Martin, 2006). A 53-83-kD complex of α-syn has been 
shown to bind anti-apoptotic 14-3-3 protein (Xu et al., 2002). 14-3-3 proteins are a 
family of highly conserved eukaryotic regulatory molecules important for the 
regulation of biological processes such as cell death (Masters and Fu, 2001). 
Sequestration of 14-3-3 by α-syn prevents the inactivation of pro-apoptotic factors 
(e.g. BCL2 family members, BAD) leading to a pro-apoptotic environment whereby 
neurons are increasingly vulnerable to apoptosis by elevated levels of α-syn (Xu et 
al., 2002). This observation was specific to expression of WT α-syn in human foetal 
DA neurons in contrast to non-DA human cortical neurons where expression of α-syn 
protected cells and increased neuron survival (Xu et al., 2002). Accumulation of α-
syn rendered endogenous levels of DA toxic, demonstrating a selective vulnerability 
in DA-producing neurons (Xu et al., 2002). In Saccharomyces cerevisiae, WT, A53T 
and A30P α-syn were all shown to trigger apoptosis, with ROS thought to be the 
primary trigger of apoptosis in this system (Flower et al., 2005). 
5.1.2.2 Autophagy 
Autophagy “self-digesting” is a form of PCD that relies on the components of 
autophagic machinery that promote proteolytic degradation of cytosolic components 
of the lysosome initiated through multiple signalling events (Table 5.1, Fig. 5.2) 
(Glick, Barth and Macleod, 2010). The self-destructive process of autophagy can be 
initiated in response to nutrient deficiency, organelle damage (e.g. through ROS), 
hypoxia, drug treatment and ER stress (Chen, Kang and Fu, 2018).  
The central pathogenic events important to understanding PD pathogenesis (e.g. 
ROS production, oxidative stress, mitochondrial dysfunction, aggregation of proteins) 
are linked to autophagy. The pentapeptide recognition sequence of α-syn is 
consistent with the CMA recognition sequence (95VKKDQ99), highlighting CMA as the 
main route for degradation of α-syn (Dice, 1990; Cuervo et al., 2004). Mutant forms 
of α-syn (e.g. A30P and A53T) and multimeric species of the protein (e.g. oligomers) 
prevent the degradation of α-syn by the CMA pathway leading to toxic aggregation in 
the cell (Webb et al., 2003; Cuervo et al., 2004; Martinez-vicente et al., 2008). In 
addition, overexpression of α-syn inhibits macroautophagy by prevention of 
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autophagosome formation via inhibition of RAB1A and subsequent mislocalisation of 
the transmembrane protein ATG9 required in an early step of macroautophagy 
(Winslow et al., 2010; Winslow and Rubinsztein, 2011).  
Mitochondrial dysfunction is intrinsically linked to PD. Several genes associated with 
familial PD including the genes PARK2 (PARKIN), PARK6 (PINK1), PARK7 (DJ-1) 
and PARK8 (LRRK2) are associated with the impairment of mitophagy (autophagic 
degradation of mitochondria) (Bonifati et al., 2003; Hague et al., 2003; Maria, Patrick 
and Muqit, 2004; Berg et al., 2005; Pchelina, Emel’ianov and Usenko, 2014; Ryan et 
al., 2015). PINK-1 and PARKIN are important in mitochondrial homeostasis whereby 
WT PINK-1 recruits PARKIN to damaged mitochondria during mitophagy, leading to 
degradation of damaged mitochondria through the trafficking of defective 
mitochondria to the lysosome-rich perinuclear area (Clark et al., 2006; Heeman et 
al., 2009; Vives-bauza et al., 2009). Loss of PINK-1 or PARKIN results in an altered 
mitophagy process, resulting in the persistence of damaged ROS-producing 
mitochondria (Pickrell and Youle, 2015). DJ-1, a transcriptional regulator, is a 
neuroprotective factor involved as a redox sensor/reductase that influences 
mitophagy (Wilson et al., 2004). Mutant forms of DJ-1 are associated with a 
decrease in consumption of H2O2 by brain mitochondria, resulting in cell death 
through increased ROS production (Lopert and Patel, 2014). Mutant DJ-1 interacts 
with α-syn to cause the formation of α-syn aggregates, which further inhibits cellular 
autophagy (e.g. CMA) (Xilouri et al., 2009; Zondler et al., 2014). Mutant LRRK2 is 
associated with a wide range of negative cellular effects on mitochondria including 
regulating mitochondrial dynamics, mitochondrial uncoupling (leading to increased 
basal oxygen consumption and reduced ATP level) (Li, Tan and Yu, 2014). LRRK2 
mutants impair the autophagy/lysosomal pathway resulting in a defective CMA 
complex, impairing autophagy which subsequently leads to the inhibition of α-syn 




Ferroptosis, a recently discovered form of non-apoptotic form of cell death, is 
exclusively dependent on intracellular iron in contrast to other metals (Table 5.1, Fig. 
5.3) (Dixon et al., 2012; Yang et al., 2014). The key characteristics of ferroptosis 
involve the iron-dependent accumulation of ROS, reduction in cellular glutathione 
(GSH) levels, loss of glutathione peroxidase 4 (GPX4) activity and lipid peroxidation 
(phosphatidylethanolamines containing arachidonic and adrenic acid) that eventually 
leads to cellular death through loss of membrane functionality (Fig. 5.3) (Friedmann 
Angeli et al., 2014; D’Herde and Krysko, 2017; Doll et al., 2017; Ito et al., 2017; 
Kagan et al., 2017). Morphologically, ferroptotic cells display rounding up of cells, 
mitochondrial abnormalities and normal nuclei in contrast to cells undergoing 
apoptosis/necrosis/autophagy (Xie et al., 2016). Dysregulation of ferroptosis has 
been implicated in multiple pathological processes including neurodegenerative 
Figure 5.2. Signalling pathways in ferroptosis. The inability to detoxify iron-associated ROS by GPX4 and GSH is 
central to cell death in ferroptosis (Friedmann Angeli et al., 2014; Yang et al., 2014). ROS generated from iron 
interacts with the bisallylic methylene of a polyunsaturated fatty acid (PUFA; such as arachidonic and adrenic 
acid) in the lipid bilayer creating a lipid peroxyl radical LOO·, which  interacts with another bisallylic methylene to 
generate LOOH (Repetto, Ferrarotti and Boveris, 2010; Kagan et al., 2017). Propagation of LOOH can occur by 
way of interaction with new substrates thus creating new radicals, damaging multiple residues within lipid 
bilayers. To prevent this cycle of LOO· production, antioxidants are able to donate an electron to the radicals, 
resulting in termination of this process (Gaschler and Stockwell, 2017). Lipid peroxidation results in wide ranging 
alterations of the lipid bilayer, impacting membrane fluidity, lipid-lipid and lipid-protein interactions, membrane 
integrity, ion and nutrient transport, membrane-initiated signalling pathways leading to cell death (Catalá and 
Díaz, 2016; Gaschler and Stockwell, 2017). Reprinted by permission from Springer Nature: License Number 
4658830436428, .Springer Nature, Cell Death and Differentiation, Ferroptosis: process and function, Y Xie, W 
Hou, X Song, Y Yu, J Huang et al. Jan 22, 2016 (Xie et al., 2016).  
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diseases, cancer, acute renal failure, hepatic and heart ischaemia/reperfusion injury, 
T cell immunity and drug-induced hepatotoxicity (Friedmann Angeli et al., 2014; 
Linkermann et al., 2014; Yang et al., 2014; Lőrincz et al., 2015; Matsushita et al., 
2015; Martin-Sanchez et al., 2017).  
GSH is an important antioxidant synthesised in cells from the amino acids L-cystine, 
L-glutamic acid and glycine (Cardoso et al., 2017). GSH is required as a substrate 
for the lipid repair function of GPX4, a class of selenium-containing enzymes 
expressed principally in the brain, testes and spermatozoa (Cardoso et al., 2017). 
The primary function of GPX4, along with other GPX enzymes is as an antioxidant to 
protect against oxidative stress. Existing as a membrane-anchored glycoprotein, 
GPX4 is required for a vital lipid repair function by mediating the reduction of lipid 
hydroperoxides (LOOH) (Thomas et al., 1990; Wang et al., 2013; Pitts et al., 2014). 
Ferroptosis inducers, such as ras-selective lethal small molecule-3 (RSL3) and 
erastin, induce cell death by increasing the amount of lethal lipid ROS generated 
through inactivation of GPX4 and inhibition of the system xc- cystine/glutamate 
antiporter, respectively (Yagoda et al., 2007; Dixon et al., 2012; Yang et al., 2014). 
Erastin contributes to ferroptosis by preventing the uptake of cystine through 
inhibition of the system xc- cystine/glutamate antiporter (Dixon et al., 2012). Cystine 
starvation results in the depletion of GSH and fundamentally the loss of GPX4 
activity (Dolma et al., 2003; Gao et al., 2015; Feng and Stockwell, 2018; Gaschler et 
al., 2018). Depletion of GSH itself by inhibition of the glutamate-cystine ligase 
complex with L-buthionine sulfoximine can also lead to the same iron- and ROS-
dependent phenotype (Friedmann Angeli et al., 2014). Addition of iron chelators (e.g. 
deferoxamine, deferiprone) to reduce iron overload protects against ferroptosis-
induced cell death (Yang and Stockwell, 2008; Dixon et al., 2012). Compounds that 
prevent lipid peroxidation are also able to inhibit ferroptosis (e.g. Vitamin E, 
ferrostatin-1, liproxstatin-1) (Do Van et al., 2016; Ito et al., 2017; Feng and Stockwell, 
2018). 
The role of iron in neurons of the SNPc has been previously discussed in Chapter 1 
section 1.2.4. This section will instead focus on the link of ferroptosis to PD. Iron 
accumulation in the SNPc, genetic disorders resulting in brain iron accumulation 
(e.g. haemochromatosis) and neuroprotection by chelation of iron provide evidence 
for the role of iron in PD pathogenesis (Sofic et al., 1988; Gorell et al., 1995; Costello 
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et al., 2004; Weinreb et al., 2013; Devos et al., 2014). As a consequence of oxidative 
stress, decreased GSH levels and increased levels of lipid peroxidation are common 
features in the SNPc of PD patients (Dexter et al., 1989; Jenner et al., 1992; Sian et 
al., 1994).  
α-Syn, the major protein component of LBs has been linked to the pathogenesis of 
PD and is intrinsically linked to iron. α-Syn has an iron response element within the 
5’-untranslated region (UTR) of mRNA that regulates the translation of the protein, 
resulting in increased protein translation in cases of iron overload (Friedlich, Tanzi 
and Rogers, 2007). In addition, α-syn has a strong binding affinity for both ferric and 
ferrous iron which is associated with aggregate formation in vitro and cell culture 
systems (Ostrerova-Golts et al., 2000; Li, Uversky and Fink, 2001; Golts et al., 2002; 
Peng et al., 2010; Xiao et al., 2018). Additionally, the presence of dopamine in the 
SNPc enhances the pro-aggregative effect of iron on α-syn, due to ROS present in 
cells catalysing the oxidation of iron to the ferric form and promoting α-syn 
aggregation (Hashimoto et al., 1999; Ostrerova-Golts et al., 2000). α-Syn has also 
been demonstrated to modulate iron homeostasis through the interaction of α-syn 
with TfR in the trafficking of iron (Bourdenx et al., 2015). The discovery of an iron-
dependent mechanism of cell death suggests a potential to pharmacologically 













5.2 Aims and objectives 
Ferroptosis has recently been linked to cell death pathways in PD; however, it is not 
clear how α-syn aggregation is involved in ferroptosis. The overriding hypothesis is 
that disruption of α-syn functional interactions with the plasma membrane (including 
iron importation and dopamine vesiculation) induces a harmful ROS environment 
that leads to cell death by ferroptosis. The ROS environment favours structural 
changes of α-syn, including oligomerisation, subsequently leading to propagation of 
pathogenic species in a prion-like mechanism.  
The specific aims of this chapter were: 
• To determine whether treatment with iron (Fe2+) and/or oligomeric α-syn 
activate the ferroptosis pathway, resulting in lipid peroxidation in 2D and 3D 
SH-SY5Y models (described in Chapters 3 and 4).  
• To determine the influence of ferroptosis on the formation of α-syn aggregates 
using both Fe2+ and ferroptosis inducers (e.g. erastin and RSL3).  
• To determine the expression levels of the ferroptosis-associated GPX protein, 
GPX4, alongside levels of cellular ROS following treatment with Fe2+ and/or 















5.3.1 Iron (III) chloride is internalised by SH-SY5Y in 2D and 3D cultures and is 
toxic to cells at high concentrations 
To determine whether iron (II) chloride contributes to ferroptosis and aggregation of 
α-syn in SH-SY5Y cell models, the concentration of iron (II) chloride to use for future 
experiments was determined. SH-SY5Y were grown in monolayer undifferentiated 
cultures or differentiated in 3D cultures prior to treatment with iron. ICP-MS analysis 
was undertaken to determine iron uptake in SH-SY5Y cultures (Fig. 5.4) and the 
resazurin cell viability assay was undertaken to determine the toxicity of iron (II) 
chloride (Fig. 5.5).  
 
Figure 5.3. ICP-MS analysis of iron content of 2D and 3D SH-SY5Y following 24 hr treatment with iron (II) 
chloride. (A) Iron calibration curve. (B) 2D-undifferentiated SH-SY5Y. (C) 3D-differentiated SH-SY5Y. (B, C) 
Protein levels were normalised to 500 μg protein prior to ICP-MS analysis. Data presented as individual data 
points and median (straight line) of three independent biological repeats. No statistical significance was observed 
between groups. 
ICP-MS analysis revealed iron content of 2D, and 3D cultures increased in a dose-
dependent manner following treatment with iron (II) chloride and appropriate controls 
(Fig. 5.4). In 2D cultures, intracellular iron concentrations rose to 0.03 µg/mL ± 0.01 
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in the 1000 µM iron (II) chloride treatment group. In 3D cultures, intracellular iron 
concentrations were increased in comparison to 2D cultures at 0.09 µg/mL ± 0.01 in 
the 1000 µM iron (II) chloride treatment group.
 
Figure 5.4. Resazurin reduction cell viability assays of 2D and 3D SH-SY5Y at 24, 48 or 72 hrs following 
treatment with iron (II) chloride. (A) 2D-undifferentiated SH-SY5Y. (B) 3D-differentiated SH-SY5Y. Data 
presented as mean and +/- SEM of at least three independent biological repeats. No statistical significance was 
observed between groups. 
Measurement of cell viability using the resazurin assay revealed exposure to iron (II) 
chloride caused a concentration-dependent reduction in the viability of both 2D and 
3D SH-SY5Y (Fig. 5.5). In 2D cultures (Fig. 5.5 A), viability decreased substantially 
at >1000 µM, with 10,000 µM iron (II) chloride leading to 100% death of the cell 
populations (0% viability). Due to the high levels of iron needed to induce cell death 
in both cell populations (Fig. 5.5) and the possibility that the iron was potentially 
precipitating out of solution at these high concentrations, a ‘continual stress 
treatment’ was included (described in Chapter 2 Fig. 2.1). In this treatment, fresh iron 
(II) chloride (+ NTA) was added to cell populations every 24 hrs for 72 hrs. In the 
“continual stress” group a lower concentration of 5000 μM iron (II) chloride was 
sufficient to induce 100% cell death (0% viability) (Fig. 5.5 A). 3D SH-SY5Y were 
more resistant to cell death induced by iron (II) chloride (Fig. 5.5 B), with viabilities 
following treatment of 10000 µM iron (II) chloride at 24, 48 and 72 hrs at 62% ± 16, 
56% ± 15 and 37% ± 23, respectively. Concentrations of 200 µM and 1000 µM iron 
(II) chloride were chosen for use in future experiments. Cell survival was also 
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confirmed by visual inspection in addition to the resazurin assay, whereby cells with 
0% viability were rounded and detaching from the culture vessel (data not shown). It 
is important to note that the normal cellular concentration of iron in neurons of the 
SNPc is 0.54 ± 0.2 mM (Reinert et al., 2019).  
5.3.2 Iron induced increased expression of α-synuclein 
Iron has been shown to accelerate the formation of α-syn aggregates in previous cell 
culture and in vitro systems (Ostrerova-Golts et al., 2000; Golts et al., 2002; Wan et 
al., 2017). To determine whether iron (II) chloride treatment induced the formation of 
α-syn aggregates in this culture system, 2D and 3D cultures were treated with iron 
(II) chloride and appropriate controls for 24 or 72 hrs and investigated using 
immunocytochemistry, confocal imaging and western blotting (Fig. 5.6, 5.7 and 5.8). 
Using immunocytochemistry and confocal analysis, aggregate volume was slightly 
increased (not statistically significant) in 1000 µM iron (II) chloride treatment group at 
0.96 µm3 ± 0.05 in comparison to media control at 0.73 µm3 ± 0.21, solvent control at 
0.93 µm3 ± 0.24 and 200 µM iron (II) chloride at 0.86 µm3 ± 0.04 (Fig. 5.6 A and 5.6 
A). Aggregate volume was substantially decreased at 72 hrs and 72 hrs ("continual 
stress) in comparison to the aggregate volume at 24 hrs when comparing groups 
e.g. media at 24 hrs compared to media at 72 hrs (Fig. 5.7).  
Aggregate volume at 72 hrs was again slightly increased in the 1000 µM iron (II) 
chloride group at 0.14 µm3 ± 0.04 in comparison to media control 0.08 µm3 ± 0.02, 
solvent control at 0.11 µm3 ± 0.01 and 200 µM iron (II) chloride at 0.1 µm3 ± 0.03 
(Fig. 5.6 B and 5.7 B). In contrast, aggregate volume was highest in the media 
control in the 72 hrs ("continual stress") treatment group at 0.13 µm3 ± 0.50 in 
comparison to solvent control at 0.11 µm3 ± 0.32, 200 µM iron (II) chloride at 0.10 
µm3 ± 0.03 and 1000 µM iron (II) chloride at 0.11 µm3 ± 0.01 (Fig. 5.6 C and 5.7 C). 
Western blot analysis of α-syn protein levels from 2D iron (II) chloride treated 
cultures revealed similar levels of α-syn in all groups (media, solvent, 200 µM iron (II) 
chloride and 1000 µM iron (II) chloride) at 24 and 72 hrs (Fig. 5.7 A, B and 5.8 A and 
B). Increased levels of both α-syn and phosphorylated α-syn (p-α-syn) were 
observed in the 72 hr ("continual stress") group in both iron (II) chloride treatment 
groups when compared to media and solvent controls (Fig. 5.7 C and 5.8 C). The 




Figure 5.5. Aggregation of α-syn in 2D cultures following treatment with iron (II) chloride. Double immunostaining of α-syn (red) and nuclei (blue) following treatment at 




Figure 5.6. Volume (µm3) of α-syn-positive aggregates in 2D cultures following treatment with iron (II) chloride. 
(A) 24 hrs. (B) 72 hrs. (C) 72 hrs ("continual stress"). Data presented as individual data points and median 
(straight line) of three independent biological repeats. No statistical significance was observed between groups. 
± 0.4197 and 1.528 ± 0.1869 in the 200 and 1000 µM iron (II) chloride treatment 
groups, respectively (Fig. 5.7 C). The same trend was observed when detecting p-α-
syn at S129, with levels increased in the 200 and 1000 µM iron (II) chloride treatment 
groups at 2.15 ± 0.38 and 2.32 ± 0.74, respectively, compared to media control at 1 
± 0.74 (Fig. 5.8 C).  
To determine whether α-syn expression was increased in 3D cultures, cells were 
treated with iron (II) chloride for 24 or 72 hrs and stained with an anti-α-syn antibody. 
Increased staining was principally observed in the 1000 µM iron (II) chloride following 
72 hr treatment, however, no obvious aggregates were observed in any of the 
treatment groups (Fig. 5.9 A). At 24 hrs, % cells positive for α-syn staining increased 
from 42% in the media control group to 58%, 77% and 56 % in the solvent, 200 and 
1000 µM iron (II) chloride groups, respectively (Fig. 5.9 B). At 72 hrs, % cells positive 
for α-syn staining increased from 67% in the media control group to 70%, 82% and 










Figure 5.7. Fold change of α-syn in 2D cultures following treatment with iron (II) chloride compared to media control as analysed by western blotting. (A, 
B, C) Western blotting undertaken using the α-syn211 antibody and the representative blots (D, E, F). (A, D) 24 hr treatment. (B, E) 72 hr treatment. (C, 
F) 72 hrs ("continual stress") treatment. Data presented as individual data points and median (straight line) of three independent biological repeats. (C) 
Statistical significance determined by Kruskal-Wallis test with post-hoc Conover-Inman. (A, B) No statistical significance between groups. (C) Result of 




























































































































































































D E F 
Figure 5.8. Fold change of phosphorylated-α-syn in 2D cultures following treatment with iron (II) chloride compared to media control as analysed by western blotting. (A, B, 
C) Densitometry analysis of western blots undertaken using an antibody recognising the phosphorylation of α-syn at S129 and the representative blots (D, E, F). (A, D) 24 
hr treatment. (B, E) 72 hr treatment. (C, F) 72 hrs ("continual stress") treatment. Data presented as individual data points and median (straight line) of three independent 




































































































































































Figure 5.9. α-Syn staining of 3D cultures following treatment with iron (II) chloride. (A) Representative images of α-syn staining in 3D cultures following 
treatment with either media only, solvent control, 200 µM iron (II) chloride or 1000 µM iron (II) chloride for 72 hrs. Scale bar represents 100 µm. (B) % α-syn 
immunopositivity at 24 hrs. (C) % α-syn immunopositivity at 72 hrs. (B, C) Data presented as individual data points and median (straight line) of three 
independent biological repeats (except for C, media only control only has two data points). No statistical significance was determined between groups. 
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5.3.3 Ferroptosis is not an effective pathway for inducing SH-SY5Y cell death 
 
Figure 5.10. Resazurin cell viability assays of 2D and 3D SH-SY5Y following 24 hr treatment with erastin, RLS3 
and staurosporine. (A) Erastin. (B) RSL3. (C) Staurosporine. (A, B, C) Appropriate solvent controls were also 
incubated for 24 hrs. Data presented as mean and +/- SEM of at least three independent biological repeats. 
Ferroptosis, a form of non-apoptotic cell death, has been linked to the pathogenesis 
of PD through the involvement of iron deposition, ROS generation, lipid peroxidation 
and eventual cell death (Do Van et al., 2016). However, it is not known whether the 
iron-induced aggregation of α-syn is related to this mechanism of necroptosis,  
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5.3.4 Iron induces oxidative stress in SH-SY5Y 
 
Figure 5.11. Glutathione assay of SH-SY5Y cells treated for 24 hrs with iron (II) chloride. (A) Resazurin cell 
viability assay of menadione (positive control for ROS generation) and solvent control (ethanol). Data presented 
as mean and +/- SEM of three independent biological repeats. (B) GSH concentration per well. (C) GSSG 
concentration per well. (D) Ratio of GSH/GSSG. (B, C, D) Data presented as individual data points and median 
(straight line) of three independent biological repeats. Statistical significance was determined using Kruskal-
Wallis with post-hoc Conover-Inman. Result of initial statistical test (Kruskal-Wallis) for (B) P= 0.0513 (not 
statistically significant) (C) P= 0.0237 (D) P= 0.0329. 
therefore the relationship of α-syn aggregation to ferroptosis was investigated. First, 
the ferroptosis inducers erastin and RSL3 were investigated for the ability to induce 
cell death in SH-SY5Y cultures. Change in cell viability was investigated in both 2D 
and 3D cultures using the resazurin reduction assay (Fig. 5.10 A, B). Treatment with 
erastin or RSL3 revealed no significant changes in cell viability in 2D or 3D cultures 
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when compared to solvent controls. Increasing concentration of erastin to 50 μM did 
not alter cell viability when compared to solvent controls (data not shown). In 
contrast, SH-SY5Y were highly sensitive to an inducer of apoptosis, staurosporine, 
resulting in 100% cell death (0% cell viability) at 2 µM (2D) and 1 µM (3D) (Fig. 5.10 
C).Reduction of reduced GSH and increase in oxidised GSH (GSSG) concentrations 
in cells is indicative of cellular oxidative stress and a cardinal feature of ferroptosis. 
To determine whether GSH levels were altered during iron (II) chloride treatment, 
cellular levels of both reduced and oxidised GSH was determined using the using the 
GSH/GSSG-GloTM Glutathione Assay kit (Promega) (Fig. 5.11).  Menadione was 
used as a positive control for inducing oxidative stress in cultures (Fig. 5.11 A). The 
concentration of reduced GSH increased slightly (not significant) following treatment 
with 10 μM menadione (positive control) but remained unchanged in both 200 and 
1000 μM iron (II) chloride groups when compared to solvent only control (Fig. 5.11 
B). In contrast, treatment with 200, 1000 μM iron (II) chloride and 10 μM menadione 
increased the levels of GSSG significantly when compared to solvent-only control, 
indicating cellular defence against oxidative stress induced by iron (II) chloride and 
menadione (Fig. 5.11 C). A reduced GSH:GSSG ratio is also used to demonstrate 
the cellular response to oxidative stress and was shown to be significantly decreased 
after 1000 μM iron (II) chloride and 10 μM menadione when compared to solvent 
only control and 200 μM iron (II) chloride (Fig. 5.11 D). 
Generation of cellular ROS following iron treatment was investigated using the 
CellROX® green oxidative stress reagent. CellROX® green is a DNA dye that upon 
oxidation is mainly localised in the nucleus and mitochondria. In the absence of 
ROS, CellROX® green is non-/very weakly fluorescent and is distributed throughout 
the cytoplasm. Cellular ROS is detected following 72 hr treatment with both 200 and 
1000 µM iron (II) chloride and 10 µM menadione (positive control) as evidenced by 
the association of CellROX® green with the cell nucleus (Fig. 5.12). In contrast, 
weak staining was observed throughout the cytoplasm of SH-SY5Y in both media 
and solvent controls (Fig. 5.12). At 72 hrs ("continual stress"), there was a complete 
absence of nuclear-associated CellROX® green staining in all groups (Fig. 5.13). 
ICP-MS measurement of iron concentration in cell cultures revealed a decrease in 




Figure 5.12. CellRox Green assay of iron (II) chloride treated 2D cultures at 72 hrs following treatment. Images 
presented are representative of three independent biological repeats. 2D SH-SY5Y cultures were incubated with 
media, NTA-only solvent control, 200 μM iron (II) chloride, 1000 μM iron (II) chloride, and positive control (10 μM 
menadione) for 72 hours. After incubation, 5 μM CellRox Green reagent was added to cells detect intracellular 
ROS. In media and solvent control, the ROS-specific signal was low and diffusely distributed throughout the 
cytoplasm. In 200 μM, 1000 μM iron (II) chloride , and positive control samples focal nuclear staining was 
observed consistent with ROS-mediated oxidation of the CellRox Green reagent and subsequent binding of the 






Figure 5.13. CellRox Green assay of iron (II) chloride treated 2D cultures at 72 hrs (“continual stress”) following 
treatment. Figure 5.12. Images presented are representative of three independent biological repeats. 2D SH-
SY5Y cultures were incubated with media, NTA-only solvent control, 200 μM iron (II) chloride, 1000 μM iron (II) 
chloride, and positive control (10 μM menadione) for 72 hours. After incubation, 5 μM CellRox Green reagent was 
added to cells detect intracellular ROS. In all groups, the ROS-specific signal was low and diffusely distributed 
throughout the cytoplasm. In 200 μM, 1000 μM iron (II) chloride , and positive control samples focal nuclear 
staining was observed consistent with ROS-mediated oxidation of the CellRox Green reagent and subsequent 
binding of the oxidised reagent to DNA. Scale bar represents 100 μm. 





Figure 5.14. ICP-MS analysis of iron levels in 2D SH-SY5Y following treatment with iron (II) chloride for either 24 
or 72 hrs. Data presented as individual data points and median (straight line) of three independent biological 
repeats. No statistical significance was determined between groups. 
5.3.5 Iron-induced oxidative stress shares features of ferroptosis in SH-SY5Y 
including ablation of GPX4 expression and presence of lipid peroxidation 
Although SH-SY5Y cells were not sensitive to treatment with ferroptosis inducers, 
ROS production and ferroptotic markers (lipid peroxidation, GSH levels and GPX4 
levels) were investigated in cultures following iron (II) chloride treatment. The 
resulting lipid peroxidation following iron (II) chloride treatment was investigated 
using the BODIPY™ 581/591 C11 lipid peroxidation dye. Lipid peroxidation was 
shown to affect cells in the 1000 µM iron (II) chloride treatment group following 12 hr 
treatment as shown by the reduction in non-oxidised lipid (red staining) and increase 
in oxidised lipids (green) (Fig. 5.15). It is clear to see that only a small percentage of 
cells are affected, with approximately 3/4 cells (~1% of cells) per field of view 
showing oxidised lipids (green) (Fig. 5.15). 
Investigation of lipid peroxidation at later time points of 24 and 72 hrs following 
treatment with 1000 µM iron (II) chloride demonstrated slightly more cells positive for 
lipid peroxidation (Fig. 5.16). Interestingly, cells positive for lipid peroxidation do not 
show the typical complete reduction in staining for non-oxidised (red) to oxidised 
(green) lipids, but rather show co-localisation of both (Fig. 5.15). Flow cytometry 
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Figure 5.15. Lipid peroxidation following 12-hr treatment with iron (II) chloride. Representative images of SH-
SY5Y treated with media only, solvent control, 200 µM iron (II) chloride or 1000 µM iron (II) chloride. Cells 
positive for lipid peroxidation are identified by reduction in red staining (loss of non-oxidised lipids) and increase 
in green staining (gain of oxidised lipids; white arrows). Scale bar represents 200 µm. Images shown are 











Figure 5.16. Lipid peroxidation of SH-SY5Y following treatment with 1000 µM iron (II) chloride at 12, 24, 72 and 
72 hrs ("continual stress"). Cells positive for lipid peroxidation are identified by reduction in red staining (loss of 
non-oxidised lipids) and increase in green staining (gain of oxidised lipids; white arrows). Scale bar represents 












Figure 5.17. Cell counts of lipid peroxidation in SH-SY5Y following treatment with media, NTA-only solvent 
control, 200 μM, and 1000 μM iron (II) chloride at 12, 24, 72 and 72 hrs ("continual stress"). (A) 12 hours. (B) 24 
hours. (C) 72 hours. (D) 72 hours (“continual stress”). Cells positive for lipid peroxidation are identified by 
reduction in red staining (loss of non-oxidised lipids) and increase in green staining (gain of oxidised lipids; white 
arrows). No statistical differences between groups in A-C. (D) Result of initial Kruskal-Wallis test  P= 0.0249. (A-
D) Data presented as all data points of independent biological repeats.  
lipid peroxidation within treatment groups (Fig. 5.18). At all time points measured, 
lipid peroxidation increased in both 200 and 1000 µM iron (II) chloride groups when 
compared to media and solvent only controls (Fig. 5.16, 5.17). Statistical significance 
was observed only in the 72 hr (“continual stress”) group in cell counts (Fig. 5.17 D), 





Figure 5.18. Flow cytometry analysis of lipid peroxidation in iron-treated 2D cultures. (A) 24 hrs. (B) 72 hrs. (C) 
72 hrs ("continual stress"). Data presented as individual data points and median (straight line). Statistical 
significance was determined using Kruskal-Wallis with post-hoc Conover-Inman. Result of initial statistical test 
(Kruskal-Wallis) for (B) P= 0.4264 (not statistically significant) (C) P= 0.0234 (D) P= 0.0906 (not statistically 
significant). 
GPX4, an antioxidant defence enzyme active in repairing oxidative damage in lipids, 
is a key inhibitor of ferroptosis. Ablation of GPX4 activity by either pharmacological 
methods (erastin or RSL3) or knock-out leads to lipid peroxidation and cellular death 
(Yang et al., 2014; L. Chen et al., 2015). GPX4 levels in 2D cultures following 
treatment with iron (II) chloride were determined using western blotting (Fig. 5.19). At 
all-time points assayed, GPX4 expression was drastically reduced in the 1000 μM 
iron (II) chloride group when compared to media and solvent-only controls. In this 
group, GPX4 expression was completely abolished at 24 hrs (Fig. 5.19 A) and only 
slightly increased at 72 hrs (0.13 ± 0.06; Fig. 5.19 B) and 72 hrs (“continual stress”) 




Figure 5.19. Fold change of GPX4 in 2D cultures following treatment with iron (II) chloride compared to media control as analysed by western blotting. Densitometry analysis of 
GPX4 levels (A-C) and western blots (D-F). Lanes 1-3 media, lanes 4-6 solvent control, lanes 7-9 200 μM iron (II) chloride, and 1000 μM iron (II) chloride. (A, D) 24 hrs. (B, E) 
72 hrs. (C, F) 72 hrs ("continual stress"). Data presented as individual data points and median (straight line) of three independent biological repeats. Statistical significance 




5.3.6 Treatment of iron-treated cells with the ferroptosis inhibitor liproxstatin-1 
is associated with reduction in phosphorylated α-syn 
Ferroptosis inhibitors, liproxstatin-1 and ferrostatin-1, have previously been shown to 
prevent lipid peroxidation as free radical-trapping antioxidants (Zilka et al., 2017). 
Treatment with 100 nM liproxstatin-1 in addition to iron (II) chloride in the 72 hr 
(“continual stress”) group revealed the reduction in p-α-syn levels (Fig. 5.20) in 
contrast to omission of liproxstatin-1 (Fig. 5.8). A significant decrease in p-α-syn was 
observed in both the 200 and 1000 μM iron (II) chloride groups (P= 0.0117) (Fig. 
5.20).  
 
Figure 5.20. Comparison of phosphorylated α-syn levels at 72 ("continual stress") following treatment with iron 
(II) chloride and iron (II) chloride + 100 nM liproxstatin-1 as analysed by western blotting. Data presented as 
individual data points and median (straight line) of three independent biological repeats. Accompanying western 
blots shown in Appendix Figures 3 and 5. 
5.3.7 SH-SY5Y express low/negligible levels of key proteins implicated in 
ferroptosis   
Expression of mitochondrial voltage-dependent anion channels (VDACs 1, 2, 3), 
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implicated in the susceptibility of cells to ferroptosis and factors in PD 
neurodegeneration (Yagoda et al., 2007; Dixon et al., 2012; Do Van et al., 2016). As 
SH-SY5Y was resistant to ferroptosis inducers, the expression of these proteins was 
determined using qPCR. The LUHMES has previously been shown to be sensitive to 
ferroptosis (Do Van et al., 2016) and was used to determine differences in 
expression of VDACs and SLCs compared to SH-SY5Y. Expression levels of all 
proteins were increased in the ferroptosis-sensitive LUHMES cell line in comparison 
to both 2D and 3D SH-SY5Y cultures (Fig. 5.21). Expression of VDAC 1 and VDAC 
3 was significantly increased in differentiated LUHMES (VDAC 1: 6.56 +/- 5.68; 
VDAC 3: 6.04 +/- 4.45) in contrast to 2D undifferentiated SH-SY5Y (VDAC 1: 0.17 +/- 
0.05; 
 
Figure 5.21. VDAC and SLC expression in 2D undifferentiated SH-SY5Y, 3D differentiated SH-SY5Y and 
differentiated LUHMES as determined by qPCR. Data presented as individual data points and median (straight 
line) of three independent biological repeats. qPCR data presented as relative gene expression normalised to β-
actin. (A) VDAC 1, 2 and 3 expression levels. (B) SLC3A2, SLC7A11 and SLC7A5 expression levels. Statistical 
significance determined by Kruskal-Wallis test with post-hoc Conover-Inman. Results of initial Kruskal-Wallis test 
(A) VDAC1 P= 0.039, VDAC2 P= 0.0509 (not statistically significant) and VDAC3 P= 0.0273. (B) SLC3A2 P= 
0.0509 (not statistically significant), SLC7A11 P= 0.039 and SLC7A5 P=0.3012 (not statistically significant). 
VDAC 3: 0.0008 +/- 0.001) and 3D undifferentiated SH-SY5Y (VDAC 1: 0.12 +/- 
0.09; VDAC 3: 0.16 +/- 0.13) (Fig. 5.21 A). Expression of VDAC 2 was 55-80 times 
higher in LUHMES compared to SH-SY5Y (Fig. 5.21 A). SLC expression was also 
increased in LUHMES, with significantly higher expression of SLC7A11 (6.99 +/- 
7.31) compared to 2D undifferentiated SH-SY5Y (0.00009 +/- 0.00008; Fig. 5.21 B).  
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5.3.8 LUHMES are sensitive to iron and erastin-induced cell death 
Given the increased expression of VDACs and SLCs in the LUHMES cell line, 
sensitivity of LUHMES to iron and erastin was investigated by resazurin reduction 
assay (Fig. 5.22). Differentiated LUHMES showed greater susceptibility to iron-
induced cell death at 24 hrs compared to SH-SY5Y cultures (Fig. 5.22 A). LUHMES 
were also sensitive to the ferroptosis inducer erastin (Fig. 5.22 B) in contrast to SH-




Figure 5.22. Resazurin cell viability assays of LUHMES following 24 hr treatment with iron (II) chloride and 
erastin. (A) Iron (II) chloride. (B) Erastin. Appropriate solvent controls were also incubated for 24 hrs. Data 
presented as mean and +/- SEM of at least three independent biological repeats. * P = ≤0.05, ** P= ≤0.01, *** P= 
≤0.001. *= 2D vs. 3D SH-SY5Y, #= 2D SH-SY5Y vs. LUHMES and •= 3D SH-SY5Y vs. LUHMES.  
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5.3.9 Addition of oligomeric species to SH-SY5Y did not induce lipid 
peroxidation 
Oligomeric species of α-syn were shown to form Lewy body-like aggregates in 3D 
SH-SY5Y cultures (Chapter 4; Taylor-Whiteley et al., 2019). Lipid peroxidation has 
previously been linked to the addition of α-syn species, therefore oligomeric species 
of α-syn were investigated in relation to the ability to induce features of ferroptosis 
(Angelova et al., 2015). By staining unoxidised (red)/oxidised (green) lipids using the 
lipid peroxidation sensor BODIPY C11 581/591, no increase in oxidised lipids was 
observed following treatment with oligomeric species (Fig. 5.23 A). Quantification of 
lipid peroxidation signals using flow cytometry again revealed no increase in oxidised 
lipid signal (Fig. 5.23 B, C). In contrast to iron (II) chloride treatment (Fig. 5.19), 
addition of oligomeric α-syn species did not reduce levels of the ferroptosis-




Figure 5.23. Lipid peroxidation in 2D cultures following treatment with seeding oligomers. (A) Representative 
images of SH-SY5Y treated with media only, solvent control, 10% v/v monomer and 10% v/v oligomer after 24 hr 
treatment. Cells positive for lipid peroxidation are identified by reduction in red staining (loss of non-oxidised 
lipids) and increase in green staining (gain of oxidised lipids; white arrows). Scale bar represents 200 µm. Images 
shown are representative of three biological repeats. (B, C) Flow cytometry analysis of lipid peroxidation reveals 
no change in lipid peroxidation following treatment of seeding oligomers at either 24 hrs (B) or 72 hrs (C). Data 
presented as individual data points of one independent biological repeat. 















































































































































































































































Figure 5.24. Fold change of GPX4 in 2D cultures following treatment with seeding oligomers compared to media 
control as analysed by western blotting. (A) GPX4 blot. (B) Loading control. (A, B) All biological repeats were run 
on the same blot. Lanes 1-3 represent media sample, lanes 4-6 represent 10% v/v solvent, lanes 7-9 represent 
10% v/v monomer and lanes 10-12 represent 10% v/v oligomer treatments (C) Fold change of GPX4 levels. Data 
presented as individual data points and median (straight line) of three independent biological repeats. Results of 
























Ferroptosis, a newly discovered cell death pathway, involving the iron-dependent 
generation of ROS, depletion of GPX4, lipid peroxidation and subsequent cell death 
has recently been implicated in the pathogenesis of PD (Dixon et al., 2012; Do Van 
et al., 2016). Post-mortem features of PD have long since implicated cellular ROS, 
altered GSH levels and lipid peroxidation in the pathogenesis of the condition 
(Dexter et al., 1987, 1989; Jenner et al., 1992; Sian et al., 1994). The discovery of 
the ferroptosis pathway links both the potential susceptibility of the dopaminergic 
cells of the SNPc, iron accumulation with age and a mechanism of cell death with the 
potential for pharmacological manipulation. However, in familial and sporadic PD, the 
presence of a highly aggregated insoluble form of α-syn as the major protein 
component in Lewy bodies has implicated the protein in the pathogenesis of the 
disorder (Spillantini et al., 1997; Anderson et al., 2006). The newly discovered link of 
PD to ferroptosis and the relevance of α-syn to the disease have raised the 
possibility that α-syn is involved in this pathway and could potentially interact to 
exacerbate toxicity. To date, there are no studies that have explored whether α-syn 
is involved in ferroptotic cell death. Utilising the 3D SH-SY5Y model presented in 
chapters 3 and 4 of this thesis, the aggregation of α-syn in iron overload and the link 
to ferroptosis was investigated. 
Iron has previously been demonstrated to induce the aggregation of α-syn both in 
vivo and in vitro (Uversky, Li and Fink, 2001; Duan et al., 2008). The discovery of an 
iron-responsive element (IRE) in the 5' untranslated region suggests a role in iron 
regulation (Friedlich, Tanzi and Rogers, 2007). In agreement with previous studies, 
iron treatment was associated with the reduction of cell viability in a dose-dependent 
manner (Fig. 5.5) and α-syn aggregation (Fig. 5.6) (W. J. Li et al., 2010; He et al., 
2011; Wan et al., 2017). To the best of our knowledge, this is the first study to 
investigate iron-induced α-syn aggregation in a 3D model (Fig. 5.9). Unlike the large 
LB-like structures observed after oligomer treatment in 3D (Chapter 4 Fig. 4.8, 4.9 
and 4.10; Taylor-Whiteley et al., 2019), increased diffuse α-syn staining was 
observed. Therefore, iron treatment alone is not able to induce LB formation.  
α-Syn undergoes many PTMs (e.g. phosphorylation, ubiquitination, acetylation etc.), 
the PTM commonly associated with PD and associated synucleinopathies is 
phosphorylation at serine 129 within the c-terminal region of the protein (Fujiwara et 
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al., 2002; Anderson et al., 2006; Fauvet et al., 2012; Muntané, Ferrer and Martinez-
Vicente, 2012). Phosphorylation of α-syn at serine 129 is thought to play a central 
role in the pathogenesis of PD due to the observation that ~90% of α-syn in 
aggregates is phosphorylated at S129 in contrast to ~4% of total α-syn that is 
phosphorylated at this position in normal brain (Fujiwara et al., 2002; Muntané, 
Ferrer and Martinez-Vicente, 2012). Levels of p-α-syn in blood plasma and skin 
biopsies are significantly higher in patients with PD when compared to healthy age-
matched controls (Allsop et al., 2013; Doppler et al., 2014). Taken together, these 
observations implicate p-α-syn as an important PTM related to PD and 
synucleinopathies. Using western blotting, α-syn levels were increased following 
treatment with iron (II) chloride (Fig. 5.8). Levels of α-syn and p-α-syn at S129 were 
only increased in the 72 hr ("continual stress") group following treatment with 200 
and 1000 µM iron (II) chloride (Fig. 5.8 C, F), consistent with previous results (Wang 
et al., 2019). Interestingly, the addition of the ferroptosis inhibitor liproxstatin-1 to 
iron-treated cultures was associated with reduced levels of p-α-syn in the 72 hrs 
(“continual stress”) group (Fig. 5.19). Removal of cellular ROS using an oxidative 
stress scavenger, N-acetylcysteine (NAC), was shown to result in the reduction of p-
α-syn by downregulation of kinases (polo-like kinase 2/casein kinase 2) responsible 
for specific phosphorylation of α-syn at S129 (R. Wang et al., 2019). Liproxstatin-1 is 
an antioxidant preventing the propagation of toxic lipid peroxides in the cell (Zilka et 
al., 2017). The results presented here suggest that the increase of p- α-syn following 
iron overload could be associated with oxidative stress, consistent with the reduction 
of p-α-syn following liproxstatin-1 treatment. 
Although Fe2+ is the predominant form within the cell, Fe3+ has the greater affinity for 
α-syn; however, phosphorylation of α-syn (ser129 and tyrosine 125) has been 
associated with increased binding affinity for Fe2+ (Binolfi et al., 2006b; Lu et al., 
2011). The significantly shorter half-life of p-α-syn (t1/2 = 54.9 ± 6.4 min) compared to 
non-phosphorylated (t1/2 > 240 min) and specific degradation of p-α-syn (S129) by 
the proteasome or autophagic pathway indicates a cellular role of p-α-syn in 
clearance (Cuervo et al., 2004; Machiya et al., 2010). Taken together, the iron-
binding capacity of p-α-syn and the shorter half-life of p-α-syn indicate a potential 
role in an iron-induced oxidative stress response, potentially mediating clearance of 
toxic species (M. Takahashi et al., 2007; R. Wang et al., 2019). The work presented 
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here demonstrates under iron-induced oxidative stress, p-α-syn levels increase (if 
only in the 72 hr “continual stress” group). Interestingly, the increase in p-α-syn 
levels (Fig. 5.8) is in conjunction with much lower intracellular iron levels when 
compared to the 72 hr treatment group (Fig. 5.18). Where intracellular iron 
concentration was higher at 72 hrs (Fig. 5.18), this co-ordinated with much lower 
levels of p-α-syn, suggesting p-α-syn may have a role in the efflux of iron from the 
cell, protecting the cell from iron-mediated cellular ROS. This is supported by the 
observation that intracellular ROS was detected at 72 hrs (Fig. 5.14) as determined 
by the nuclear-associated CellROX™ green signal, in contrast to 72 hrs (“continual 
stress”) group whereby CellROX™ signals were unchanged between controls and 
treatments (Fig. 5.15). An experiment to measure amounts of α-syn, especially p-α-
syn, in cell culture media would indicate whether p-α-syn is indeed effluxed from the 
cell under these conditions.  
In the SNPc, the oxidative environment would require efficient protein degradation 
pathways to prevent the accumulation of oxidation-damaged proteins, however in 
aging both the proteasome and autophagic pathway undergo decline, resulting in 
reduced efficiency and function with advancing age (Rubinsztein, Mariño and 
Kroemer, 2011; Jana, 2012). This is supported by the observation of a reduction in 
proteasome activity observed in post-mortem SNPc of PD patients compared to age-
matched controls (McNaught et al., 2003). Importantly, familial mutations that affect 
the protein Parkin, a protein involved in targeting proteins to the proteasome, leads 
to an early-onset form of the disease (Arkinson and Walden, 2018). Mutant forms of 
α-syn have an inhibitory effect on the 20S proteasome, leading to reduced 
degradation of soluble species and increased formation of aggregates (Tanaka et al., 
2001; Emmanouilidou et al., 2010). Aggregated forms of α-syn need to be unfolded 
before clearance, therefore aggregated forms of α-syn require clearance through 
other pathways, such as autophagy (Alvarez-Erviti et al., 2011). The increase in iron 
concentration in the SNPc as a consequence of aging is well known and 
interestingly, iron deposition has also been shown to lead to autophagic function 
(Wan et al., 2017). 
Taken together, the increased levels of both α-syn and p-α-syn due to oxidative 
stress could, in an aging brain where proteasomal and autophagic pathways are 
inhibited, result in the accumulation of α-syn species that in turn aggregate into LB 
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structures. Within this study, no proteasomal/autophagic inhibition treatment was 
added to the cells and this may be the reason for the lack of α-syn aggregates 
forming (Fig. 5.9), especially when we consider the short amount time the 
experiments were conducted over (72 hrs). In a highly ROS-rich environment such 
as the SNPc, the impaired ability to clear toxic species from neurons will, in turn, 
exacerbate the formation of ROS, resulting in cellular defects. In contrast to the 
oligomer-induced aggregate formation that was observed in as little as 24 hrs 
(Chapter 4), the lack of iron-induced aggregates in 3D suggests different 
mechanisms of aggregate formation. 
SH-SY5Y were highly sensitive to apoptosis induced by staurosporine (Fig. 5.8C) 
(Belmokhtar, Hillion and Ségal-Bendirdjian, 2001; Robert et al., 2012). The RAS-
selective lethal (RSL) compounds, erastin and RSL3, initiate cell death by activating 
ferroptosis through inhibition of either system xc- (erastin) or GPX4 (RSL3) leading to 
depletion of GSH (Dixon et al., 2012). In this study, the ferroptosis-inducers erastin 
and RSL3 had little effect on cell viability in these cultures (Fig. 5.8). This is in 
contrast to previous studies whereby erastin induced cell death in SH-SY5Y at >5 
µM (Geng et al., 2018; Zille et al., 2019). The knockdown of the iron export protein, 
ferroportin, was shown to exacerbate erastin-induced cell death through the 
disruption of iron efflux from the cell and subsequent increase in lipid ROS (Geng et 
al., 2018). However, even when erastin concentration was increased to 50 µM 
erastin (data not shown) there was no change in cell viabilities between treated and 
solvent control in WT SH-SY5Y used in this study. The targets for erastin (VDACs 1, 
2, 3 and SLC7A5) were shown to be expressed at negligible levels in SH-SY5Y 
cultures when compared to expression in a ferroptosis-sensitive cell line (LUHMES). 
Resistance to erastin treatment is due to the absence of erastin targets in our SH-
SY5Y model (Fig. 5.19) (Yagoda et al., 2007; Dixon et al., 2012). The differences in 
expression of VDAC isoforms may be one of the reasons SNPc neurons undergo 
degeneration in PD (Sun et al., 2012; Triplett et al., 2015; Do Van et al., 2016). 
SLC7A11 repression leads to sensitivity to ferroptosis through the reduction in 
cystine uptake, however, SH-SY5Y again expressed negligible levels of SLC7A11 
but did not show sensitivity to ferroptosis, suggesting ferroptosis is not an effective 
pathway to induce cell death in this cell line (Jiang et al., 2015). In contrast, the 
LUHMES cell line expresses all VDAC isoforms in addition to SLC3A2, SLC7A11 
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and SLC7A5, the cell line is more susceptible to iron-induced cell death and is 
sensitive to ferroptosis in concordance with previous studies (Fig. 5.20) (Do Van et 
al., 2016). 
Although SH-SY5Y did not show sensitivity to ferroptosis inducers, features of 
ferroptosis include iron-dependent ROS generation, depletion of GSH, inactivation of 
GPX4 and lipid peroxidation were investigated following treatment with iron (II) 
chloride in SH-SY5Y cultures. Measurement of lipid peroxidation demonstrated the 
increase in oxidised (green) lipids following treatment with 1000 μM iron (II) chloride 
at all time points measured (Fig. 5.9, 5.10 and 5.11). Flow cytometry analysis of lipid 
peroxidation reveals increased lipid peroxidation at 72 hrs (Fig. 5.11) where total α-
syn and p-α-syn levels were lower (Fig. 5.6) when compared to 72 hr (“continual 
stress”) (Fig. 5.6 and 5.11). In the latter, elevated levels of α-syn and p-α-syn were 
associated with reduced levels of lipid peroxidation, suggesting a protective role of α-
syn by prevention of lipid peroxidation in the context of iron-dependent cellular ROS.  
GSH assay revealed the increase in GSSG, but there was no reduction in GSH 
levels (Fig. 5.12). GPX4, a major regulator of ferroptosis is essential for maintaining 
the redox capacity of the cell (Yang et al., 2014). GPX4 levels as determined by 
western blotting were shown to be decreased in both iron (II) chloride treatment 
groups. In the 1000 μM iron (II) chloride group there was a complete absence in 
GPX4 expression at 24 hrs, with only marginal increases at 72 hrs and 72 hrs 
(“continual stress”) (Fig. 5.13). Levels of intracellular ROS as measured by the 
CellROX™ green fluorescent dye revealed ROS in 200 and 1000 μM iron (II) 
chloride groups in addition to the positive control (10 μM menadione). Cell death by 
iron-induced ROS in SH-SY5Y shared some features of ferroptosis, but the low 
expression of key proteins thought to play a role in ferroptosis (such as VDAC 
isoforms) and lack of sensitivity to ferroptosis inducers erastin and RSL3 suggest cell 







Chapter 6 : General Discussion  
6.1 General Discussion 
PD is the fastest growing neurological disorder in the world, with the incidence of 
disease predicted to double worldwide by 2040 (Dorsey and Bloem, 2018; Marras et 
al., 2018; Parkinson’s UK, 2018). Currently, there are no disease-modifying 
therapies available to alter disease progression; instead available therapies treat 
clinical symptoms rather than the cause of disease. The lack of such disease-
modifying therapies is due in part to the incomplete knowledge of the molecular 
mechanisms involved in disease onset and progression. α-Syn has been linked to 
PD through both genetic and pathological evidence. Oligomeric species of α-syn 
have been implicated as the toxic species involved in both the spread of pathology 
and in mechanisms of cellular dysfunction, leading to cell death (Bengoa-Vergniory 
et al., 2017). 
The overall aim of this thesis was to develop a 3D cell culture model of PD utilising 
the human neuroblastoma SH-SY5Y cell line to investigate the propagation and 
intracellular aggregation induced by α-syn oligomers. In addition, the aggregation 
propensity of α-syn in relation to the cell death pathway, ferroptosis, was 
investigated. Chapter 3 presents data on the development of the 3D cell culture 
model. Specifically, the phenotype of SH-SY5Y cultured in 3D was characterised. 
Chapter 4 investigated the intracellular aggregation of α-syn within the 3D model. 
This section focussed on characterising the morphology of inclusions within 2D and 
3D cultures. Data presented highlighted the morphology of inclusions in 3D cultures 
akin to in vivo LBs. Chapter 5 set out to investigate the impact of ferroptosis on the 
aggregation and propagation of α-syn in the 3D model. A summary of key findings 
from this body of work is provided below.  
6.1.1 Human neuroblastoma cells cultured 3D express a dopaminergic, post-
mitotic phenotype and develop intracellular inclusions reminiscent of LB-like 
inclusions  
In this study, the development of a 3D cell culture model of PD was described and 
demonstrated the development of LB-like intracellular inclusions upon the addition of 
oligomeric α-syn to culture media. The mechanism of LB formation remains poorly 
understood, mainly due to the lack of whole-animal or cell-based models that 
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recapitulate the development of these inclusions. Much of the literature investigating 
α-syn aggregation has been performed in 2D in a variety of cell lines, including 
animal-derived cell lines. Normally, in vivo, cells in the physiological environment 
have constant interaction with other cells and ECM, which is important to regulate a 
variety of cellular characteristics. These characteristics, including cell shape and cell 
differentiation, are inhibited in 2D environments due to the lack of cell-to-cell and 
cell-to-ECM communication (Baker and Chen, 2012; Caddeo, Boffito and Sartori, 
2017). Three-dimensional cell cultures address these challenges and allow for 
interaction of cells to the ECM and each other to further mimic the in vivo 
environment. Increasingly, 3D cell culture methods are being developed to provide a 
more biologically-relevant culture system (Eglen and Klein, 2017). In Chapter 3, the 
development of a 3D cell culture model of PD was described. Utilising a human-
relevant SH-SY5Y neuroblastoma cell line, cells were differentiated initially in 2D to 
confirm an appropriate differentiation protocol for use within the 3D Matrigel™-based 
environment. Differentiation of SH-SY5Y with RA and sequential treatment of BDNF 
yielded a homogenous population of dopaminergic (expression of DAT, DRD2, 
VMAT2), post-mitotic (lack of expression of Ki67) neuron-like (expression of TUBB3 
and MAP2) cells. Upon encapsulation in the 3D matrix, cells retained a 
dopaminergic, post-mitotic neuron-like phenotype. The cell culture method described 
in this thesis is robust and easy to handle in standard laboratory settings.  
Characterising the effect of prefibrillar oligomers is important to understanding the 
aberrant aggregation of α-syn and its role in the propagation of misfolded α-syn 
species (Killinger and Kordower, 2019). Seeding oligomers of α-syn are known to 
induce intracellular aggregation of endogenously expressed protein in a seeded-
nucleation mechanism, and this mechanism is likened to a prion-like propagation of 
misfolded protein  (Danzer et al., 2007; Volpicelli-Daley et al., 2011; Shrivastava et 
al., 2020). Using the 3D model developed in Chapter 3, the intracellular aggregation 
of α-syn was investigated upon addition of oligomeric species to differentiated 
neuron-like cultures. Data presented in Chapter 4 demonstrated that addition of 
exogenous α-syn species to undifferentiated and RA-differentiated 2D cultures 
developed inclusion morphology previously seen in cell models, whereby inclusions 
were punctate and numerous throughout the cytoplasm (Danzer et al., 2007; Illes-
Toth et al., 2015). This is in contrast to the large, singular LB observed in in vivo 
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pathology. However, the addition of preformed oligomers to RA + BDNF-
differentiated cultures in 2D highlighted the development of singular, large α-syn-
positive cellular inclusions, reminiscent of in vivo pathology. One caveat of this 
culture method (in 2D) was that cells easily detached from the culture vessel. 
Importantly, the differentiation of cells in the 3D environment prevented the 
detachment of cells from culture vessels. The morphology of inclusions formed 
following treatment with exogenous α-syn oligomers to 3D cultures highlighted the 
development of LB-like aggregates (Taylor-Whiteley et al., 2019). These inclusions 
were highly reminiscent of in vivo LBs with similar morphologies and positive for 
markers α-syn and ubiquitin. Unfortunately, p-α-syn species were not detected in 
these inclusions. This could be because p-α-syn species were not detectable given 
the antibody used in this study or that aggregates formed without the need for 
phosphorylation (Volpicelli-Daley et al., 2011). Another explanation could be that p-α-
syn aggregates were undetectable given the short time frame of the experiment (24 
hrs) and that phosphorylation could be a late-stage modification of α-syn aggregates 
(Walker et al., 2013). Importantly, these inclusions formed without the need for 
genetic manipulation of the cell line. Given that α-syn structure and function is highly 
dependent on the complex equilibrium between monomer and multimeric structures 
in vivo, overexpression of α-syn alters this equilibrium and promotes aggregation 
through molecular crowding (Bartels, Choi and Selkoe, 2011; Davies, Moualla and 
Brown, 2011; Burré, Sharma and Südhof, 2014; Sian and Peter, 2020). Therefore, 
this model highlights the development of LB-like pathology without the need for 
overexpression of α-syn or other genetic manipulation. 
Domert et al. (2016) described a similar 3D cell culture method for utilising SH-SY5Y 
cultured in an ECM-based matrix and investigated the uptake of α-syn monomers, 
oligomers, and fibrils in this culture system. In agreement with findings in this study, 
α-syn species were taken up by cells and developed intracellular aggregates over 24 
hours with minimal (or completely absent) cellular toxicity as investigated by the XTT 
assay. In contrast, the aforementioned study investigated the transfer of these 
species between donor and acceptor cells and did not exclusively demonstrate the 
formation of large LB-like cellular aggregates, as shown here (Domert et al., 2016). 
Interestingly, the oligomers were produced by incubation of the reactive aldehyde of 
4-HNE with α-syn (Domert et al., 2016). 4-HNE is a reactive aldehyde produced 
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when oxygen radicals produced during oxidative stress oxidise polyunsaturated fatty 
acids in cellular membranes (Xiang et al., 2013; Barrera et al., 2018). Because 
oxidative stress is integral to the pathogenesis of PD, this method for producing 
oligomers may provide a more relevant biological structure, in contrast to formation 
of oligomers by other methods (e.g. incubation with high concentrations of 
monomeric α-syn).  Previously, work in other groups required the use of agents such 
as lipofectamine to introduce α-syn species to the intracellular environment, 
however, there are studies (including this) that do not require the use of these agents 
(P. Desplats et al., 2009; Nonaka et al., 2010). This may be due to differences in 
oligomer preparations between studies. For example, seeding oligomers (type B and 
C) are readily taken up by cells and induce intracellular aggregation, whereas other 
oligomer preparations promote membrane interaction, calcium influx and cell death 
(Danzer et al., 2007; Grozdanov and Danzer, 2018). This model is adaptable for use 
in many laboratories and is amenable for use in diverse areas of PD research, 
including in development for high-throughput screening.  
6.1.2 Aggregation of α-syn is not associated with a ferroptotic pathway in SH-
SY5Y 
Recently, ferroptosis, a cell death pathway intrinsically linked to iron metabolism,  
ROS production, and lipid peroxidation has been linked to neurodegeneration in PD 
(Do Van et al., 2016; Guiney et al., 2017). Several key features of ferroptosis can be 
linked to the molecular mechanisms of PD, with literature reports frequently 
describing depletion of the intracellular antioxidant glutathione, accumulation of lipid 
peroxidation products, decreased levels of GPX4, and neuroprotection from iron 
chelators or lipophilic antioxidants (Cardoso et al., 2017; Galluzzi et al., 2018). The 
dysregulation of iron can be observed by the use of MRI imaging of patients and 
analysis of post-mortem tissue, showing an increase in iron levels in the brain that 
are associated with aging and in neurodegenerative disease (Dexter et al., 1987; 
Kwan et al., 2012; Acosta-cabronero et al., 2016). Additionally, α-syn has been 
pathologically linked to iron import and dysregulated iron homeostasis (Davies, 
Moualla and Brown, 2011; McDowall et al., 2017). Targeting iron has shown some 
success in early phase clinical trials of iron chelators (e.g. deferiprone). Early 
indications are a slowing of the progression of motor deficits and reducing motor 
symptoms in early PD patients and represent the first successful disease-modifying 
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therapy for PD, but requires replication in a larger phase III trials (Devos et al., 
2014). However, at the time of writing, no study has investigated the role of α-syn 
concerning ferroptotic cell death (Guiney et al., 2017). 
Data presented in Chapter 5 investigated the influence of ferroptosis on the 
intracellular aggregation of α-syn in both 2D and 3D SH-SY5Y cell culture models. 
Importantly, in these models, intracellular α-syn aggregation was shown to form LB-
like aggregates (Chapter 4). In this study, evidence was provided that aggregation of 
α-syn is not associated with ferroptotic cell death in the SH-SY5Y cell line. Many 
studies have used iron (II) chloride to increase the intracellular load of iron in a time- 
and dose-dependent manner to determine cellular effects of iron (ranging from 5 μM 
to 1000 μM) (Guan et al., 2017; Wan et al., 2017; Dige and Okoi, 2019). In 
agreement with these studies, iron (II) chloride (200μM and 1000 μM) increased 
cellular total iron content in SH-SY5Y and was therefore used to investigate the 
influence of iron, aggregation of α-syn, and induction of ferroptosis. Results 
presented here demonstrate increased expression of α-syn following treatment with 
iron (II) chloride as analysed by ICP-MS analysis, western blotting, and 
immunocytochemistry. Treatment with ferroptotic inducers did not result in cellular 
death of SH-SY5Y either in 2D or 3D cultures. However, treatment with an apoptosis 
inducer, staurosporine, resulted in extensive cell death, highlighting the sensitivity of 
the cell line to this mechanism of cell death (Dächert et al., 2016; Sato et al., 2018). 
Resistance to ferroptosis inducers by SH-SY5Y was attributed to low expression of 
key proteins associated with ferroptotic cell death including the proteins VDAC1, 
VDAC2, VDAC3, SLC3A5, SLC7A5 and SLC7A11 (Do Van et al., 2016). Taken 
together, this data suggests that SH-SY5Y are not sensitive to ferroptosis, and 
therefore, not an appropriate cellular model for the study of ferroptosis. In contrast, 
this body of work highlights the preferred use of LUHMES cells when investigating 
ferroptosis, due to higher expression of the aforementioned proteins and sensitivity 
to ferroptosis inducers (Do Van et al., 2016).  
Although the SH-SY5Y cell line was not sensitive to cell death induced by the 
ferroptosis inducers erastin or RSL3, iron (II) chloride treatment was associated with 
several features of the ferroptotic pathway. These features include ablation of GPX4 
expression, decreased GSH: GSSG ratio, increased ROS, and increase in lipid 
peroxidation (Imai et al., 2017; Galluzzi et al., 2018; Zille et al., 2019). Importantly, 
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cell death mechanisms do not always operate in singular, discreet pathways, 
instead, several pathways may converge to induce cell death. Apoptosis can occur in 
conjunction with necroptosis and/or autophagy and autophagy can occur in 
association with necroptosis (Chen, Kang and Fu, 2018). For example, once 
activated, the apoptotic initiator caspase, caspase-8, can trigger downstream 
apoptosis signalling but can also inhibit necroptosis through the inactivation of RIPK1 
and RIPK3 (Wang et al., 2009; Linkermann et al., 2014). Specifically, induction of 
cellular ROS can trigger ROS-dependent apoptosis and also ROS-dependent 
autophagy (Redza-dutordoir and Averill-bates, 2016; Cordani et al., 2019). This is 
important given that ferroptosis is another form of cell death associated with ROS 
accumulation in cellular models, and has similar molecular mechanisms of another 
mechanism of cell death, oxytosis (Ito et al., 2017; Lewerenz et al., 2018). 
Delineating key differences between these pathways may help to identify treatments 
for several diseases, including in PD (Magtanong and Dixon, 2020).  
Under normal conditions, <4% of the total α-syn is phosphorylated at p129, but there 
is a dramatic accumulation of p-α-syn in brains of patients with PD (Chen and Feany, 
2005; Muntané, Ferrer and Martinez-Vicente, 2012). Therefore, p-α-syn has been 
implicated as a key player in the pathogenesis of PD. Additionally, although p-α-syn 
is not required for aggregate formation, it is associated with efflux of α-syn from the 
cell due to presence of p-α-syn in CSF and blood plasma (Foulds et al., 2011; 
Killinger and Kordower, 2019). In this study, increased levels of p-α-syn were 
increased as a result of 'continual stress' treatment with iron (II) chloride and this was 
ablated by the addition of the ferroptosis inhibitor lip-1. Lip-1 is a potent ferroptosis 
inhibitor able to prevent lipid peroxidation via a ROS scavenging function (Zilka et al., 
2017). It could be hypothesised that Lip-1 reduced expression of α-syn through the 
modification of α-syn oligomerisation. 4-HNE, a product of lipid peroxidation, is 
capable of inducing oligomerisation of α-syn through the covalent modification of 
histidine and lysine residues to produce a structure capable of inducing seeding in 
an SH-SY5Y cell model (Formation and Park, 2013). Therefore, it could be that Lip-1 
reduced the formation of lipid peroxidation products (e.g. 4-HNE), consequently 
reducing the formation of oligomeric species of α-syn of which are phosphorylated 
(Canerina-amaro et al., 2019). Recent data suggests Lip-1 can also induce 
upregulation of GPX4 which would reduce ROS accumulation, subsequent lipid 
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peroxidation, and formation of lipid peroxidation-modified α-syn aggregates (Wu et 
al., 2019). In the study by Singh et al. (2012), curcumin, a ROS scavenging 
molecule, was shown to bind to oligomeric species and reduce their toxicity through 
modification of their morphology and hydrophobic surface exposure. Therefore, if 
iron-induced ROS induced the formation of oligomeric α-syn which is subsequently 
phosphorylated, a mechanism in which Lip-1 binds to α-syn to prevent 
oligomerisation would reduce accumulation of pre-fibrillar oligomers capable of either 
toxic cellular effects or cell-to-cell spreading (Singh et al., 2013). At present, there is 
no data available to determine whether Lip-1 binds to α-syn to interfere with protein 
aggregation. Therefore, Lip-1 highlights an attractive pharmaceutical compound in 
the treatment of PD, potentially to reduce lipid peroxidation (and induction of lipid 
peroxidation-associated cell death, e.g. ferroptosis in ferroptosis-sensitive cells), and 
reduction in the spread of pathology (by reducing the formation of ROS-induced 
oligomeric species). 
Another important consideration must be given to the normal cellular function of α-
syn as a cellular ferrireductase (Davies, Moualla and Brown, 2011; McDowall et al., 
2017). Structurally, as a ferrireductase, α-syn is a tetrameric structure that reduces 
Fe3+ to Fe2+, to provide an important source of bioavailable iron required for cellular 
functions (e.g. as a cofactor for TH, mitochondrial functions) (Wei Wang et al., 2011; 
Mcdowall et al., 2017). Wang et al. (2011) demonstrated the α-syn tetrameric 
structure to be dependent on subunit concentration and environmental factors, with 
an equilibrium existing between unfolded monomer, compact oligomer, and amyloid-
forming species. Therefore, overexpression of α-syn (or modification of the protein 
by point-mutations, posttranslational modifications, the formation of ROS-induced 
adducts) can result in a shift in the equilibrium from tetramer to oligomeric species. 
This shift in equilibrium would drastically reduce the function of α-syn as a 
ferrireductase, and it has been shown that the ferrireductase function of α-syn is 
altered in PD (McDowall et al., 2017). The effect on the cell would be catastrophic. A 
loss of Fe2+-dependent activities through the aggregation of α-syn and loss of 
ferrireductase activity would result in bioenergetic deficiencies and cell death. 
Increased activity of α-syn as a tetramer would induce excess Fe2+, increased 
oxidative stress via Fenton’s reaction, and result in cell death (Davies, Moualla and 
Brown, 2011). Therefore, the cell must efficiently maintain cellular levels of α-syn to 
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maintain functionality and cellular survival. In a situation whereby a cell has defective 
protein clearance mechanisms (e.g. decline in lysosomal-autophagy/proteasomal 
mechanisms), reduced chaperone activities (e.g. HSC70/HSP90), and increased 
oxidative environment as seen in aging cells, all create an environment preferential 
to the aggregation of α-syn (Burmann et al., 2020). 
6.3 Concluding Remarks  
Together, data presented in this thesis have contributed novel findings and furthered 
knowledge in the field of α-syn research. Results have described a novel 3D human-
relevant neuronal cell culture model and demonstrated that upon the addition of 
seeding oligomers develop LB-like α-syn inclusions reminiscent of in vivo pathology. 
Importantly, this model system does not require the overexpression of α-syn as in 
previous culture models. Additionally, the relationship between ferroptosis and α-syn 
aggregation was explored. The novel data presented in this thesis highlight the 
resistance of the SH-SY5Y cell line to ferroptosis yet demonstrate the potential 
implications of iron exposure, α-syn aggregation, and ferroptosis in the pathogenesis 
of PD. Furthermore, the work presented in this PhD project has raised new avenues 
for future study, which have the potential to extend knowledge of the role α-syn in PD 














Chapter 7 : Appendix 
 
 
Appendix Figure 1. Exogenous addition of α-syn oligomers induces the intracellular aggregation of α-syn in 2D 
RA-differentiated SH-SY5Y cultures. Double immunostaining with α-syn (Texas Red, red) and nuclei (DAPI, blue) 
reveals the presence of multiple, small inclusions throughout the cytoplasm in 10% v/v oligomer-treated cultures 
when compared to diffuse staining in 10% v/v solvent control (sodium phosphate buffer + 20% ethanol) and 10% 




Appendix Figure 2. Exogenous addition of α-syn oligomers induces the intracellular aggregation of α-syn in 2D 
RA + BDNF-differentiated SH-SY5Y cultures. Double immunostaining with α-syn (Texas Red, red) and nuclei 
(DAPI, blue) reveals the presence of singular, large inclusions in 10% v/v oligomer-treated cultures when 
compared to diffuse staining in 10% v/v solvent control (sodium phosphate buffer + 20% ethanol) and 10% v/v 
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Recapitulating Parkinson’s disease pathology in a
three-dimensional human neural cell culture model
Teresa R. Taylor-Whiteley1, Christine L. Le Maitre1, James A. Duce2,3, Caroline F. Dalton1
and David P. Smith1,*
ABSTRACT
Extensive loss of dopaminergic neurons and aggregation of the
protein α-synuclein into ubiquitin-positive Lewy bodies represents a
major neuropathological hallmark of Parkinson’s disease (PD). At
present, the generation of large nuclear-associated Lewy bodies from
endogenous wild-type α-synuclein, translationally regulated under its
own promoter in human cell culture models, requires costly and time-
consuming protocols. Here, we demonstrate that fully differentiated
human SH-SY5Y neuroblastoma cells grown in three-dimensional
cell culture develop Lewy-body-like pathology upon exposure to
exogenous α-synuclein species. In contrast to most cell- and rodent-
based PD models, which exhibit multiple diffuse α-synuclein
aggregates throughout the cytoplasm, a single large nuclear
inclusion that is immunopositive for α-synuclein and ubiquitin is
rapidly obtained in our model. This was achieved without the need for
overexpression of α-synuclein or genetic modification of the cell line.
However, phosphorylation of α-synuclein within these inclusions was
not observed. The system described here provides an ideal tool to
screen compounds to therapeutically intervene in Lewy body
formation, and to investigate the mechanisms involved in disease
progression in synucleinopathies.
KEY WORDS: 3D cell culture, Amyloid, Lewy body, Oligomer,
Parkinson’s, Synuclein
INTRODUCTION
The presence of large cell-associated protein aggregates is the key
pathological hallmark commonly associated with many
neurodegenerative disorders (Poewe et al., 2017). In Parkinson’s
disease (PD) and other synucleinopathies, the intrinsically
disordered protein α-synuclein (α-syn) undergoes misfolding into
amyloid fibrils (Poewe et al., 2017). These fibrils form the major
protein component of intracellular deposits associated with Lewy
bodies (LBs) in the cell soma, and Lewy neurites (LNs) in axons of
surviving neurons (Theillet et al., 2016; Spillantini et al., 1997;
Langston et al., 2015). The association of α-syn with pre-synaptic
terminals from in vitro and in vivo models suggests a normal
physiological role in the regulation of neurotransmitter release and
synaptic function, but its role in disease remains poorly understood
(Iwai et al., 1995; Kahle et al., 2000; Murphy et al., 2000; Nemani
et al., 2010). Familial early-onset forms of PD are associated with
mutations in the SNCA gene, encoding α-syn (Polymeropoulos
et al., 1997; Singleton et al., 2003). Genomic duplications,
triplications and missense mutations (e.g. A53T, A30P, E46K and
H50Q) all implicate α-syn in the pathogenesis of PD (Spatola and
Wider, 2014). However, only 10% of cases are linked to a genetic
basis of the disease, with the majority of cases having an unknown
aetiology (Mcculloch et al., 2008; Wirdefeldt et al., 2011). Insights
from in vitro and in vivo models suggest that α-syn acts as a ‘prion-
like’ protein, with a propensity to misfold and form aggregates that
promote cell-to-cell propagation, which assists in the spread of
pathology (Braak et al., 2003; Li et al., 2008; Kordower et al., 2008;
Danzer et al., 2009; Aulic ́ et al., 2014; Hawkes et al., 2007).
The mechanisms underlying LB formation and the influence of
α-syn pathology on disease pathogenesis remain poorly understood,
largely due to the lack of whole-animal or cell-based models that
recapitulate the development of these inclusions. One of the
significant barriers in PD research surrounds the difficulty in
obtaining cultures of the A9-subtype dopaminergic neuronal
population that are specifically affected in the disease (Arenas
et al., 2015). Several cell culture models have been used for studying
PD, and to investigate the role of α-syn aggregation. These models
include: non-patient-specific human cell lines (SH-SY5Y,
HEK293, LUHMES); animal-derived cell lines (rat PC12, mouse
N2a cells); stem cells, including induced pluripotent cell lines
(iPSCs) and human mesenchymal (MSCs)/embryonic stem cells
(ESCs); and primary animal-derived midbrain neuron cultures
(Falkenburger et al., 2016; Smidt and Burbach, 2007). Each of these
cell types has its own strengths and limitations; for example, the use
of iPSCs that differentiate into dopaminergic neurons in vitro
overcomes the ethical issues associated with using ESCs. However,
culturing these cells is expensive and labour-intensive (as long as
75 days in culture), meaning that their use is inevitably out of reach
for many research groups (Smirnova et al., 2016; D’Antonio et al.,
2017). The cost incurred, time constraints and ethical framework
required for animal-based research are again inhibitory for many
laboratories.
To address the experimental and ethical issues of ESCs and animal
models, alternative systems have been developed to model the
complex pathogenesis of the disorder. Relatively few studies have
observed the development of LB pathology without overexpressing
high levels of human versions of α-syn (Volpicelli-Daley et al., 2011;
Falkenburger et al., 2016). In addition, a predominant number of
studies rely on the introduction of a familial mutation into α-syn (e.g.
A53T) to increase aggregation propensity (Li et al., 2001; Koprich
et al., 2017). Recombinant expression of wild-type (WT) humanReceived 11 November 2018; Accepted 21 March 2019
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α-syn in Drosophila mirrors the formation of LB-like structures and
neuronal loss, but this has unfortunately not been replicated in higher-
order organisms or human-cell-based models (Feany and Bender,
2000). Interestingly, rodent models of PD that overexpress human
α-syn by mutations in the SNCA gene (e.g. the M83 strain,
overexpressing mutant human A53T α-syn) do develop inclusions
but the anatomical distribution is widely variable among animals and
often coincides with areas of substantial neuroinflammation (Sacino
et al., 2014; Lee et al., 2002; Dawson et al., 2011; Fares et al., 2016).
Importantly, impaired human α-syn fibrillisation can occur in rodent
models due to an interaction with endogenously expressed mouse
α-syn. Such interactions highlight a fundamental experimental caveat
when investigating LB formation in mouse models or rodent-derived
primary neuronal cultures (Fares et al., 2016). Species differences
between rodent models (including primary rodent cell culture
systems) make it difficult to model and extrapolate findings to
human subjects (Goldie et al., 2014; Ioannidis, 2012; Pound and
Bracken, 2014).
In previous human-cell-based models, limitations have also arisen
from the use of traditional two-dimensional (2D) monolayers.
Intracellular α-syn aggregates are often observed as multiple
cytoplasmic punctate inclusions rather than recapitulating the
typical large singular inclusions associated with human pathology
(Danzer et al., 2009; Desplats et al., 2009; Aulic ́ et al., 2014).
Formation of LB-like pathology in human cell culture models has
only been achieved through overexpression of α-syn, either driven
from viral promoters or in cell lines not associated with the disease,
such as those from human embryonic kidney lines (HEK-293)
(Volpicelli-Daley et al., 2011; Luk et al., 2009; Sacino et al., 2013).
Such viral promotors do not allow the study of transcriptional and
translational modulations brought about during the disease state. To
address these issues, in vitro 3D culture systems are increasingly
being utilised for a multitude of disease models, with the aim of more
closely mimicking an in vivo environment with tissue-like cell
density and cell-to-cell as well as cell-to-extracellular-matrix contacts
(Griffith and Swartz, 2006; Tang-Schomer et al., 2014; Choi et al.,
2014; Smirnova et al., 2016). Taken together, the limitations of both
in vitro and in vivo models demonstrate a greater need to develop a
human-relevant culture system to model LB pathology.
The use of human-derived neuroblastoma cell lines, such as the
SH-SY5Y catecholaminergic neuroblastoma cell line, remains a
popular choice in PD research (Xicoy et al., 2017). Although the
SH-SY5Y cell line does display genetic anomalies, it is important to
note that nearly all pathways dysregulated in PD remain intact in this
line (Krishna et al., 2014) and punctate intracellular inclusions can
be induced by exposure to preformed amyloid material (Illes-Toth
et al., 2015). In addition, upon differentiation, this proliferative
immature neuroblast expresses the characteristic proteins associated
with dopaminergic neurons, including tyrosine hydroxylase (TH)
and dopamine transporter (DAT), making it a comparable model of
the cell type affected in the disease state (Presgraves et al., 2004;
Lopes et al., 2010; Kovalevich and Langford, 2013).
Differentiation to a fully mature neuronal phenotype can be
achieved using all-trans retinoic acid (RA), followed by treatment
with brain-derived neurotrophic factor (BDNF) (Encinas et al.,
2000). This procedure yields a preferentially homogenous
population of cells compared to other differentiation protocols,
including short- or long-term treatment with RA alone (Encinas
et al., 2000). Although the importance of using differentiated SH-
SY5Y in PD research is becoming increasingly apparent, a large
number of publications still either use the undifferentiated line, do
not report their differentiation protocol or employ a differentiation
protocol that solely utilises RA. These procedures then do not fully
provide a mature neuronal phenotype (Goldie et al., 2014; Xicoy
et al., 2017).
Here, we developed an easily replicable cell culture methodology
that recapitulates the formation of LB-like inclusions. The Encinas
et al. (2000) protocol was adapted to generate neuron-like cells in a
2D cell culture format that could subsequently be maintained within
a 3D matrix. By incorporating the RA+BDNF-differentiated cells
into a 3D matrix, we have been able to induce the formation of
nuclear-associated ubiquitinated LB-like α-syn aggregates upon
treatment with preformed α-syn oligomers. The formation of
these LB-like aggregates was achieved without the need for
overexpression of α-syn or modification of the genomic material.
RESULTS
Differentiated SH-SY5Y in 2D culture express markers
of dopaminergic neurons
Controversy remains as to whether RA or RA+BDNF promotes
SH-SY5Y cell differentiation and the development of a terminal
neural dopaminergic phenotype (Korecka et al., 2013; Xicoy et al.,
2017; Lopes et al., 2010). Thus, transcriptional and translational
analysis of key neuronal markers was carried out to
limit assumptions regarding the phenotypic state of the SH-SY5Y
cell line used here. Undifferentiated SH-SY5Y cells display a
characteristic morphology of two distinct phenotypes: neuroblastic
(‘N-type’; Fig. 1A, arrow); and substrate adherent (‘S-type’;
Fig. 1A, asterisk). In agreement with others (Korecka et al., 2013;
Forster et al., 2015; Ito et al., 2017), upon treatment with RA or
RA+BDNF, the neuroblastic SH-SY5Y cells differentiated to a
more neuron-like phenotype. Average neurite lengths and standard
deviations of 51.22±22.87 µm (undifferentiated), 64.91±33.07 µm
(RA) and 130.50±77.91 µm (RA+BDNF) were observed (Fig. 1A),
with interquartile ranges of 34.43-62.53, 40.83-80.85 and 74.83-
164.8 µm, respectively. Significantly longer neurite length was
observed in both RA and RA+BDNF groups compared to
undifferentiated cells, with increased network complexity in the
RA+BDNF group (Fig. 1A). Following treatment with RA, the non-
differentiating ‘S-type’ population was increasingly visible at day 5
and, if continuously cultured up to 14 days, under these conditions,
progressively overgrew the cultures (data not shown). The addition
of BDNF and withdrawal of RA promoted the development of a
homogenous population of cells with a negligible amount of
‘S-type’ cells surviving (Encinas et al., 2000).
Key to the development of an effective cell culture model of PD is
the expression of relevant neuronal markers. Cells at all stages of
differentiation were stained with antibodies for the neuron markers
neurofilament 200 (NF200) (Fig. 1B) and βIII-tubulin (encoded by
TUBB3) (data not shown). NF200 staining was reduced following
differentiation with RA (7±3%) compared to undifferentiated
SH-SY5Y (43±21%), potentially relating to an increased
population of ‘S-type’ cells within the culture. NF200
immunopositivity was increased in RA+BDNF (64±17%)
compared to undifferentiated and RA groups. Ki67 is a protein
associated with cell proliferation that is present in the G1, S and G2
phases of cell cycling and mitosis but absent in the G0 resting state.
Undifferentiated neuroblastoma cultures expressed this marker
[591,943±171,477 corrected total cell fluorescence (CTCF)/cell].
A significant reduction in expression seen in the RA (193,629±
160,908 CTCF/cell) and RA+BDNF (180,465±105,445 CTCF/
cell) cells indicate that they are terminally differentiated (Fig. 1C).
Tyrosine hydroxylase (TH) is a key enzyme in the production and
homeostasis of dopamine (DA) within catecholamine neuronal cell
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Fig. 1. Characterisation of SH-SY5Y cells following differentiation with RA alone or sequential treatment with RA+BDNF. (A) Representative phase-
contrast images of SH-SY5Y differentiated with RA alone and sequential treatment with RA+BDNF. Neurite length measurements were determined bymeasuring
200 neurites per treatment group, with three independent biological repeats. All data points are presented, with the mean shown as a straight line. Neuroblastic
(‘N-type’; arrow) and substrate adherent (‘S-type’; asterisk) cells are shown. (B-D) Immunocytochemistry analysis of differentiated cultures stained for NF200,
Ki67 and dopamine (DA) (red). Nuclei were visualised using DAPI staining (blue). Individual data points presented with mean (straight line) for% immunopositivity
(B) and CTCF/cell data (C,D) of three independent biological repeats. (E) mRNA levels of genes specifically associated with dopaminergic neurons were
evaluated by qPCR. Undifferentiated cells (blue), RA treatment group (red) and RA+BDNF treatment group (green). Relative gene expression normalised to
reference genes (ACTB and YWHAZ) and undifferentiated SH-SY5Y. Neuronal (TUBB3 and MAP2) and dopaminergic (DAT, DRD2 and VMAT2) markers
showed increased expression in the RA+BDNF group (green) relative to the undifferentiated cells (blue). Immature neuronal marker (NES) expression was not
significantly changed following differentiation with RA or RA+BDNF. Data presented asmean±s.e.m. of at least three independent experiments. (A-E) Differences
between treatments were tested for significance using the Kruskal–Wallis test with post hoc Dwass-Steel-Chritchlow-Fligner for >6 data points and Conover-
Inman for <6 data points. P-values are displayed in the figures. Scale bars: 100 µm (A); 50 µm (B-D).
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types (Daubner et al., 2011) and is expressed in all three cell types
(Fig. S1). An anti-DA antibody that has been demonstrated to be
specific for DA through cross-reactivity studies (Banks et al., 2017)
was used to determine the presence of this neurotransmitter. These
terminally differentiated SH-SY5Y cells were also shown to retain a
dopaminergic phenotype, whereby DA immunoreactivity was
significantly increased in RA+BDNF (21,800±7126 CTCF/cell)-
treated cultures compared to undifferentiated cells (19,884±6371
CTCF/cell) or those treated with RA (10,216±5823 CTCF/cell)
(Fig. 1D).
Evaluation of the mRNA levels after each differentiation protocol
by quantitative real-time PCR (qPCR) was used to determine the
transcriptional levels of genes specifically associated with
dopaminergic neurons (Fig. 1E). Increased expression of the
neuronal markers βIII-tubulin (TUBB3) and microtubule-
associated protein 2 (MAP2) upon RA+BDNF treatment
confirmed the development of a more neuronal phenotype than
observed with RA-treated or undifferentiated SH-SY5Y cells.
Nestin (NES), an immature neuronal marker, was not significantly
changed by differentiation with either RA alone or RA+BDNF
treatment. A greater dopaminergic phenotype in RA-BDNF
differentiated cultures was observed, indicated by elevated
expression levels of DAT, DA receptor D2 and vesicular
monoamine transporter member 2 when compared to the other
two cell populations (Fig. 1E). Overall, these observations are in
linewith previously published work on differentiated SH-SY5Y cell
lines in which RA+BDNF treatment was utilised, and demonstrate
that these conditions result in terminally differentiated cells
expressing many of the key markers of a dopaminergic neuron
(Ito et al., 2017; Agholme et al., 2010; Xicoy et al., 2017).
Exogenous α-syn oligomers induce intracellular aggregation
Within the PD brain, LB pathology is only observed in a discrete
cell population within ex vivomaterial (Braak et al., 2003). Here, we
wanted to determine whether the extent of cellular differentiation
resulted in alterations in the intracellular aggregation propensity of
the cell line. Previous studies by us and others have shown that a
distinct subtype of soluble oligomeric α-syn can seed intracellular
aggregation of endogenous α-syn in undifferentiated SH-SY5Y
lines (Danzer et al., 2009; Illes-Toth et al., 2015). Following
addition of oligomeric α-syn to undifferentiated SH-SY5Y cells, the
presence of multiple punctate α-syn-positive cytoplasmic inclusions
with an average inclusion size of 0.28 µm2 was confirmed in our
model (Fig. 2A,B). The addition of the same oligomer treatment on
RA-differentiated cultures also produced several small cytoplasmic
inclusions within each cell, but the average inclusion size was
significantly larger (0.82 µm2) than in the undifferentiated
SH-SY5Y cells (Fig. 2A,B). In both undifferentiated and
RA-differentiated SH-SY5Y cells, all surviving cells developed
the punctate inclusions (Fig. 2C).
In contrast, the addition of the same soluble oligomeric α-syn
preparation to RA+BDNF-differentiated culture media
demonstrated the development of a single perinuclear inclusion,
consistent with a large LB-like aggregate (Fig. 2A, asterisks and
arrows), with an average inclusion size of 8.95 µm2. Cellular
inclusions could be detected 24 h after treatment, but only 31% of
Fig. 2. Exogenous addition of α-syn oligomers induces the intracellular aggregation of α-syn in 2D SH-SY5Y cultures. (A) Double immunostaining of
undifferentiated and differentiated SH-SY5Y cells reveals intracellular aggregation of α-syn following 24 h incubation with seeding oligomers. α-Syn inclusions in
undifferentiated cells display several distinct, punctate accumulations dispersed throughout the cytoplasm, consistent with aggregates. In contrast, the RA+BDNF
cell lines show a single prominent accumulation (red; arrows) and obscure the nucleus (asterisks). Scale bars: 50 µm. (B) Quantification of inclusion area
(reflected as µm2) shows inclusions that are present in differentiated cells to be much larger than those in undifferentiated cells (measurements obtained from
three independent experiments; n=50). All data points are present, with mean shown as a straight line. (C) The percentage of cells containing inclusions was
determined by counting 100 cells per repeat. Cells were deemed to contain inclusions if aggregation matched that in reference images when compared to
controls. Data points are presented from three independent biological repeats. (B,C) Differences between treatments were tested for significance using Kruskal–
Wallis test with post-hoc Dwass-Steel-Chritchlow-Fligner for >6 data points and Conover-Inman for <6 data points. P-values are displayed in the figures.
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the cell population developed these structures (Fig. 2C). To our
knowledge, this is the first observation of single large inclusions
within a genetically unmodified cell culture model.
SH-SY5Y differentiation in 3D culture retains a dopaminergic
phenotype
Despite the promising initial phenotypic outcomes from the
RA+BDNF-differentiated cells cultured in a 2D format, the protocol
was not robust. These cells tended to detach from the culture vessel
before the end of BDNF treatment and as such presented a wide
variation in inclusion size (Fig. 2B) and viability (Fig. S2A). This
detachment from the culture vessel meant that, although images could
be produced of cells containing LB-like inclusions, the experiment
itself was not repeatable enough for future investigations. We,
therefore, sought to adapt our culturing procedure to allow for greater
retention of cells after RA+BDNF differentiation. It was hoped that
differentiation of these cells in a 3D matrix would stabilise the cell
population during the development of LB-like inclusions and allow
more robust handling methods during processing and analysis.
A variety of cell densities were used to evaluate the optimal cell
conditions for differentiation in 3D. In 300 µl matrix volumes (in
24-well inserts), incremental increases in densities from 1×106 cells/
ml to 1.25×107 cells/ml steadily decreased the viability of cells
within the matrix (∼17%) as measured by lactate dehydrogenase
(LDH) concentration (Fig. 3A). Upon differentiation in the 3D
matrix, gene expression of DRD2, MAP2 and VMAT2 were
increased (compared to undifferentiated SH-SY5Y) (Fig. 3B). A
substantial increase in VMAT2 expression within the same cells
differentiated in 3D compared to 2D indicated the development of a
more neuronal phenotype.
Based on these observations, a cell density of 7.5×106 cells/ml
was selected for further studies. At this cell density, the expression
levels of DAT, DRD2, MAP2, TUBB3 and VMAT2 were all
increased in relative abundance to the undifferentiated cells, and
NES expression was decreased in comparison to other cell densities.
Cells displayed a homogenous distribution within the matrix, in
contrast to lower densities where clusters of cells were observed
(Fig. S2B). In addition, this was the highest cell density at which cell
viability was unaffected. Hence, 7.5×106 cells/ml was the optimal
balance between viability and homogeneity within the matrix. To
demonstrate comparable differentiation of SH-SY5Y cultures after
7 days of treatment with RA+BDNF in 2D or 3D, all cells were
confirmed to be immunonegative for Ki67 and immunopositive for
NF200 and DA (Fig. 3C).
Fig. 3. Neuron-like cells cultured in 3D retain a dopaminergic phenotype. (A) Cell number optimisation of 3D-differentiated SH-SY5Y using LDH cell viability
assay. An incremental increase in cell density is associated with decreased cell viability (∼17% decrease from 1×106 cells/ml to 1.25×107 cells/ml). LDH cell
viability assay was normalised to cell-density-matched positive controls. All data points are present, with mean shown as a straight line of at least four independent
repeats. (B) mRNA levels of genes specifically associated with dopaminergic neurons were evaluated by qPCR in different cell densities. Relative gene
expression normalised to reference genes (ACTB and YWHAZ) and undifferentiated SH-SY5Y. Expression of neuronal (TUBB3, MAP2 and NES) and
dopaminergic (DAT, DRD2 and VMAT2) markers was evaluated in cell densities. A density of 7.5×106 cells/ml demonstrated increased expression of DRD2,
MAP2 andVMAT2, and was chosen for further experiments. Data presented asmean±s.e.m. of at least three independent experiments. (C) 3D-differentiated SH-
SY5Y cultures retain a post-mitotic neuronal dopaminergic phenotype in 3D as determined by the absence of Ki67 staining and positive staining for NF200 and
dopamine. Positive control for Ki67 staining is undifferentiated SH-SY5Y cultured in 3D. Scale bars: 100 µm.
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Seeded inclusions in 3D cultures are reminiscent of human
Lewy bodies
In vivo LBs are phenotypically more complex than the punctate
aggregates of α-syn seen in 2D cell culture models. To determine the
morphological changes in intracellular aggregates in 3D culture, fully
differentiated cells within the matrix were treated with preformed
α-syn oligomers. Similar to our observations in 2D cultures (Fig. 2),
inclusions in our 3D cell culture model were detectable 24 h after
α-syn oligomer treatment (Figs 4 and 5). Immunostaining of these
nuclear-associated inclusions in our 3D model confirmed that they
were α-syn positive (Fig. 4A) and an equivalent size to those seen
in vivo (Fig. 5A). Fig. 4B shows the percentage of α-syn
immunopositivity in 3D cultures treated for 24 h with media,
solvent or α-syn in monomeric or oligomeric preparations. The
data demonstrate that oligomer-treated cells develop significantly
more inclusions than control cells. The percentage of cells containing
observable inclusions also significantly increased relative to controls
(Fig. 4C). Immunostaining for ubiquitin in the oligomer-treated 3D
cell cultures demonstrated diffuse nuclear-associated staining that
colocalised with the LB-like aggregates (Fig. 5B). Co-staining
using both anti-α-syn and anti-ubiquitin antibodies demonstrates
colocalisation of both proteins within the same inclusion (Fig. 5C).
These inclusions are highly reminiscent of in vivo material
(Shults, 2006), and completely absent in the isotype controls and
untreated cultures (Fig. S3). Immunohistochemical detection of
phosphorylated α-syn at S129 using a selective antibody was not able
to show evidence of phosphorylation following 24 h treatment. This
would indicate that the aggregates have either formed without the
requirement for phosphorylation or that the S129 epitope is protected
within these aggregates (Walker et al., 2013). The lack of observable
phosphorylation within the inclusions would suggest that this
post-translational modification may not be required for aggregate
formation within this model, or occurs within a timeframe exceeding
that used here. If so, then the LB-like inclusions observed here could
represent an early aggregated morphology. Overall, the 3D
differentiated SH-SY5Y culture model presented here can produce
LB-like aggregates when treated with preformed oligomeric material
that recapitulates characteristic in vivo LB.
DISCUSSION
Previously, our group (Illes-Toth et al., 2015) and others (Danzer
et al., 2007, 2009) have reported the induction of punctate
Fig. 4. Exogenous α-syn oligomers seed the development of intracellular inclusions in 3D SH-SY5Y cultures. (A) Representative images of α-syn staining
with syn211 monoclonal antibody (brown) with nuclei visualised using DAPI staining (blue/purple). α-syn oligomer treatment to cells leads to strong
immunoreactivity for α-syn compared to isotype controls (Fig. S2), media only, or treatment with solvent or α-syn monomer. Arrows indicate the location of the
intracellular inclusions. Scale bars: 100 µm. (B) Percentage of α-syn immunopositivity in 3D cultures treated for 24 h with media, solvent or α-syn in monomeric
or oligomeric preparations. Cells were deemed to contain inclusions if aggregation matched that in reference images when compared to controls. Data presented
as mean±s.e.m. of three independent experiments. (C) Monomeric and oligomeric α-syn treatments resulted in an increase in the percentage of cells with
inclusions. Statistical significance in the oligomer-treated cultures related to the increase in large inclusions compared with media and solvent controls. Data
presented as mean±s.e.m. of three independent experiments. (*, compared to media; •, compared to solvent). Evaluation of immunohistochemical staining was
performed by counting 200 cells per slide, with ten slides counted per repeat (2000 cells counted in each treatment group for three independent experiments).
(B,C) Statistical differences were determined using the Kruskal–Wallis test with post hoc Conover-Inman (*/•P≤0.05, **/••P≤0.01).
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intracellular aggregates in 2D undifferentiated cells when specific
preparations of oligomeric α-syn are added to the media. Findings
presented here describe a human 3D cell culture model that
recapitulates LB-like formation. Inclusions are initiated by
oligomeric α-syn preparations when introduced to terminally
differentiated post-mitotic, neuron-like SH-SY5Y cells within a
3D matrix. Elevated expression of TUBB3 and MAP2 upon
differentiation indicated stronger neuronal characteristics than
when undifferentiated, and the detection of DAT, DRD2 and DA
confirmed a dopaminergic phenotype. Importantly, although the
LB-like structures present in our model do not show evidence of
phosphorylation, they are positive for α-syn and ubiquitin, closely
resembling the morphology of inclusions found within the human
pathology (Goedert et al., 2013).
Certain forms of α-syn located in the extracellular environment
have recently been shown to be internalised by neurons through
several receptor-mediated mechanisms and induce self-aggregation
of endogenous α-syn (Bieri et al., 2018). The oligomers used in this
study have previously been shown to induce the intracellular
aggregation of α-syn by providing a nucleation site that recruits
endogenous α-syn in the development of cell-associated aggregates
(Danzer et al., 2009). This prion-like propagation has been proposed
to explain the spread of the disease through the neuronal network
and justify the post-mortem observations of α-syn aggregates in a
PD patient that had undergone midbrain embryonic neuronal
transplants (Braak et al., 2003; Kordower et al., 2008). Following
internalisation, the ability of α-syn to trigger oligomerisation of
endogenous α-syn potentially occurs through the oxidative or other
stress responses (Deas et al., 2016; Di Maio et al., 2016). Although
the precise series of events surrounding the development of these
inclusions remains to be established, a model system such as the
one described here opens the opportunity to investigate these
mechanisms within a controlled environment and without the need
to genetic modify or overexpress α-syn.
In multifactorial disorders such as PD, dissecting the complex
pathological processes into simpler molecular events may allow us to
better interpret disease progression. Using the 3D cell culture model
described here may allow us to identify therapeutic interventions and
the pathways leading to LB development before translating them to
more complex models of the brain (e.g. transgenic mouse models) in
which confounders such as neuroinflammation and innate immunity
could mask the pathways required to be studied.
MATERIALS AND METHODS
Expression and purification of recombinant wild-type α-syn
HumanWT α-syn was prepared as described previously (Smith et al., 2008).
Briefly, α-syn was expressed in Escherichia coli BL21 (DE3) cells (New
England Biolabs, Ipswich, MA, USA). Expression was induced using
autoinduction media (Formedium, Norfolk, UK) at 37°C for 24 h. Bacterial
cells were harvested by centrifugation at 4°C, 10,000 g and resuspended in
lysis buffer [10 mM Tris-HCl (pH 8.0), 100 µg/ml lysozyme (Sigma-
Aldrich, Poole, UK), 1 mM phenylmethylsulphonyl fluoride (PMSF;
Sigma-Aldrich), 20 µg/ml DNase (Sigma-Aldrich), 20 µg/ml RNase
(Sigma-Aldrich) and protease inhibitor cocktail (Life Technologies,
Paisley, UK)]. The protein pellet was subjected to anion exchange
followed by size exclusion chromatography. Lyophilised purified α-syn
was stored at −20°C. Protein concentration was measured using a UV/vis
spectrophotometer (CECIL 1000) at absorbance 280 nm with an extinction
coefficient of 5960 M−1 cm−1.
Preparation of seeding oligomers
Seeding oligomers were prepared as previously described by Danzer et al.
(2009), omitting the addition of 10 µM FeCl2. Briefly, lyophilised α-syn
was dissolved in 50 mM sodium phosphate buffer (pH 7.0) containing 20%
ethanol to a final concentration of 7 µM. Following overnight incubation at
21°C with continuous shaking, oligomers were concentrated 1:14 using
Fig. 5. α-Syn-seeded inclusions in 3D are indicative of in vivo Lewy body inclusions. α-Syn oligomer treatments to 3D-differentiated cultures develop α-syn-
positive inclusions that demonstrate the same morphology as in vivo Lewy bodies (LBs; A) and are positive for the marker ubiquitin (B). Dotted line in purple
highlights cell nuclei, whereas brown dotted line highlights stained area. (C) Immunofluorescence shows colocalisation of α-syn (red) and ubiquitin (green)
staining. Nuclei were visualised using DAPI staining (blue). Scale bars: 50 µm (left) and 10 µm (right). In vivo pathology image displayed with permission from
Springer Nature. This image is not published under the terms of the CC-BY license of this article. For permission to reuse, please see Chesselet et al. (2012).
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ultracentrifugation (VivaSpin 500 columns, MWCO 30 kDa, GE
Healthcare, Buckinghamshire, UK), allowing the separation of oligomeric
species from monomeric protein. Each batch of oligomers was used for
experiments straight away.
Cell culture, media and reagents
SH-SY5Y human neuroblastoma cells were purchased from the European
Collection of Authenticated Cell Cultures (cat. no. 94030304; Public Health
England, Salisbury, UK). All cell lines were confirmed to be mycoplasma
free at 3-month intervals. Cell cultures were maintained at 37°C, 5% CO2
in DMEM high glucose with L-glutamine media (Lonza, Slough, UK)
supplemented with 10% (v/v) foetal bovine serum (FBS; Life Technologies)
and 1% (v/v) penicillin/streptomycin (P/S; Life Technologies); all
experiments were completed within ten passages. For treatment with
seeding oligomers, undifferentiated SH-SY5Y cells were allowed to adhere
and expand to 70% confluence before treatment with monomeric α-syn,
oligomeric α-syn or appropriate solvent controls for 24 h. For 2D
differentiation into neuronal-like cells, cells were pre-differentiated in
DMEM high glucose with L-glutamine supplemented with 10% (v/v) FBS,
1% (v/v) P/S and 10 µM all-trans-RA (Sigma-Aldrich). After 5 days in the
presence of RA, cells were washed with serum-free DMEM and media
changed to 50 ng/ml BDNF-supplemented (BDNF; cat. no. 450-02;
PeproTech, London, UK) serum-free DMEM for 7 days. Following
incubation, differentiated SH-SY5Y cells were treated with monomeric α-
syn, oligomeric α-syn or appropriate solvent controls for 24 h at 10% v/v
(0.01 mg/ml concentration referring to the monomer’s concentration) (Illes-
Toth et al., 2015; Danzer et al., 2007). Phase-contrast images of differentiated
cells were captured using an Olympus Inverted microscope. Neurite length
wasmeasured using the free open source software, ImageJ 1.50i, whereby 200
neurites per treatment were measured, in three independent experiments.
Immunofluorescence staining
For immunofluorescence staining, 2D cultures were fixed with ice-cold
methanol for 15 min at −20°C followed by washing with phosphate buffered
saline (PBS) solution containing 0.1% (v/v) Tween-20 (PBS-T; Sigma-
Aldrich). After washing, unspecific binding sites were blockedwith a solution
containing PBS and 1% (w/v) bovine serum albumin (BSA; Sigma-Aldrich)
for 1 h at room temperature under gentle continuous shaking. After blocking,
cells were washed in PBS-T before incubation with primary antibody in
blocking solution for 1 h at room temperature under gentle continuous
shaking. The following antibody dilutions were used in this study: anti-α-
synuclein (syn211; 1:2000 dilution; cat. no. 32-8100; Invitrogen,
ThermoFisher Scientific, Loughborough, UK), anti-DA (1:200; ab6427;
Abcam, Cambridge, UK), anti-hypophosphorylated NF200 (1:100; ab82259;
Abcam) and anti-Ki67 (1:200; ab16667; Abcam). Following primary-
antibody incubation, cells were washed with PBS-T and incubated with
secondary antibody [Texas Red™ goat anti-mouse IgG (H+L); cat. no.
100125662; ThermoFisher Scientific] for 1 h at room temperature in the dark.
Nuclei were counterstained with 0.1 µg/ml 4′,6-diamidino-2-phenylindole,
dihydrochloride (DAPI; Sigma-Aldrich) for 5 min. Slides were mounted with
immersion oil, sealed with nail varnish and left to cure overnight at 4°C in the
dark prior to image capture using an Olympus BX60 brightfield/fluorescence
microscope. Evaluation of immunofluorescence staining was performed by
counting 200 cells per repeat, with immunopositive cells expressed as a
percentage of total count. To quantify total fluorescence per cell, fluorescent
images were analysed using the image analysis software ImageJ 1.50i using
the CTCF calculation, in which the background fluorescence in a selected area
is subtracted from the fluorescence value of a measured area, using the
calculation: CTCF=[Integrated density−(Mean fluorescence reading of
background×Fluorescence of area of selection)]/Cell number. Three
independent biological repeats were performed in total.
3D cell culture and differentiation
Cells were pre-differentiated with RA in uncoated T75 flasks for 5 days
prior to seeding into 3D Matrigel™ cultures. Matrigel™ was diluted to
6 mg/ml total protein with ice-cold serum-free DMEM and vortexed with
cell pellets for 10 s, to a final cell concentration of approximately 7.5×106
cells per ml of diluted Matrigel™. Using pre-chilled pipettes, Matrigel™/
cell mixtures were transferred to either pre-warmed 8-well chamber slides or
tissue culture inserts (ThinCerts; 0.4 µm pore size, Greiner Bio-One,
Gloucestershire, UK), at 100 µl and 300 µl volumes, respectively, and
incubated at 37°C for 1 h to form a colloidal gel. Following solidification of
the 3D gels, pre-warmed serum-free DMEM supplemented with 50 ng/ml
BDNF was added to the cultures and cells differentiated for a further 7 days.
Media was changed every 3-4 days. After 7 days in 3D, cultures were treated
with monomeric α-syn, oligomeric α-syn or appropriate solvent controls for
24 h at 10% v/v (0.01 mg/ml concentration referring to the monomer’s
concentration) (Illes-Toth et al., 2015; Danzer et al., 2007).
Cryostat sectioning and histological staining of 3D cultures
For cryostat sectioning, 3D cultures grown in tissue inserts were frozen and
stored at −80°C before sectioning. The frozen samples were cut into 10 µm
sections (Leica CM3050 S Research Cryostat, LeicaMicrosystems, Newcastle
upon Tyne, UK) at −25°C and mounted on X-tra® adhesive glass slides
(Leica Microsystems) and stored at −80°C prior to staining. For
immunohistochemistry, 10 µm frozen sections from 3D thick-layer cultures
were fixed with ice-cold 1:1 methanol and acetone, and endogenous
peroxidases blocked. Staining with anti-α-synuclein monoclonal antibody
(syn211; 1:100 dilution; Invitrogen) was performed using the Mouse on
Mouse Polymer IHC Kit according to the manufacturer’s protocols
(ab127055; Abcam, Cambridge, UK). Staining with anti-ubiquitin (1:50
dilution; cat. no. ab7780; Abcam) rabbit primary antibodies was performed
using the following method. Following Tris-buffered saline (TBS) washes,
non-specific binding sites were blocked at room temperature for 2 h with 25%
(v/v) normal goat serum (cat. no. 11819220; ThermoFisher Scientific,
Loughborough, UK) and 1% (w/v) BSA in TBS. Sections were incubatedwith
primary antibody overnight at 4°C. Slides were washed in TBS, and a 1:500
dilution of biotinylated goat anti-rabbit secondary antibody (cat. no. ab6720;
Abcam) in 1% (w/v) BSA/TBS was applied for 30 min at room temperature.
Binding of the secondary antibody was detected using a streptavidin-biotin
complex (Vector Laboratories, Peterborough, UK) techniquewith 0.08% (v/v)
hydrogen peroxide in 0.65 mg/ml 3,3-diaminobenzidine tetrahydrochloride
(DAB; Sigma-Aldrich) in TBS. Sections were counterstained with Mayer’s
Haematoxylin (Leica Microsystems), dehydrated, cleared and mounted
with Pertex mounting medium (Leica Microsystems). Evaluation of
immunohistochemical staining was performed by counting 200 cells per
slide, with ten slides counted per repeat (2000 cells counted in each treatment
group for three independent experiments); immunopositive cell values are
expressed as a percentage of the total count.
Immunofluorescence of 3D cultures
For immunofluorescence of 3D cultures, frozen sections were fixed with 1:1
ice-cold methanol:acetone. Blocking was performed using the Mouse on
Mouse Polymer IHC Kit according to the manufacturer’s protocols
(ab127055; Abcam). Slides were incubated with anti-α-syn (syn211;
1:100 dilution; Invitrogen) and anti-ubiquitin (1:1000; cat. no. ab7780;
Abcam) primary antibodies for 1 h at room temperature. Following PBS-T
washes, secondary antibodies [Alexa Fluor® 488 goat anti-rabbit IgG (H+L)
cat. no. ab150077, Abcam, and Texas Red™ goat anti-mouse IgG (H+L)
cat. no. 100125662, ThermoFisher Scientific] were incubated at 1:1000
dilution for 1 h at room temperature. Nuclei were counterstained with
0.1 µg/ml DAPI (Sigma-Aldrich) for 5 min. Slides were mounted with
immersion oil, sealed with nail varnish and left to cure overnight at 4°C in
the dark before image capture using a Leica LSM 800 confocal microscope.
RNA extraction, cDNA synthesis and qPCR
Total RNAwas extracted using either TRIzol® Reagent (Life Technologies)
or the ReliaPrep™ RNA Cell Miniprep System (Promega, Southampton,
UK) according to the manufacturers’ protocols. Complementary DNAs
(cDNAs) were synthesised by the nanoScript 2 Reverse Transcriptase kit
(Primerdesign, Chandler’s Ford, UK) from equal amounts of purified RNA
(1 µg). Target genes were investigated using qPCR conducted on either
undifferentiated or differentiated SH-SY5Y populations using pre-validated
primer sets (Primerdesign). Reaction volumes of 20 µl were prepared using
PrecisionPLUS 2× Real-Time PCR MasterMix premixed with ROX and
SYBR green (Primerdesign). The amplification was performed under the
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following conditions: 2 min at 95°C and then 40 cycles at 95°C for 15 s and
60°C for 60 s followed by a post-PCR melt-curve analysis performed on a
StepOnePlus™ Real-Time PCR System (Applied Biosystems, Lutterworth,
UK). The sizes of PCR products were confirmed using agarose gel
electrophoresis. Reference gene analysis was undertaken using the
geNormPLUS kit (Primerdesign) and Qbase+ software (Primerdesign) to
identify inherently stable reference genes between different treatment
groups. Gene expression levels were normalised against reference genes
ACTB (β-actin) and YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta polypeptide) for each sample and
fold changes were calculated using the 2−ΔΔCt method (Schmittgen and
Livak, 2008) by setting the expression levels of each gene in
undifferentiated SH-SY5Y cells as 1. Data collected from at least three
independent biological replicates was calculated and plotted as mean log10-
fold changes ±s.e.m.
Cell viability
Cell viability of 2D or 3D cultures was analysed with either resazurin
(mitochondrial activity) or lactate dehydrogenase (LDH; cell membrane
integrity) levels. For the resazurin reduction assay, a 3 mg/ml stock solution
of resazurin was prepared in cell culture media and further diluted to 10 µg/
ml. Following treatment with oligomeric or monomeric species and
appropriate solvent controls, media was removed and 100 µl of culture
media with 10 µg/ml resazurin was incubated with the cells for 2 h.
Fluorescence (Ex530nm/Em590nm) was measured on a CLARIOstar® plate
reader (BMG LABTECH, Buckinghamshire, UK). Culture media was
incubated with resazurin in parallel as a blank control. As a positive control,
cells were incubated with 1% (v/v) Triton X-100. Cell viability was
calculated as a percentage of live cells normalised to negative controls minus
relative fluorescence intensity (RFU) of blank wells. For LDH assay, the
Pierce LDH Cytotoxicity Assay Kit was used according to the
manufacturer’s instructions (cat. no. 88953; ThermoFisher Scientific).
Briefly, 50 µl of medium from each well was transferred to a 96-well plate,
followed by addition of 50 µl of reaction mixture, and incubated for 30 min
at room temperature in the dark. Cell culture media was included in parallel
as a blank control. After addition of 50 µl stop solution, absorbance
measurements at 490 nm and 680 nm were recorded on a CLARIOstar®
plate reader (BMG LABTECH). The A680nm (background signal from the
instrument) was subtracted from the A490nm followed by subtraction of
blanks. Percentages of live cells were determined by normalisation of the
absorbance values from the test sample to positive controls.
Statistical analysis
Statistical analysis was undertaken using StatsDirect version 3.0.126. Data
was unpaired and determined to be non-parametric following the Shapiro–
Wilk test of normality; therefore, a Kruskal–Wallis test was undertaken with
post hoc analysis. Post hoc analysis was only undertaken if the initial
significance test was at P<0.05. Dwass-Steel-Chritchlow-Fligner was used
for data points >6 and Conover-Inman post hoc analysis for <6 data points.
P-values are denoted on the graphs. Results of all statistical analysis
performed are shown in Table S1.
Acknowledgements
We thank the Biomolecular Sciences Research Centre, Sheffield Hallam University
for funding the PhD studentship that has supported the work performed in this study.
Competing interests
The authors declare no competing or financial interests.
Author contributions
Conceptualization: T.R.T.-W., D.P.S.; Methodology: T.R.T.-W.; Validation:
T.R.T.-W.; Formal analysis: T.R.T.-W.; Investigation: T.R.T.-W.; Writing - original draft:
T.R.T.-W., C.L.L.M., J.A.D., C.F.D., D.P.S.; Writing - review & editing: T.R.T.-W.,
C.L.L.M., J.A.D., C.F.D., D.P.S.; Supervision: C.L.L.M., J.A.D., C.F.D., D.P.S.; Project
administration: D.P.S.; Funding acquisition: D.P.S.
Funding
Sheffield Hallam University funded the PhD studentship that has supported thework
performed in this study.
Data availability
qPCR and image analysis data have been deposited online at https://figshare.com/
articles/_/7791314.
Supplementary information
Supplementary information available online at
http://dmm.biologists.org/lookup/doi/10.1242/dmm.038042.supplemental
References
Agholme, L., Lindström, T., Kågedal, K., Marcusson, J. and Hallbeck, M. (2010).
An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with
morphological and biochemical characteristics of mature neurons. J. Alzheimer’s
Dis. 4, 1069-1082. doi:10.3233/JAD-2010-091363
Arenas, E., Denham, M. and Villaescusa, J. C. (2015). How to make a midbrain
dopaminergic neuron. Development 142, 1918-1936. doi:10.1242/dev.097394
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